0001739104-23-000023.txt : 20231107 0001739104-23-000023.hdr.sgml : 20231107 20231107161447 ACCESSION NUMBER: 0001739104-23-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 231384094 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 10-Q 1 elan-20230930.htm 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2023 elan-20230930
false2023Q30001739104--12-3100017391042023-01-012023-09-3000017391042023-11-02xbrli:shares00017391042023-07-012023-09-30iso4217:USD00017391042022-07-012022-09-3000017391042022-01-012022-09-30iso4217:USDxbrli:shares00017391042023-09-3000017391042022-12-310001739104us-gaap:CommonStockMember2021-12-310001739104us-gaap:AdditionalPaidInCapitalMember2021-12-310001739104us-gaap:RetainedEarningsMember2021-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100017391042021-12-310001739104us-gaap:RetainedEarningsMember2022-01-012022-03-3100017391042022-01-012022-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001739104us-gaap:CommonStockMember2022-01-012022-03-310001739104us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001739104us-gaap:CommonStockMember2022-03-310001739104us-gaap:AdditionalPaidInCapitalMember2022-03-310001739104us-gaap:RetainedEarningsMember2022-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100017391042022-03-310001739104us-gaap:RetainedEarningsMember2022-04-012022-06-3000017391042022-04-012022-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-012022-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-012022-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001739104us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001739104us-gaap:CommonStockMember2022-06-300001739104us-gaap:AdditionalPaidInCapitalMember2022-06-300001739104us-gaap:RetainedEarningsMember2022-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000017391042022-06-300001739104us-gaap:RetainedEarningsMember2022-07-012022-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012022-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001739104us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001739104us-gaap:CommonStockMember2022-09-300001739104us-gaap:AdditionalPaidInCapitalMember2022-09-300001739104us-gaap:RetainedEarningsMember2022-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000017391042022-09-300001739104us-gaap:CommonStockMember2022-12-310001739104us-gaap:AdditionalPaidInCapitalMember2022-12-310001739104us-gaap:RetainedEarningsMember2022-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001739104us-gaap:RetainedEarningsMember2023-01-012023-03-3100017391042023-01-012023-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001739104us-gaap:CommonStockMember2023-01-012023-03-310001739104us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001739104us-gaap:CommonStockMember2023-03-310001739104us-gaap:AdditionalPaidInCapitalMember2023-03-310001739104us-gaap:RetainedEarningsMember2023-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100017391042023-03-310001739104us-gaap:RetainedEarningsMember2023-04-012023-06-3000017391042023-04-012023-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001739104us-gaap:CommonStockMember2023-04-012023-06-300001739104us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001739104us-gaap:CommonStockMember2023-06-300001739104us-gaap:AdditionalPaidInCapitalMember2023-06-300001739104us-gaap:RetainedEarningsMember2023-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000017391042023-06-300001739104us-gaap:RetainedEarningsMember2023-07-012023-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001739104us-gaap:CommonStockMember2023-07-012023-09-300001739104us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001739104us-gaap:CommonStockMember2023-09-300001739104us-gaap:AdditionalPaidInCapitalMember2023-09-300001739104us-gaap:RetainedEarningsMember2023-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001739104us-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300001739104us-gaap:RevolvingCreditFacilityMember2022-01-012022-09-300001739104elan:SecuritizationFacilityMember2023-01-012023-09-300001739104elan:SecuritizationFacilityMember2022-01-012022-09-300001739104us-gaap:CustomerConcentrationRiskMemberelan:CustomerAMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-30xbrli:pure0001739104us-gaap:CustomerConcentrationRiskMemberelan:CustomerAMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300001739104us-gaap:ProductMember2023-09-300001739104us-gaap:ProductMember2022-12-310001739104elan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2023-01-012023-09-300001739104elan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberelan:ProductReturnConcentrationRiskMember2022-01-012022-09-300001739104elan:PetHealthMember2023-07-012023-09-300001739104elan:PetHealthMember2022-07-012022-09-300001739104elan:PetHealthMember2023-01-012023-09-300001739104elan:PetHealthMember2022-01-012022-09-300001739104elan:CattleMember2023-07-012023-09-300001739104elan:CattleMember2022-07-012022-09-300001739104elan:CattleMember2023-01-012023-09-300001739104elan:CattleMember2022-01-012022-09-300001739104elan:PoultryMember2023-07-012023-09-300001739104elan:PoultryMember2022-07-012022-09-300001739104elan:PoultryMember2023-01-012023-09-300001739104elan:PoultryMember2022-01-012022-09-300001739104elan:SwineMember2023-07-012023-09-300001739104elan:SwineMember2022-07-012022-09-300001739104elan:SwineMember2023-01-012023-09-300001739104elan:SwineMember2022-01-012022-09-300001739104elan:AquaMember2023-07-012023-09-300001739104elan:AquaMember2022-07-012022-09-300001739104elan:AquaMember2023-01-012023-09-300001739104elan:AquaMember2022-01-012022-09-300001739104elan:FarmAnimalMember2023-07-012023-09-300001739104elan:FarmAnimalMember2022-07-012022-09-300001739104elan:FarmAnimalMember2023-01-012023-09-300001739104elan:FarmAnimalMember2022-01-012022-09-300001739104elan:ContractManufacturingMember2023-07-012023-09-300001739104elan:ContractManufacturingMember2022-07-012022-09-300001739104elan:ContractManufacturingMember2023-01-012023-09-300001739104elan:ContractManufacturingMember2022-01-012022-09-300001739104country:US2023-07-012023-09-300001739104country:US2022-07-012022-09-300001739104country:US2023-01-012023-09-300001739104country:US2022-01-012022-09-300001739104us-gaap:NonUsMember2023-07-012023-09-300001739104us-gaap:NonUsMember2022-07-012022-09-300001739104us-gaap:NonUsMember2023-01-012023-09-300001739104us-gaap:NonUsMember2022-01-012022-09-300001739104elan:NutriQuestLLCMember2023-01-032023-01-030001739104srt:MaximumMemberelan:NutriQuestLLCMember2023-01-030001739104elan:NutriQuestLLCMember2023-01-030001739104elan:MarketedProductsMemberelan:NutriQuestLLCMember2023-01-030001739104us-gaap:InProcessResearchAndDevelopmentMemberelan:NutriQuestLLCMember2023-01-030001739104us-gaap:OtherIntangibleAssetsMemberelan:NutriQuestLLCMember2023-01-030001739104elan:NutriQuestLLCMemberelan:NutriQuestLLCMember2023-01-012023-09-300001739104elan:NutriQuestNutricaoAnimalLtdaMember2023-08-012023-08-010001739104elan:NutriQuestNutricaoAnimalLtdaMember2023-08-010001739104elan:MicrobiomeRDPlatformCarveOutMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-12-31elan:employee00017391042022-02-010001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeAndSpekeMember2021-08-012023-09-300001739104elan:OtherReceivablesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeAndSpekeMember2021-08-012023-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeAndSpekeMember2023-05-012023-05-310001739104elan:BexCaFeLLCMemberus-gaap:InProcessResearchAndDevelopmentMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-06-300001739104elan:BexCaFeLLCMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-06-300001739104elan:BexCaFeLLCMemberelan:FutureMilestonePaymentsAndSalesRoyaltiesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-06-300001739104elan:BexCaFeLLCMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-09-300001739104elan:BexCaFeLLCMemberelan:FutureMilestonePaymentsAndSalesRoyaltiesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-300001739104us-gaap:InProcessResearchAndDevelopmentMemberelan:BexCaFeLLCMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-12-310001739104elan:SpekeSiteMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001739104elan:TangibleEquityUnitMember2020-01-012020-01-310001739104elan:TangibleEquityUnitMember2020-01-310001739104elan:TangibleEquityUnitMember2023-02-010001739104elan:TangibleEquityUnitMembersrt:MaximumMember2023-02-010001739104elan:IncrementalTermFacilityDueJune302025Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001739104elan:IncrementalTermFacilityDueJune302025Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-12-310001739104elan:IncrementalTermFacilityDueAugust122028Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001739104elan:IncrementalTermFacilityDueAugust122028Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-12-310001739104elan:IncrementalTermFacilityDueApril192029Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001739104elan:IncrementalTermFacilityDueApril192029Memberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-12-310001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2023-09-300001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2022-12-310001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-09-300001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001739104elan:SecuritizationFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-09-300001739104elan:SecuritizationFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2022-12-310001739104us-gaap:SeniorNotesMemberelan:A4272SeniorNotesDue2023Member2023-09-300001739104us-gaap:SeniorNotesMemberelan:A4272SeniorNotesDue2023Member2022-12-310001739104us-gaap:SeniorNotesMemberelan:SeniorNotesDue2028Member2023-09-300001739104us-gaap:SeniorNotesMemberelan:SeniorNotesDue2028Member2022-12-310001739104us-gaap:SeniorNotesMemberelan:A500TangibleEquityUnitsMember2023-09-300001739104us-gaap:SeniorNotesMemberelan:A500TangibleEquityUnitsMember2022-12-310001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001739104us-gaap:RevolvingCreditFacilityMemberelan:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001739104us-gaap:SeniorNotesMemberelan:A4272SeniorNotesDue2023Member2023-08-310001739104us-gaap:SeniorNotesMemberelan:SeniorNotesDue2028Member2018-08-310001739104elan:SecuritizationFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-08-030001739104elan:SecuritizationFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-08-032023-08-030001739104elan:SecuritizationFacilityMemberelan:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-08-032023-08-030001739104us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-07-012023-09-300001739104elan:SecuritizationFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2023-08-042023-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-07-012023-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-07-012022-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-01-012023-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-01-012022-09-300001739104us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001739104us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001739104us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-012023-03-310001739104us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-05-012023-05-010001739104srt:WeightedAverageMember2023-09-300001739104us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-30iso4217:CHF0001739104us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001739104us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300001739104us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001739104us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300001739104us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001739104us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300001739104us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001739104us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2023-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001739104us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310001739104us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001739104elan:NutriQuestLLCMember2023-09-300001739104elan:SerestoClassActionLawsuitsMember2023-04-012023-06-300001739104elan:SerestoClassActionLawsuitsMember2023-09-300001739104elan:TangibleEquityUnitMembersrt:MinimumMember2023-01-012023-09-300001739104elan:TangibleEquityUnitMembersrt:MaximumMember2023-01-012023-09-300001739104elan:TangibleEquityUnitMembersrt:MinimumMember2020-01-222023-01-310001739104elan:TangibleEquityUnitMember2023-02-012023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from _________ to _______
COMMISSION FILE NUMBER 001-38661
2015-Elanco-logo.jpg
Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA
 82-5497352
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2500 INNOVATION WAY, GREENFIELD, INDIANA 46140
(Address and zip code of principal executive offices)

Registrant’s telephone number, including area code (877) 352-6261
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of November 2, 2023 was 492,798,113.


ELANCO ANIMAL HEALTH INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2023
TABLE OF CONTENTS
PART 1. Financial Information
Item 1.
Item 2.
Item 3.
Item 4.
PART II. Other Information
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

2023 Q3 Form 10-Q | 1
FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY
This Quarterly Report on Form 10-Q (Form 10-Q) includes forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements concerning the impact on Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us or our) caused by the integration of business acquisitions, expected synergies and cost savings, product launches, global macroeconomic conditions, expectations relating to liquidity and sources of capital, our expected compliance with debt covenants, cost savings, expenses and reserves relating to restructuring actions, our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following:
•heightened competition, including from generics;
•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
•changes in regulatory restrictions on the use of antibiotics in farm animals;
•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
•consolidation of our customers and distributors;
•an outbreak of infectious disease carried by farm animals;
•demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern;
•the potential impact on our business and global economic conditions resulting from regional conflicts;
•the success of our research and development (R&D) and licensing efforts;
•misuse, off-label or counterfeiting use of our products;
•unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;
•fluctuations in our business results due to seasonality and other factors;
•the impact of weather conditions, including those related to climate change, and the availability of natural resources;
•risks related to the modification of foreign trade policy;
•risks related to currency exchange rate fluctuations;
•our dependence on the success of our top products;
•the impact of customer exposure to rising costs and reduced customer income;
•the lack of availability or significant increases in the cost of raw materials;
•the impact of increased or decreased sales into our distribution channels resulting in fluctuations in our revenues;
•risks related to the write-down of goodwill or identifiable intangible assets;
•risks related to the evaluation of animals;
•manufacturing problems and capacity imbalances;
•the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters;
•actions by regulatory bodies, including as a result of their interpretation of studies on product safety;
2023 Q3 Form 10-Q | 2
•risks related to tax expense or exposure;
•risks related to environmental, health and safety laws and regulations;
•risks related to our presence in foreign markets;
•challenges to our intellectual property rights or our alleged violation of rights of others;
•our dependence on sophisticated information technology and infrastructure and the impact of breaches of our information technology systems;
•risks related to the use of machine learning and artificial intelligence by us and our competitors;
•the impact of increased regulation or decreased financial support related to farm animals;
•adverse effects of labor disputes, strikes, work stoppages and the loss of key personnel or highly skilled employees;
•risks related to underfunded pension plan liabilities;
•our ability to complete acquisitions and successfully integrate the businesses we acquire, including Kindred Biosciences, Inc. (KindredBio) and the animal health business of Bayer Aktiengesellschaft (Bayer Animal Health);
•the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that limit our operating flexibility, changes in our credit ratings that lead to higher borrowing expenses and may restrict access to credit and changes in interest rates that may adversely affect earnings and cash flows;
•risks related to certain governance provisions in our constituent documents; and
•any failure to maintain an effective system of disclosure controls and internal control over financial reporting, including arising from an identified material weakness.
See Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the United States (U.S.) Securities and Exchange Commission (SEC) (2022 Form 10-K), and Part II of this Form 10-Q, for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this quarterly report. Any forward-looking statement made by us in this quarterly report speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.


2023 Q3 Form 10-Q | 3
PART I

ITEM 1. FINANCIAL STATEMENTS

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Operations (Unaudited)
(in millions, except per-share data)
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Revenue$1,068 $1,026 $3,382 $3,426 
Costs, expenses and other:
Cost of sales487 472 1,415 1,465 
Research and development86 78 248 241 
Marketing, selling and administrative313 298 993 963 
Amortization of intangible assets
140 128 410 398 
Asset impairment, restructuring and other special charges
16 26 91 152 
Goodwill impairment1,042 — 1,042 — 
Interest expense, net of capitalized interest72 60 210 179 
Other expense, net9 8 41 11 
2,165 1,070 4,450 3,409 
(Loss) income before income taxes(1,097)(44)(1,068)17 
Income tax (benefit) expense(1)21 22 41 
Net loss$(1,096)$(65)$(1,090)$(24)
Loss per share:
Basic $(2.22)$(0.13)$(2.21)$(0.05)
Diluted$(2.22)$(0.13)$(2.21)$(0.05)
Weighted-average shares outstanding:
Basic492.7 488.4 492.1 488.3 
Diluted492.7 488.4 492.1 488.3 

See accompanying notes to condensed consolidated financial statements.
2023 Q3 Form 10-Q | 4
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
(in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss$(1,096)$(65)$(1,090)$(24)
Other comprehensive loss:
Cash flow hedges, net of taxes— 62 (19)179 
Foreign currency translation, net of taxes(197)(418)(65)(973)
Defined benefit pension and retiree health benefit plans, net of taxes(4)(2)(6)(4)
Other comprehensive loss, net of taxes(201)(358)(90)(798)
Comprehensive loss$(1,297)$(423)$(1,180)$(822)

See accompanying notes to condensed consolidated financial statements.

2023 Q3 Form 10-Q | 5
Elanco Animal Health Incorporated
Condensed Consolidated Balance Sheets
(in millions, except share data)
September 30, 2023December 31, 2022
(Unaudited)
Assets 
Current Assets
Cash and cash equivalents$369 $345 
Accounts receivable, net
911 797 
Other receivables224 205 
Inventories1,690 1,538 
Prepaid expenses and other371 394 
Total current assets3,565 3,279 
Noncurrent Assets
Goodwill4,902 5,993 
Other intangibles, net4,475 4,842 
Other noncurrent assets410 378 
Property and equipment, net
992 999 
Total assets$14,344 $15,491 
Liabilities and Equity
Current Liabilities
Accounts payable$296 $390 
Sales rebates and discounts356 324 
Current portion of long-term debt39 388 
Other current liabilities574 600 
Total current liabilities1,265 1,702 
Noncurrent Liabilities
Long-term debt5,870 5,448 
Deferred taxes643 662 
Other noncurrent liabilities432 390 
Total liabilities8,210 8,202 
Commitments and Contingencies
Equity
Common stock, no par value, 5,000,000,000 shares authorized, 492,683,420 and 474,237,738 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
— — 
Additional paid-in capital8,763 8,738 
Accumulated deficit(2,147)(1,057)
Accumulated other comprehensive loss(482)(392)
Total equity6,134 7,289 
Total liabilities and equity$14,344 $15,491 

See accompanying notes to condensed consolidated financial statements.
2023 Q3 Form 10-Q | 6
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Equity (Unaudited)
(Dollars and shares in millions)
Common StockAccumulated Other Comprehensive Loss
SharesAmountAdditional Paid-in CapitalAccumulated DeficitCash Flow HedgeForeign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
December 31, 2021
473.1 $— $8,696 $(979)$25 $(253)$19 $(209)$7,508 
Net income— — — 51 — — — — 51 
Other comprehensive income (loss), net of tax— — — — 109 (85)(1)23 23 
Stock-based compensation activity, net1.0 — 3 — — — — — 3 
March 31, 2022474.1 — 8,699 (928)134 (338)18 (186)7,585 
Net loss— — — (10)— — — — (10)
Other comprehensive income (loss), net of tax— — — — 8 (470)(1)(463)(463)
Stock-based compensation activity, net— — 13 — — — — — 13 
June 30, 2022474.1 — 8,712 (938)142 (808)17 (649)7,125 
Net loss— — — (65)— — — — (65)
Other comprehensive income (loss), net of tax— — — — 62 (418)(2)(358)(358)
Stock-based compensation activity, net— — 12 — — — — — 12 
September 30, 2022474.1 $— $8,724 $(1,003)$204 $(1,226)$15 $(1,007)$6,714 
December 31, 2022
474.2 $— $8,738 $(1,057)$182 $(672)$98 $(392)$7,289 
Net income— — — 103 — — — — 103 
Other comprehensive income (loss), net of tax— — — — (48)130 — 82 82 
Stock-based compensation activity, net1.0 — 6 — — — — — 6 
Conversion of tangible equity units (TEUs) into common stock17.2 — — — — — — — — 
March 31, 2023492.4 — 8,744 (954)134 (542)98 (310)7,480 
Net loss— — — (97)— — — — (97)
Other comprehensive income (loss), net of tax— — — — 29 2 (2)29 29 
Stock-based compensation activity, net0.2 — 8 — — — — — 8 
June 30, 2023492.6 — 8,752 (1,051)163 (540)96 (281)7,420 
Net loss— — — (1,096)— — — — (1,096)
Other comprehensive income (loss), net of tax— — — — — (197)(4)(201)(201)
Stock-based compensation activity, net0.1 — 11 — — — — — 11 
September 30, 2023492.7 $— $8,763 $(2,147)$163 $(737)$92 $(482)$6,134 

See accompanying notes to condensed consolidated financial statements.
2023 Q3 Form 10-Q | 7
Elanco Animal Health Incorporated
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Nine Months Ended September 30,
 20232022
Cash Flows from Operating Activities
Net loss$(1,090)$(24)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization523 514 
Goodwill impairment 1,042 — 
Stock-based compensation expense31 44 
Asset impairment and write-down charges5 81 
Proceeds from interest rate swap settlements57 207 
Changes in operating assets and liabilities, net of acquisitions
(446)(385)
Other non-cash operating activities, net(8)2 
Net Cash Provided by Operating Activities114 439 
Cash Flows from Investing Activities
Net purchases of property and equipment and software(99)(94)
Cash paid for acquisitions(19)— 
Purchases of intangible assets(14)(11)
Other investing activities, net(2)2 
Net Cash Used for Investing Activities(134)(103)
Cash Flows from Financing Activities
Proceeds from Revolving Credit Facility350 563 
Repayments of Revolving Credit Facility(53)(813)
Proceeds from Securitization Facility250 — 
Repayments of Securitization Facility(97)— 
Proceeds from issuance of long-term debt— 425 
Repayments of long-term borrowings(388)(607)
Other financing activities, net(6)(33)
Net Cash Provided by (Used for) Financing Activities56 (465)
Effect of exchange rate changes on cash and cash equivalents(12)(49)
Net increase (decrease) in cash and cash equivalents24 (178)
Cash and cash equivalents – beginning of period345 638 
Cash and cash equivalents – end of period$369 $460 

See accompanying notes to condensed consolidated financial statements.
2023 Q3 Form 10-Q | 8
Elanco Animal Health Incorporated
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Tables present dollars and shares in millions, except per-share and per-unit data)

Note 1. Basis of Presentation and Summary of Significant Accounting Policies
We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our 2022 Form 10-K. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period.
In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.
The significant accounting policies set forth in Note 4 to the consolidated financial statements in our 2022 Form 10-K appropriately represent, in all material respects, the current status of our accounting policies.
Revision of Previously Issued Consolidated Financial Statements
In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified and corrected relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. In conjunction with making these corrections, we made other adjustments to the prior years to revise uncorrected errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. Further information is included in Note 2 and Note 21 to the consolidated financial statements in our 2022 Form 10-K.

Note 2. Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:
StandardDescriptionEffective DateEffect on the Financial Statements or Other Significant Matters
ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope; ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.
Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements.

Note 3. Revenue
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligations, which is
2023 Q3 Form 10-Q | 9
generally once the goods have been shipped and the customer has assumed title. For contract manufacturing organization (CMO) arrangements, we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services.
We have a single customer that accounted for approximately 10% and 11% of revenue for the nine months ended September 30, 2023 and 2022, respectively. Product sales with this customer resulted in accounts receivable of $96 million and $73 million at September 30, 2023 and December 31, 2022, respectively.
Provisions for sales rebates and discounts are recorded as a reduction to revenue in the period the related sales are recognized and are based on specific agreements. In determining the appropriate accrual amount, we consider our historical experience with similar incentive programs, current sales data and estimates of inventory levels at our channel distributors. The following table summarizes the activity in our global sales rebates and discounts liability:
Nine Months Ended September 30,
20232022
Beginning balance$324 $319 
Reduction of revenue558 524 
Payments(522)(521)
Foreign currency translation adjustments(4)(18)
Ending balance$356 $304 
Adjustments to revenue recognized as a result of changes in estimates during the nine months ended September 30, 2023 and 2022 for product shipped in previous periods were not material. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2023 and 2022.
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Pet Health$495 $469 $1,688 $1,718 
Farm Animal:
Cattle242 227 700 722 
Poultry184 176 545 529 
Swine93 95 284 284 
Aqua42 47 132 132 
Total Farm Animal561 545 1,661 1,667 
Contract Manufacturing (1)
12 12 33 41 
Revenue$1,068 $1,026 $3,382 $3,426 
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party.
The following table summarizes our revenue disaggregated by geographic area:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
United States$479 $475 $1,522 $1,536 
International589 551 1,860 1,890 
Revenue$1,068 $1,026 $3,382 $3,426 

Note 4. Acquisitions, Divestitures and Other Arrangements
NutriQuest U.S. Acquisition
On January 3, 2023, we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest). NutriQuest is a provider of swine, poultry and cattle nutritional health products to animal producers. The acquisition allows us to expand our existing nutritional health offerings and furthers our efforts to explore innovative antibiotic alternatives.

2023 Q3 Form 10-Q | 10
The composition of the purchase price was as follows:
Up-front cash consideration$16 
Deferred cash consideration due January 4, 20245 
Fair value of contingent consideration37 
Total purchase consideration$58 
The NutriQuest acquisition was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date, with the excess of the purchase price over the fair value of the acquired assets recorded as goodwill. The determination of estimated fair value requires management to make significant estimates and assumptions. Contingent consideration for this acquisition includes up to $85 million of cash consideration payable if specific development, sales and geographic expansion milestones are achieved, as outlined in the asset purchase agreement. The initial fair value of this contingent consideration liability of $37 million was estimated at the acquisition date using a Monte Carlo simulation model, which represented a Level 3 measurement under the fair value measurement hierarchy (see Note 10. Fair Value for further information).
The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:
Inventories$3 
Intangible assets:
Marketed products29 
Acquired in-process research and development (IPR&D)10 
Other intangible assets15 
Total identifiable assets57 
Goodwill1 
Total consideration transferred$58 
Other intangible assets consist of customer relationships and trade names. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk and competitive trends impacting the asset and each cash flow stream, as well as other factors.
The accounting for this acquisition has not been finalized as of September 30, 2023. The purchase price allocation is preliminary and subject to change, including the valuation of the contingent consideration and intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. Revenue attributable to the NutriQuest acquisition for the nine months ended September 30, 2023, was approximately $16 million.
NutriQuest Brazil Acquisition
On August 1, 2023, we acquired certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil) for total purchase consideration of $19 million. The composition of the purchase price included cash paid on the closing date of approximately $3 million, with consideration payable through 2026 valued at approximately $16 million, a portion of which is contingent upon the continuation of certain terms and conditions set forth in the asset purchase agreement. The NutriQuest Brazil acquisition was accounted for as a business combination under the acquisition method of accounting.
The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:
Inventories$3 
Definite-lived intangible assets15 
Total identifiable assets18 
Goodwill1 
Total consideration transferred$19 
2023 Q3 Form 10-Q | 11
The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately nine years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach. The purchase price allocation for this acquisition is preliminary as of September 30, 2023, and subject to change, including the valuation of the intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. Neither revenue nor income before taxes included within our condensed consolidated statements of operations from NutriQuest Brazil were material for the three and nine months ended September 30, 2023.
Divestitures
Microbiome R&D platform carve-out
In April 2022, we signed an agreement to transfer assets associated with our microbiome R&D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retained a non-voting, minority stake in the company. In addition, we entered into transitional services agreements with the company for certain services. Assets transferred included intellectual property and laboratory equipment. The book values of those assets were not material. We recorded a gain on disposal of the assets of approximately $3 million during the year ended December 31, 2022.
Shawnee and Speke
During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx began manufacturing existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which was included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets.
Based on the terms of the agreements and cash proceeds received to date, as of September 30, 2023, we had a net receivable balance from TriRx of $73 million from the sales of Shawnee and Speke, which was included within other receivables on the condensed consolidated balance sheets. In May 2023, we entered into amendments to the agreements which effectively restructured the payment schedule related to the remaining amount owed. Under the terms of the amendments we expect to receive approximately $67 million of this receivable balance upon the earlier of the date on which certain conditions are met or in equal installments over a twelve-month period beginning January 31, 2024, with the remainder due within the next 12 months. We continue to assess the collectibility of these receivables from TriRx and continue to believe amounts owed are collectible. Further, we have rights to certain collateral in the event of a default and we continue to monitor the value of this collateral.
BexCaFe Arrangement
In June 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to Bexacat, an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, Consolidation, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. There is no minimum payout due on the contingent consideration and the maximum payout related to sales royalties is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&D asset because we concluded that it did not have an alternative future use.
During the nine months ended September 30, 2023, we paid $13 million to BexCaFe in connection with development/regulatory milestones achieved upon U.S. Food and Drug Administration (FDA) approval of the original new animal drug application for Bexacat in December 2022. Remaining contingent consideration liabilities of $35 million were included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2023.


2023 Q3 Form 10-Q | 12
Note 5. Asset Impairment, Restructuring and Other Special Charges
In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash impairment charges can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions.
Components of asset impairment, restructuring and other special charges were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Restructuring charges (credits)(1)
$— $— $— $(7)
Acquisition related charges(2)
11 27 86 77 
Asset impairments and other items (3)
5 (1)5 82 
Total expense$16 $26 $91 $152 
(1)Restructuring credits in 2022 related to adjustments resulting from the reversal of severance accruals associated with 2021 restructuring programs, resulting from final negotiations and certain restructured employees filling open positions.
(2)Acquisition related charges included transaction costs directly related to acquiring businesses, such as expenditures for banking, legal, accounting, consulting and other similar services, integration charges inclusive of system and process integration and product transfers, and independent company stand-up costs related to the implementation of new systems, programs and processes.
(3)Asset impairments during the third quarter of 2023 primarily related to the write-down of certain indefinite-lived intangible assets due to increases in the relevant discount rates. Asset impairments during 2022 included a charge of $59 million related to the write-off of an IPR&D asset with no alternative future use licensed from BexCaFe and a $22 million charge related to the finalization of the write-down upon sale of the Speke site (see Note 4. Acquisitions, Divestitures and Other Arrangements for further discussion on each of these items).
The changes in our restructuring reserves during the nine months ended September 30, 2023, were as follows:
Balance at December 31, 2022$36 
Cash paid(29)
Balance at September 30, 2023$7 
These reserves were included within other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain country-specific negotiations and regulations.

Note 6. Inventories
Inventories are stated at the lower of cost and net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted-average cost method.
Inventories consisted of the following:
September 30, 2023December 31, 2022
Finished products$831 $783 
Work in process772 683 
Raw materials and supplies145 130 
Total1,748 1,596 
Decrease to LIFO cost(58)(58)
Inventories$1,690 $1,538 

Note 7. Equity
Tangible Equity Unit (TEU) Offering
In January 2020, we issued 11 million in TEUs at the stated amount of $50 per unit. Total proceeds, net of issuance costs, were $528 million. The gross proceeds and deferred finance costs from the issuance of the TEUs were allocated 86% to equity (prepaid stock purchase contracts) and 14% to debt (TEU amortizing notes) based on the
2023 Q3 Form 10-Q | 13
relative fair value of the respective components of each TEU. The TEU prepaid stock purchase contracts were converted into shares of our common stock on February 1, 2023. Holders of our TEUs received 1.5625 shares of our common stock based on the maximum settlement rate for the applicable market value being below $32.00. In total, we issued approximately 17 million shares to holders in connection with the settlement.

Note 8. Debt
Long-term debt consisted of the following:
September 30, 2023December 31, 2022
Incremental Term Facility due 2025$175 $175 
Incremental Term Facility due 2028490 494 
Incremental Term Facility due 2029247 249 
Term Loan B due 20273,849 3,881 
Revolving Credit Facility (1)
297 — 
Securitization Facility (2)
153 — 
4.272% Senior Notes due 2023 (3)
— 344 
4.900% Senior Notes due 2028 (4)
750 750 
TEU Amortizing Notes due 2023 (5)
— 7 
Unamortized debt issuance costs(52)(64)
5,909 5,836 
Less current portion of long-term debt39 388 
Total long-term debt$5,870 $5,448 
(1)During the nine months ended September 30, 2023, we drew $350 million on our Revolving Credit Facility (subsequently repaying $53 million), both to fund working capital needs and to partially fund the repayment of the 4.272% Senior Notes due 2023 (see below for further information). Our Revolving Credit Facility provides up to $750 million in borrowing capacity (with incremental capacity if certain conditions are met), bears interest at Term SOFR plus 2.10% and matures in August 2025.
(2)In August 2023, we entered into a new secured term facility that is secured and collateralized by our U.S. Net Eligible Receivables Balance (see below for further information).
(3)We redeemed the 4.272% Senior Notes due 2023 in full in August 2023 (see below for further information).
(4)Subsequent to issuance in August 2018, the 4.900% Senior Notes due 2028 have been subject to interest rate increases related to credit rating agency downgrades. As of September 30, 2023, these notes bear interest at a rate of 6.650%.
(5)The TEU Amortizing Notes due 2023 matured on February 1, 2023 (see Note 7. Equity for further information).
2023 Financing
On August 3, 2023, we entered into a new secured term facility (the "Securitization Facility") that is secured and collateralized by our U.S. accounts receivable subject to certain adjustments (defined as the Net Eligible Receivables Balance within the applicable agreement). Of the maximum borrowing capacity under the Securitization Facility of $300 million, $250 million was drawn on August 3, 2023, based on our borrowing capacity on that date. Our borrowing capacity under the Securitization Facility is subject to fluctuation monthly based on the level of our borrowing base as reported to the lender, which is correlated to our U.S. Net Eligible Receivables Balances. The Securitization Facility requires monthly interest payments over its three-year term at a variable rate based on Term SOFR plus 125 basis points. The full, outstanding balance of the Securitization Facility is due on July 31, 2026. During the three months ended September 30, 2023, we utilized the proceeds from the Securitization Facility, in addition to a $100 million draw on our Revolving Credit Facility, to redeem in full the 4.272% Senior Notes due 2023. The early redemption of the 4.272% Senior Notes due 2023 satisfied all obligations and commitments thereunder. Subsequent to our initial $250 million draw on the Securitization Facility, $97 million was repaid, resulting in a balance of $153 million outstanding as of September 30, 2023. The Securitization Facility includes various covenants specific to the underlying composition of our U.S. accounts receivables portfolio.
As of September 30, 2023, approximately 76% of our long-term indebtedness bears interest at a fixed rate, including variable-rate converted to fixed-rate through the use of interest rate swaps (see Note 9. Financial Instruments for further information). We were in compliance with all of our debt covenants as of September 30, 2023.

Note 9. Financial Instruments
To manage our exposure to market risks, such as changes in foreign currency exchange rates and interest rates, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at
2023 Q3 Form 10-Q | 14
inception. We also assess at least quarterly thereafter whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Further, we do not offset derivative assets and liabilities on the condensed consolidated balance sheets. Our outstanding positions are discussed below.
Derivatives not designated as hedges
We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. As of September 30, 2023 and December 31, 2022, we had outstanding foreign exchange contracts with aggregate notional amounts of $864 million and $784 million, respectively.
The amounts of net gains (losses) on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Foreign exchange forward contracts (1)
$1 $(5)$2 $(20)
(1)These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.
Derivatives designated as hedges
To manage our exposure to variable interest rate risk, we utilize interest rate swap contracts to effectively convert our variable-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated our interest rate swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2 in the fair value hierarchy (see Note 10. Fair Value for further information).
Our outstanding forward-starting interest rate swaps had maturities ranging between 2023 and 2028, with aggregate notional amounts of $3,800 million and $3,050 million as of September 30, 2023 and December 31, 2022, respectively. In March 2023, we entered into new interest rate swap agreements with a combined notional amount of $1,000 million, which became effective on October 1, 2023, following the maturity of certain swaps with the same combined notional amount. Additionally, on May 1, 2023, we entered into new interest rate swap agreements with a combined notional amount of $750 million, which became effective on June 1, 2023, and mature in August 2028. Also, in September 2023, we took advantage of market opportunities to further restructure our interest rate swap portfolio (see below for further details). As of September 30, 2023, when factoring in the $3,800 million of variable rate debt converted to fixed-rate through the use of interest rate swaps (excluding the expected future reclassifications to interest expense, net of capitalized interest related to past interest rate swap settlements), the weighted-average effective interest rate on our outstanding indebtedness was 6.34%.
Additionally, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a series of cross-currency fixed interest rate swaps in September 2023 with a 1 billion CHF notional amount with tenors in 2027. These instruments were determined to be, and were designated as, effective economic hedges of net investments in our CHF denominated net assets. The fair values of these instruments were estimated based on quoted market values of similar hedges and is classified as Level 2 in the fair value hierarchy. Over the life of these instruments, gains or losses due to spot rate fluctuations will be recorded as cumulative translation adjustments, as a component of other comprehensive income (loss). Gains and losses within accumulated other comprehensive income (loss) will remain in accumulated other comprehensive income (loss) until either the sale or substantial liquidation of the hedged subsidiary.
The amounts of gains (losses) on derivatives designated as cash flow hedges and net investment hedges, net of tax, recorded in other comprehensive loss were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Forward-starting interest rate swaps$— $62 $(19)$179 
Cross-currency fixed interest rate swaps9 — 9 — 
2023 Q3 Form 10-Q | 15
During the three months ended September 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive loss included gains of $24 million and a gain of $75 million, net of tax, respectively, related to mark-to-market adjustments. During the nine months ended September 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive loss included gains of $57 million and $218 million, net of tax, respectively, related to mark-to-market adjustments.
As noted above, in September 2023, we took advantage of market opportunities to restructure $3,050 million of our interest rate swap portfolio by unwinding existing swaps and simultaneously entering into new agreements with the same notional amounts and tenors extending through 2026. As a result, we received cash settlements of $57 million in the aggregate. Also, in April 2022 and September 2022, we settled certain existing interest rate swaps and simultaneously entered into new agreements with the same notional amount and covering the same tenor. As a result, we received cash settlements of $207 million in the aggregate. The cash proceeds from these interest rate swap settlements were included in net cash from operating activities in the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022.
During the three months ended September 30, 2023 and 2022, we reclassified $35 million and $11 million of net gains, respectively, into interest expense, net of capitalized interest. During the nine months ended September 30, 2023 and 2022, we reclassified $94 million of net gains and $10 million of net losses, respectively, into interest expense, net of capitalized interest. Over the next 12 months, we expect to reclassify a gain of $120 million to interest expense, net of capitalized interest related to our derivatives designated as hedges.

Note 10. Fair Value
Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a framework that utilizes the inputs market participants use to determine the fair value of an asset or liability and establishes a fair value hierarchy to prioritize those inputs. Level 1 fair value measurements are based on quoted prices in active markets for identical assets or liabilities. We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. Our Level 3 fair value measurements, which include the value of contingent consideration as of September 30, 2023, are based on unobservable inputs based on little or no market activity.
The following table summarizes the fair value information at September 30, 2023 and December 31, 2022 for assets and liabilities measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt, for which fair value is disclosed on a recurring basis:
2023 Q3 Form 10-Q | 16
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2023
Recurring fair value measurements
Prepaid expenses and other - derivative instruments$64 $— $64 $— $64 
Other noncurrent assets - derivative instruments32 — 32 — 32 
Other noncurrent assets - investments with readily determinable fair value8 8 — — 8 
Other current liabilities - derivative instruments(61)— (61)— (61)
Other current liabilities - contingent consideration(16)— — (16)(16)
Other noncurrent liabilities - contingent consideration(33)— — (33)(33)
Financial instruments not carried at fair value
Long-term debt, including current portion(5,961)— (5,877)— (5,877)
December 31, 2022
Recurring fair value measurements
Prepaid expenses and other - derivative instruments$90 $— $90 $— $90 
Other noncurrent assets - derivative instruments10 — 10 — 10 
Other noncurrent assets - investments with readily determinable fair value7 7 — — 7 
Other current liabilities - derivative instruments(64)— (64)— (64)
Financial instruments not carried at fair value
Long-term debt, including current portion(5,900)— (5,711)— (5,711)
We also had investments without readily determinable fair values and equity method investments, which were classified as other noncurrent assets on our condensed consolidated balance sheets totaling $28 million and $27 million as of September 30, 2023 and December 31, 2022, respectively. These investments are not recorded at fair value on a recurring basis, and as such, are not included in the fair value table above.
Of the total value of the contingent consideration liabilities at September 30, 2023, $42 million related to our acquisition of certain assets from NutriQuest during the first quarter of 2023 (see Note 4. Acquisitions, Divestitures and Other Arrangements for further information). We may pay up to $85 million in cash consideration related to this acquisition, which is contingent upon the achievement of specific development, sales and geographic expansion milestones, as outlined in the asset purchase agreement. The fair values of these liabilities at September 30, 2023, were estimated using the Monte Carlo simulation model, consisting of Level 3 inputs not observable in the market, including estimates relating to revenue forecasts, discount rates and volatility.

Note 11. Goodwill
The following table summarizes the changes in the carrying amount of goodwill:
Balance as of December 31, 2022$5,993 
     Additions related to acquisitions2 
     Impairment charge(1,042)
     Foreign currency translation adjustments(51)
Balance as of September 30, 2023$4,902 
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. Goodwill is not amortized, but is reviewed for
2023 Q3 Form 10-Q | 17
impairment at least annually on October 1, or more frequently if certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment.
Given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. Accordingly, we performed an interim quantitative goodwill impairment test, which resulted in a $1,042 million pre-tax impairment charge. The fair value of our single reporting unit was determined using the income approach, based on a discounted cash flow model. Significant management judgment was required in estimating our reporting unit’s fair value, including, but not limited to, estimates and assumptions regarding future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these judgments based on historical experience, relevant market size, historical pricing and expected industry trends. While we believe our estimates and assumptions underlying the September 30, 2023, interim goodwill impairment test were reasonable in view of all available information, future changes in our discount rate, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on the estimated fair value of our reporting unit, exposing us to further goodwill impairment losses.

Note 12. Income Taxes
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Income tax (benefit) expense$(1)$21 $22 $41 
Effective tax rate0.2 %(47.7)%(2.0)%234.3 %
For the three and nine months ended September 30, 2023, we recognized an income tax benefit of $1 million and income tax expense of $22 million, respectively. Our effective tax rates of 0.2% and (2.0)%, respectively, differ from the statutory income tax rates primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions.
For the three and nine months ended September 30, 2022, we recognized income tax expense of $21 million and $41 million, respectively. Our effective tax rates of (47.7)% and 234.3%, respectively, differ from the statutory income tax rate primarily due to the mix of earnings between periods resulting in projected losses in the U.S. and for various other foreign affiliates for which there was no tax benefit, as valuation allowances had been established in those jurisdictions. Income tax expense for the nine months ended September 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps.
We were included in Eli Lilly and Company's (Lilly's) U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in 2019 and remains ongoing.

Note 13. Commitments and Contingencies
Legal Matters
We are party to various legal actions that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded when it is deemed probable that we will incur a loss and we can formulate a reasonable estimate of that loss.
Seresto Class Action Lawsuits and EPA Safety Review
Claims seeking actual damages, injunctive relief and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the Seresto collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. In June 2023, the parties agreed on the monetary terms of a potential settlement of the consolidated class action lawsuits, and as a result, a charge of $15 million was recorded during the three months ended June 30, 2023. The parties must still reach agreement on non-monetary terms, and any settlement, if reached, is subject to approval by the court, and likely will be subject to other conditions. This $15 million provision was included within other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2023.
2023 Q3 Form 10-Q | 18
Also, in January 2023, a lawsuit seeking damages for alleged negligence, breach of statutory regulations, breach of statutory duties and deceptive marketing was filed in Israel against Elanco and other parties, arising out of the use of Seresto and Foresto™ flea and tick collars for cats and dogs that are marketed and sold in Europe and in Israel. We intend to defend our position vigorously, and as of the date of this filing, we are unable to estimate the probability of loss or range of loss, if any.
Seresto is a pesticide registered with the U.S. Environmental Protection Agency (the EPA). In April 2021, a non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. In response to the EPA's request for comments from the public on the petition, we submitted a comment to the EPA supporting the safety profile of Seresto and engaged in discussions with the EPA. On July 13, 2023, the EPA announced their completion of a comprehensive, multi-year review, with support from the FDA, of the Seresto flea and tick collar and confirmed the continued registration of the collar, denying the citizen's petition. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA registered pet products. Based on comprehensive data from the review, the EPA concluded that Seresto continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose unreasonable risk of harm.
Additional Legal Matters
For the litigation matters discussed below we either believe loss is not probable or are unable to estimate the possible loss or range of loss, if any. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolutions cannot be predicted. As of September 30, 2023 and December 31, 2022, we had no material liabilities established related to the litigation matters mentioned below.
On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives and other individuals. The lawsuit alleged, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit sought unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. On January 13, 2021, we filed a motion to dismiss, and on August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint. On December 7, 2022, we filed an opposition to the plaintiffs' motion, and on September 27, 2023, the Court denied the plaintiffs' motion for leave, issuing final judgment in favor of Elanco. On October 25, 2023, the plaintiffs filed a notice of appeal to the United Stated Court of Appeals for the Seventh Circuit. We continue to believe the claims made in the case are meritless, and we intend to continue to vigorously defend our position.
On October 16, 2020, a shareholder class action lawsuit captioned Saffron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives and other individuals and entities. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or TEUs issued in connection with the public offering. From February 2021 to August 2022, this case was stayed in deference to Hunter v. Elanco Animal Health Inc. On October 24, 2022, we filed a motion to dismiss. On December 23, 2022, the plaintiffs filed their opposition to the motion to dismiss. Prior to the ruling on the motion to dismiss, on June 8, 2023, the plaintiffs filed a motion for leave to file a second amended complaint, which is now the operative complaint. We filed a motion to dismiss the complaint on August 7, 2023, to which the plaintiff filed their opposition on October 13, 2023. We continue to believe the claims made in the case are meritless, and we intend to vigorously defend our position.
In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful, exclusive dealing and tying of its flea and tick products Advantage, Advantix and Seresto and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive
2023 Q3 Form 10-Q | 19
dealing related to Advantage and Advantix and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. The trial is scheduled for July 2024. We intend to defend our position vigorously.
Regulatory Matters
On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. We have recently engaged in discussions with the SEC about a possible resolution or settlement of potential disclosure claims, but there can be no assurance that a resolution or settlement will be reached. Management continues to believe that its actions were appropriate. We are unable to estimate the range of any reasonably possible loss associated with this matter.
Other Commitments
As of September 30, 2023, we had a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025.
The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. During 2022, we refunded approximately $15 million of the TIF proceeds to the developer. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive was included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning on the commencement date and offset future rent expense.

Note 14. Earnings Per Share
We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted-average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements. We also had variable common stock equivalents related to the TEU prepaid stock purchase contracts during the three and nine months ended September 30, 2022, and in the first quarter of 2023 through the settlement date of February 1, 2023 (see Note 7. Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards converted their holdings into common stock and that could have occurred if holders of unsettled TEUs had converted their holdings into common stock prior to the February 1, 2023 settlement date. The weighted-average number of potentially dilutive shares outstanding was calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) were considered to be anti-dilutive and as such, these shares were not included in the calculation of diluted loss per share.
Basic and diluted weighted-average shares outstanding were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Determination of shares:
Basic weighted-average common shares outstanding (1)
492.7 488.4492.1 488.3
Assumed conversion of dilutive common stock equivalents (2)
— — — — 
Diluted weighted-average shares outstanding492.7 488.4492.1 488.3
(1)The TEU prepaid stock purchase contracts were convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares. The minimum 14.3 million shares were included in the calculation of basic weighted-average shares from January 22, 2020 to February 1, 2023. The 17.2 million shares that were ultimately issued were included in the calculation of basic weighted-average shares subsequent to the settlement date of February 1, 2023.
(2)For the three months ended September 30, 2023 and 2022, approximately 2.7 million and 4.4 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2023 and 2022, approximately 2.7 million and 2.6 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.
2023 Q3 Form 10-Q | 20
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction
Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Form 10-Q. Certain statements in this Item 2 of Part I of this Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" of this Form 10-Q, in Item 1A, "Risk Factors" of Part II of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our 2022 Form 10-K, may cause our actual results, financial position and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.
Business Overview
Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives. We advance our vision by offering products in the Pet Health and Farm Animal product categories.
We offer a diverse portfolio of approximately 200 brands that make us a trusted partner to pet owners, veterinarians and farm animal producers. Our products are generally sold worldwide to third-party distributors and independent retailers and directly to farm animal producers and veterinarians. With the acquisition of Bayer Animal Health in 2020, we expanded our presence in retail and e-commerce channels, allowing our customers to shop where and how they want.
Key Trends and Factors Affecting Our Results of Operations
Acquisition and Integration Activity: To date in 2023, we have acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest) and certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil). Additionally, as previously disclosed, in April 2023, we successfully completed the integration of the Bayer Animal Health business into Elanco's Enterprise Resource Planning (ERP) system. During the nine months ended September 30, 2023, we incurred costs totaling $86 million related to integration activities, including the build out of processes and systems to support our global organization. We anticipate some additional costs through early 2024 as we finalize these integration activities.
Macroeconomic Factors: Our operations are exposed to and are impacted by various global macroeconomic factors. We face continuing market and operating challenges across the globe due to, among other factors, the Russia-Ukraine conflict, conditions related to the COVID-19 pandemic, supply chain disruption, higher interest rates and inflationary pressures. Continued evolution of these conditions has led to economic slowdowns in certain countries and/or regions and volatility in consumer behavior. Additionally, as discussed in more detail below, the continued rise in interest rates throughout the year, specifically in long-term treasury rates in the third quarter, led to a $1,042 million pre-tax impairment charge as of September 30, 2023. We anticipate global macroeconomic pressures to continue beyond 2023.
Russia-Ukraine Conflict: As a global animal health leader, we have an obligation to support the health of animals and people. At the center of that work is ensuring access and availability of food and avoiding the spread of disease. At this time, we are limiting our business in Russia to only the essential products that support these needs, while complying with all imposed sanctions. We do not currently manufacture products in Russia, but we continue to support the health of animals and people in the country. We have entered into an agreement pursuant to which we will supply raw material inventories to an entity in Russia that will manufacture its own products, which we will then distribute, because of new laws requiring products sold in Russia to be produced there as well. We do not conduct business with the Russian government. During the nine months ended September 30, 2023, revenue from Russian and Ukrainian customers represented approximately 1% of our consolidated revenue. Assets held in Russia as of September 30, 2023, represented less than 1% of our consolidated assets.
2023 Q3 Form 10-Q | 21
Seasonality: While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. For example, based upon historical results, approximately 75% and 60% of total annual revenue contributed by our higher-margin parasiticide products Seresto and Advantage Family, respectively, typically occurs during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere.
Product Development and Regulatory Update
A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we develop internally and may develop with partners and products that we are able to obtain through licenses or acquisitions, and the life cycle management of our existing products. We believe we are an industry leader in animal health R&D, with a track record of successful product innovation, business development and commercialization. For example, in July 2023, we launched our canine parvovirus monoclonal antibody in the U.S. after receiving conditional approval from the U.S. Department of Agriculture. This product is the first and only approved therapeutic solution to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract.
Seresto: On July 13, 2023, the EPA announced its completion of a comprehensive, multi-year review, with support from the FDA, of the Seresto flea and tick collar and confirmed the continued registration of the collar. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA-registered pet products. Based on comprehensive data from the study, the EPA concluded that Seresto continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose an unreasonable risk of harm. We believe the EPA's conclusions align with those of authorities worldwide, with Seresto being approved for use in more than 80 countries and supported by veterinary professionals around the globe. The robust scientific evidence continues to support Seresto's safe use.
Goodwill Impairment Charge
Given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. Accordingly, we performed an interim quantitative goodwill impairment test. Significant management judgment was required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that were used in the discounted cash flow method of valuation. These included, but were not limited to, estimates and assumptions regarding our future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these significant judgments based on our historical experience, relevant market size, historical pricing and expected industry trends.
Due principally to the sharp increase in long-term treasury rates in the third quarter of 2023, which led to an increased discount rate assumption relative to prior interim assessments, our quantitative test resulted in a $1,042 million pre-tax impairment charge. While we believe the estimates and assumptions underlying our goodwill impairment test were reasonable in view of all available information, future changes in our discount rate assumption, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on our reporting unit's estimated fair value and may expose us to further goodwill impairment losses. For additional information regarding this goodwill impairment, see Note 11. Goodwill to the condensed consolidated financial statements.

Results of Operations
The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.
Revision of Prior Period Financial Statements Primarily Relating to Tax Valuation Allowance Adjustment
In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. As a result of having to make the revisions related to this error, we made other immaterial revisions to our 2022 unaudited interim consolidated financial statements. All of the revisions have been reflected throughout this Form 10-Q.

2023 Q3 Form 10-Q | 22
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Revenue $1,068 $1,026 4 %$3,382 $3,426 (1)%
Costs, expenses and other:
Cost of sales487 472 3 %1,415 1,465 (3)%
% of revenue46 %46 %— %42 %43 %(1)%
Research and development86 78 10 %248 241 3 %
% of revenue8 %8 %— %7 %7 %— %
Marketing, selling and administrative313 298 5 %993 963 3 %
% of revenue29 %29 %— %29 %28 %1 %
Amortization of intangible assets140 128 9 %410 398 3 %
% of revenue13 %12 %1 %12 %12 %1 %
Asset impairment, restructuring and other special charges16 26 (38)%91 152 (40)%
Goodwill impairment1,042 — 100 %1,042 — 100 %
Interest expense, net of capitalized interest72 60 20 %210 179 17 %
Other expense, net9 8 13 %41 11 NM
(Loss) income before income taxes(1,097)(44)NM(1,068)17 NM
% of revenue(103)%(4)%NM(32)%— %NM
Income tax (benefit) expense(1)21 NM22 41 NM
Net loss$(1,096)$(65)NM$(1,090)$(24)NM
Certain amounts and percentages may reflect rounding adjustments.
NM - Not meaningful
Revenue
As a global company, our products are sold in more than 90 countries, and as a result, significant portions of our revenue and expenses are recorded in currencies other than the U.S. dollar. As a result, our revenue is influenced by changes in foreign exchange rates. During the nine months ended September 30, 2023 and 2022, approximately 51% of our revenue was denominated in foreign currencies. Foreign currency movements decreased revenue by 1% and 2% for the three and nine months ended September 30, 2023, respectively, compared to the same periods in 2022.
Further, increases or decreases in inventory levels in our distribution channels can positively or negatively impact our quarterly revenue results, leading to variations in revenue. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our control.
On a global basis, our revenue by product category for the three and nine months ended September 30, 2023 and 2022 is summarized as follows:
Three Months Ended September 30,
Revenue% of Total RevenueIncrease (Decrease)
(Dollars in millions)2023202220232022$ Change% Change
CC (1)
Pet Health$495 $469 46 %46 %$266 %6 %
Farm Animal561 545 53 %53 %163 %4 %
Subtotal1,056 1,014 99 %99 %424 %5 %
Contract Manufacturing (2)
12 12 1 %1 %—— %(2)%
Total$1,068 $1,026 100 %100 %424 %5 %
2023 Q3 Form 10-Q | 23

Nine Months Ended September 30,
Revenue% of Total RevenueIncrease (Decrease)
(Dollars in millions)2023202220232022$ Change% Change
CC (1)
Pet Health$1,688 $1,718 50 %50 %$(30)(2)%— %
Farm Animal1,661 1,667 49 %49 %(6)— %2 %
Subtotal3,349 3,385 99 %99 %(36)(1)%1 %
Contract Manufacturing (2)
33 41 1 %1 %(8)(20)%(18)%
Total$3,382 $3,426 100 %100 %(44)(1)%1 %
Note: Numbers may not add due to rounding
(1)Constant Currency (CC), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange rates. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.
(2)Represents revenue from arrangements in which we manufacture products on behalf of a third-party.
The effects of price, foreign exchange rates and volume on changes in revenue for the three and nine months ended September 30, 2023 were as follows:
Three months ended September 30, 2023
(Dollars in millions)

Revenue		PriceFX RateVolumeTotalCC
Pet Health$495 4%—%2%6%6%
Farm Animal561 3%(1)%1%3%4%
Subtotal1,056 4%(1)%1%4%5%
Contract Manufacturing12 —%2%(2)%—%(2)%
Total$1,068 4%(1)%1%4%5%
Nine months ended September 30, 2023
(Dollars in millions)

Revenue		PriceFX RateVolumeTotalCC
Pet Health$1,688 5%(2)%(5)%(2)%—%
Farm Animal1,661 4%(2)%(2)%—%2%
Subtotal3,349 4%(2)%(3)%(1)%1%
Contract Manufacturing33 —%(2)%(18)%(20)%(18)%
Total$3,382 4%(2)%(3)%(1)%1%
Note: Numbers may not add due to rounding
Pet Health revenue increased $26 million, or 6%, for the three months ended September 30, 2023, compared to the same period in 2022, driven primarily by increased pricing, improved market conditions in Europe impacting parasiticide sales and improved supply for vaccines in the U.S. These factors were partially offset by competitive pressure on certain products in the U.S. veterinary channel. Pet Health revenue decreased $30 million, or 2%, for the nine months ended September 30, 2023, compared to the same period in 2022, driven by the unfavorable impact of foreign exchange rates and lower volumes, partially offset by increased pricing. For the nine months ended September 30, 2023, lower volumes were attributable to declines in demand for retail parasiticide products in Spain and continued competitive pressure on certain parasiticide products in the U.S. These factors were partially offset by higher demand for pain and over-the-counter products in the U.S. and increased revenue from new products.
Farm Animal revenue increased $16 million, or 3%, for the three months ended September 30, 2023, compared to the same period in 2022, driven by increased pricing and higher volumes, partially offset by an unfavorable impact from foreign exchange rates. Increased volumes were driven by revenue from new products, led by Experior, and strength in European poultry, partially offset by regulatory changes impacting cattle implant products and timing of U.S. poultry rotations. Farm Animal revenue decreased $6 million, flat on a percentage basis, for the nine months ended September 30, 2023, compared to the same period in 2022, impacted by lower volumes and the unfavorable impact of foreign exchange rates, which were offset by increased pricing. Lower volumes for the nine months ended September 30, 2023, were attributable to supply disruptions in U.S. cattle vaccines, reduced sales of cattle implants due to U.S. regulatory changes, timing of poultry rotations in the U.S. and generic competition. These factors were partially offset by increased revenue from new products, led by Experior, and strength in European poultry and Aqua.

2023 Q3 Form 10-Q | 24

Cost of Sales
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Cost of sales$487 $472 3 %$1,415 $1,465 (3)%
% of revenue46 %46 %42 %43 %
Cost of sales increased $15 million for the three months ended September 30, 2023, primarily due to higher volume compared to the same period in the prior year, while cost of sales as a percentage of revenue was flat year over year. Product price increases and the impact of foreign exchange rates on international inventories sold were largely offset by inflation and planned reduced throughput at certain manufacturing sites in support of efforts to reduce inventory balances and improve cash conversion.
Cost of sales decreased $50 million for the nine months ended September 30, 2023, primarily due to lower volume compared to the same period in the prior year. Cost of sales as a percentage of revenue decreased from 43% for the nine months ended September 30, 2022, to 42% for the nine months ended September 30, 2023, due to a combination of product price increases and the impact of foreign exchange rates on international inventories sold, partially offset by inflation and planned reduced throughput at certain manufacturing sites in support of efforts to reduce inventory balances and improve cash conversion.
Research and Development
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Research and development$86 $78 10 %$248 $241 3 %
% of revenue8 %8 %7 %7 %
Research and development expenses increased $8 million and $7 million for the three and nine months ended September 30, 2023, respectively, as compared to the same periods in the prior year, primarily driven by higher employee-related expenses, project costs and the unfavorable impact of foreign exchange rates impacting our European research and development sites.
Marketing, Selling and Administrative
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Marketing, selling and administrative$313 $298 5 %$993 $963 3 %
% of revenue29 %29 %29 %28 %
Marketing, selling and administrative expenses increased $15 million and $30 million for the three and nine months ended September 30, 2023, respectively, compared to the same periods in the prior year, primarily driven by increases in marketing and promotional spend, primarily supporting the U.S. Pet Health business, employee-related expenses and travel and meeting expenses.
Amortization of Intangible Assets
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Amortization of intangible assets$140 $128 9 %$410 $3983 %
Amortization of intangible assets increased $12 million for the three and nine months ended September 30, 2023, compared to the same periods in the prior year, due to the addition of amortization of intangible assets recorded from the acquisitions of certain assets of NutriQuest and NutriQuest Brazil during the current year, as well as the impact of foreign exchange rates, primarily during the three months ended September 30, 2023.
Asset Impairment, Restructuring and Other Special Charges
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Asset impairment, restructuring and other special charges$16 $26 (38)%$91 $152(40)%
Asset impairment, restructuring and other special charges decreased $10 million for the three months ended September 30, 2023, compared to the prior year, primarily due to lower integration costs in the current year associated with the implementation of new systems, programs and processes resulting from the integration of Bayer
2023 Q3 Form 10-Q | 25
Animal Health. Asset impairment, restructuring and other special charges decreased $61 million for the nine months ended September 30, 2023, compared to the prior year, primarily due to the $59 million charge related to the expensing of an IPR&D asset licensed from BexCaFe during the prior year, which did not recur in the current year.
For additional information regarding our asset impairment, restructuring and other special charges, see Note 5. Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.
Goodwill Impairment
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Goodwill impairment$1,042 $— NM$1,042 $—NM
We performed interim quantitative goodwill impairment tests as of September 30, 2023 and 2022. Our interim impairment test as of September 30, 2022, indicated no goodwill impairment, nor have any of the subsequent qualitative assessments through June 30, 2023. However, as discussed above, due principally to the sharp increase in long-term treasury rates in the third quarter of 2023, which led to an increased discount rate assumption, our quantitative impairment test resulted in a $1,042 million pre-tax impairment charge at September 30, 2023. For additional information regarding this goodwill impairment, see Note 11. Goodwill to the condensed consolidated financial statements.
Interest Expense, Net of Capitalized Interest
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Interest expense, net of capitalized interest$72 $60 20 %$210 $17917 %
Interest expense, net of capitalized interest increased $12 million and $31 million for the three and nine months ended September 30, 2023, respectively, compared to the same periods in the prior year, primarily due to higher interest rates on our outstanding variable-rate debt and rate increases on our Senior Notes driven by credit downgrades. The increase for the nine months ended September 30, 2023, compared to the prior year, was partially offset by $19 million of debt extinguishment charges recorded in 2022, which did not recur in the current year.
Other expense, net
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Other expense, net$9 $8 13 %$41 $11NM
Other expense, net for the three months ended September 30, 2023, primarily consisted of foreign exchange losses, inclusive of devaluation losses related to the hyperinflationary environments in Turkey and Argentina, in addition to an increase in the contingent consideration liability related to the NutriQuest acquisition. The increase due to these items was partially offset by milestone income related to a license agreement. Other expense, net for the nine months ended September 30, 2023, also consisted of a settlement provision of $15 million recorded in June 2023 related to the Seresto class action lawsuits (see Note 13. Commitments and Contingencies for further information) and mark-to-market adjustments on equity investments.
Income tax (benefit) expense
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20232022% Change20232022% Change
Income tax (benefit) expense$(1)$21 NM$22 $41(46)%
Effective tax rate0.2 %(47.7)%(2.0)%234.3 %
We recognized an income tax benefit of $1 million for the three months ended September 30, 2023, compared to income tax expense of $21 million in the same period of the prior year. The effective tax rate was 0.2% for the three months ended September 30, 2023, as compared to the prior year effective tax rate of (47.7)%, and differed from the statutory income tax rate primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions.
Income tax expense decreased $19 million for the nine months ended September 30, 2023, compared to the same period in the prior year, and the effective tax rate decreased to (2.0)%, compared to 234% in the prior year period. This decrease in the effective tax rate was primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions. Income tax expense and the effective tax rate for the nine months ended September 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps during the nine months ended September 30, 2022.
2023 Q3 Form 10-Q | 26

Liquidity and Capital Resources
Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, the income taxes associated with transferring cash to the U.S. We intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our business evolves, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.
We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations, such as principal and interest payments, as well as interest rate swaps, operating lease payments, purchase obligations and costs associated with business integrations. As of September 30, 2023, we had cash and cash equivalents of $369 million and unused borrowing capacity on our Revolving Credit Facility of approximately $453 million. In addition, we have the ability to access capital markets to obtain debt financing for longer-term funding, if required. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.
Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As market conditions change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful" in Part I of our 2022 Form 10-K.
Cash Flows
The following table provides a summary of cash flows from operating, investing and financing activities for the nine months ended September 30, 2023 and 2022:
(Dollars in millions)Nine Months Ended September 30,
Net cash provided by (used for):20232022$ Change
Operating activities$114 $439 $(325)
Investing activities(134)(103)(31)
Financing activities56 (465)521 
Effect of exchange-rate changes on cash and cash equivalents(12)(49)37 
Net increase (decrease) in cash and cash equivalents$24 $(178)$202 
Operating activities
Cash provided by operating activities decreased $325 million to $114 million for the nine months ended September 30, 2023, compared to $439 million for the nine months ended September 30, 2022. The decrease in cash from operating activities primarily related to a larger net loss, changes in operating assets and liabilities and a decrease of $150 million of proceeds from interest rate swap settlements year-over-year.
Investing activities
Cash used for investing activities was $134 million for the nine months ended September 30, 2023, compared to $103 million for the nine months ended September 30, 2022. The increase in cash used for investing activities was primarily driven by cash paid for the acquisitions of certain assets of NutriQuest and NutriQuest Brazil of $19 million during the nine months ended September 30, 2023.
Financing activities
Cash provided by financing activities was $56 million for the nine months ended September 30, 2023, compared to cash used for financing activities of $465 million for the nine months ended September 30, 2022. Cash provided by financing activities during the nine months ended September 30, 2023, reflected proceeds of $350 million from our Revolving Credit Facility, and $250 million from our Securitization Facility, largely offset by $388 million of repayments of long-term borrowings, inclusive of the $344 million repayment of our 4.272% Senior Notes due 2023, as well as repayments of $53 million on our Revolving Credit Facility and $97 million on our Securitization Facility. Cash used for financing activities of $465 million during the nine months ended September 30, 2022, primarily reflected the tender offer completed during the period, as well as net repayments on our Revolving Credit Facility
2023 Q3 Form 10-Q | 27
and the repayment of indebtedness outstanding under our term loan B credit facility, partially offset by proceeds from the issuance of our incremental term facilities.
Description of Indebtedness
For a complete description of our existing debt and available credit facilities as of September 30, 2023 and December 31, 2022, see Note 10. Debt within Item 8, “Financial Statements and Supplementary Data,” of Part II of our 2022 Form 10-K. New developments are discussed in Note 8. Debt of this Form 10-Q.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our 2022 Form 10-K. There were no significant changes or developments in the application of our critical accounting policies during the nine months ended September 30, 2023.
Goodwill Impairment Testing
We evaluate goodwill for impairment on an annual basis and when certain qualitative impairment indicators are present that would more likely than not reduce the fair value of our single reporting unit below its carrying amount.
In the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a goodwill impairment review. Based on our qualitative assessment, we concluded it was more likely than not that the fair value of our single reporting unit was less than its carrying value, and therefore, we performed a quantitative goodwill impairment test, which involved comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimated the fair value of our single reporting unit using the income approach, concluding that the fair value of our single reporting unit exceeded the carrying amount by more than 20% as of September 30, 2022, and, therefore, no impairment existed with respect to our goodwill. Given that our market capitalization remained lower than our book value, we reevaluated our impairment testing from a qualitative perspective on a quarterly basis, with no change to our previous conclusion that no impairment existed through June 30, 2023. However, given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. As part of this assessment, we concluded it was more likely than not that the fair value of our single reporting unit was below its carrying amount, and as such, we performed an interim quantitative goodwill impairment test.
Significant management judgment was required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that were used in the discounted cash flow method of valuation. These included, but were not limited to, estimates and assumptions regarding our future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these judgments based on our historical experience, relevant market size, historical pricing and expected industry trends. These assumptions are subject to change in future periods because of, among other things, additional information, financial information based on further historical experience, changes in competition, our investment decisions, volatility in foreign currency exchange rates, results of research and development and changes in macroeconomic conditions, including rising interest rates and inflation.
Due principally to the sharp increase in long-term treasury rates in the third quarter of 2023, which led to an increased discount rate assumption relative to prior interim assessments, our quantitative goodwill impairment test resulted in a $1,042 million pre-tax impairment charge as of September 30, 2023. While we believe the estimates and assumptions underlying our goodwill impairment test were reasonable in view of all available information, future changes in our discount rate assumption, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on our reporting unit's estimated fair value and may expose us to further goodwill impairment losses.

2023 Q3 Form 10-Q | 28
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Foreign Exchange Risk
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.
We generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. Since 2018, we have concluded that our Argentina subsidiary is operating in a hyperinflationary market. As a result, we applied hyperinflationary accounting for our Argentina subsidiary and changed the functional currency to the U.S. dollar. During the first quarter of 2022, Turkey’s three-year cumulative inflation rate also exceeded 100%, and as such, we concluded that Turkey became a hyperinflationary economy for accounting purposes. As of April 1, 2022, we applied hyperinflationary accounting for our subsidiary in Turkey and changed its functional currency to the U.S. dollar. During the nine months ended September 30, 2023, revenue in Argentina and Turkey each represented less than 1% of our consolidated revenue, while assets held in Argentina and Turkey as of September 30, 2023, each represented less than 1% of our consolidated assets.
The application of hyperinflationary accounting for our subsidiaries in Argentina and Turkey has resulted in approximately $13 million of foreign currency related expense during the nine months ended September 30, 2023, which was included within other expense, net in the condensed consolidated statements of operations. In the future, we may incur larger currency devaluations, which could have a material adverse impact on our results of operations.
Interest Risk
Effective April 1, 2023, we transitioned the reference rates used in our credit facilities so that, as a result, our variable-rate debt is now exclusively indexed to Term SOFR. At September 30, 2023, we held interest rate swap agreements with a notional value of $3,800 million that had the economic effect of modifying this amount of our variable-rate debt to fixed-rate. When including variable-rate converted to fixed-rate through the use of interest rate swaps, as of September 30, 2023, approximately 76% of our long-term indebtedness bore interest at a fixed rate.

ITEM 4. CONTROLS AND PROCEDURES
(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized and reported on a timely basis.
Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2023. As disclosed in Item 9A of Part II of our 2022 Form 10-K, management concluded that a material weakness existed as of December 31, 2022, resulting from the ineffective review of the annual income tax provision, including the valuation allowance related to deferred tax assets. We have developed and are implementing a remediation plan which requires the effective operation of certain quarterly and annual controls. Therefore, the material weakness cannot be fully remediated until we assess the effectiveness of our internal control over financial reporting for the year ending December 31, 2023. Based on this evaluation, the chief executive officer and the chief financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures remained ineffective.
(b)Changes in Internal Controls. During the third quarter of 2023, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than the aforementioned material weakness.


2023 Q3 Form 10-Q | 29
PART II

ITEM 1. LEGAL PROCEEDINGS
See Note 13. Commitments and Contingencies to the condensed consolidated financial statements for a summary of our legal proceedings, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS
Our risk factors are documented in Item 1A of Part I of our 2022 Form 10-K, which is incorporated herein by reference. Other than the revisions set forth below, there have been no material changes from the risk factors previously disclosed in the 2022 Form 10-K.
The following risk factors have been changed from the risk factors that were previously disclosed:
Unanticipated safety, quality or efficacy concerns or identified concerns associated with our products may harm our reputation and have an adverse impact on our performance.
Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not scientifically or clinically supported, potentially leading to product recalls, withdrawals or suspended or reduced sales, as well as product liability and other claims. Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a product’s sales.
For example, lawsuits seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been filed against us arising out of the use of Seresto, a non-prescription flea and tick collar for cats and dogs, based on media reports alleging that the collar has caused injury and death to pets. Further, in 2021, the U.S. House of Representatives' then-subcommittee chair requested that we produce certain documents and information related to the Seresto collar, made a request to temporarily remove Seresto collars from the market and, during a hearing at which our President and Chief Executive Officer (CEO) testified, again called for removal of the collars from the market.
Since that time, on July 13, 2023, the EPA announced the completion of its comprehensive, multi-year review of the Seresto flea and tick collar and confirmed the continued registration of the collar. However, if any similar claims with respect to our products are resolved adversely to us, or if a regulatory agency determines that a recall or cancellation of registrations of any of our products is necessary, such action could cause harm to our reputation, reduce our product sales, result in monetary penalties and other costly remedies against us, and could therefore have a material adverse effect on our business, financial condition and results of operations.
In addition, we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products in general, by food producers, veterinarians and pet owners. Any concern as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns, including those relating to Seresto, and the related harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of whether such reports are accurate.
Changes in our credit rating could increase our interest expense and restrict our access to, and negatively impact the terms of, current or future financings or trade credit.
Credit rating agencies continually revise their ratings for the companies that they follow, including us. Credit rating agencies also evaluate our industry as a whole and may change their credit ratings for us based on their overall view of our industry. We cannot be sure that credit rating agencies will maintain their ratings on us and certain of our debt. The acquisition of Bayer Animal Health had a negative impact on our credit ratings, leading to higher borrowing expenses. Additionally, S&P, Moody's and Fitch downgraded our credit ratings in February, March and April 2023, respectively. Because the ratings of certain of our senior unsecured notes have been downgraded, we have been required to pay additional interest under the senior unsecured notes. Any further downgrades could result in requirements to pay additional interest under the 4.900% Senior Notes due 2028. Moreover, any decision to downgrade our ratings could restrict our access to, and negatively impact the terms of, current or future financings and trade credit extended by our suppliers of raw materials or other vendors.
Changes in interest rates may adversely affect our earnings and/or cash flows.
During the first quarter of 2023, certain of our credit facilities bore interest at variable interest rates that used the London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we transitioned the reference rate used in our credit facilities from LIBOR to Term SOFR.
2023 Q3 Form 10-Q | 30
Term SOFR measures the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. While this change did not have a material impact on our condensed consolidated financial statements, we continue to be exposed to the risk of rising interest rates, given our level of variable-rate indebtedness. Term SOFR rate increases over the course of 2023 have led to an increase in both our interest expense and cash paid for interest. Additionally, the increased interest rate environment, particularly long-term treasury rates, played a critical role in the goodwill impairment charge of $1,042 million we recorded during the third quarter of 2023. Any further increases in Term SOFR or other benchmark rates, including long-term treasury rates, would expose us to additional interest rate risk, additional expense and the potential for additional future impairments. We are also exposed to the risk of rising interest rates to the extent we fund our operations with short-term or variable-rate borrowings.
We use machine learning and artificial intelligence (AI) in our business, and challenges with properly managing its use could result in competitive or reputational harm and legal liability and adversely affect our results of operations.
We use AI in multiple ways in our business and continue to expand the use of AI in our operations. Given that machine learning and AI are new and rapidly evolving technologies, their use presents a number of operational, compliance and reputational risks. AI algorithms are currently known to sometimes produce unexpected results or behave in unpredictable ways that can generate irrelevant, nonsensical, deficient, factually inaccurate or biased content and results. Accordingly, AI presents emerging operational, legal and ethical issues, and if our use of AI becomes controversial, we may experience reputational harm to our brand, competitive harm or legal liability. At the same time, our competitors may incorporate AI into their operations more quickly than we do or with more successful outcomes, which would also harm our business. We also expect there will be new laws or regulations concerning the use of AI technology, which might be burdensome to comply with and may limit our ability to use this technology. We might not be able to attract and retain the talent to support our AI technology initiatives and maintain our systems. Any disruption or failure in our AI systems or those of third parties on whom we rely could result in delays and operational challenges, and the various operational, compliance and reputational issues could adversely affect our business and results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES
(none)

ITEM 3. DEFAULTS UPON SENIOR SECURITIES
(none)

ITEM 4. MINE SAFETY DISCLOSURES
(none)

ITEM 5. OTHER INFORMATION
During the three months ended September 30, 2023, no director or officer of the Company adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.
2023 Q3 Form 10-Q | 31
ITEM 6. EXHIBITS
The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.

Exhibit NumberDescription
10.1 
31.1 
31.2 
32 
101 Interactive Data Files.
104 Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101).

2023 Q3 Form 10-Q | 32
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELANCO ANIMAL HEALTH INCORPORATED
(Registrant)
Date:November 7, 2023/s/ Jeffrey N. Simmons
Jeffrey N. Simmons
President and Chief Executive Officer
(Principal Executive Officer)
Date:November 7, 2023/s/ Todd S. Young
Todd S. Young
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)



2023 Q3 Form 10-Q | 33
 EX-31.1 2 ex311elanco-20230930xceoce.htm EXHIBIT 31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER Document

EXHIBIT 31.1
CERTIFICATIONS
I, Jeffrey N. Simmons, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 7, 2023
By:/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 ex312elanco-20230930xcfoce.htm EXHIBIT 31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER Document

EXHIBIT 31.2
CERTIFICATIONS
I, Todd S. Young, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 7, 2023
By:/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-32 4 ex32elanco-20230930xsectio.htm EXHIBIT 32 - CERTIFICATIONS OF CEO AND CFO Document

EXHIBIT 32
CERTIFICATION OF THE
CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:November 7, 2023/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer
(Principal Executive Officer)
 
Date:November 7, 2023/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-101.SCH 5 elan-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquisitions, Divestitures and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Asset Impairment, Restructuring and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Earning Per Share link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Earning Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue - Activity in Sales Rebates and Discounts Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Schedule of The Composition of The Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Acquisitions, Divestitures and Other Arrangements - NutriQuest US Acquisition & NutriQuest Brazil Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Divestitures and BexCaFe Arrangement (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments - Net Losses/Gains on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Fair Value - Schedule of Fair Value Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Goodwill - Goodwill Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Goodwill - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Earning Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 elan-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 elan-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 elan-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Consolidated Entities [Axis] Consolidated Entities [Axis] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Other noncurrent liabilities Other Noncurrent Liabilities [Member] Range [Domain] Statistical Measurement [Domain] Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Debt Debt Disclosure [Text Block] Other current liabilities Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Up-front cash consideration Payments to Acquire Businesses, Gross Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Other expense, net Nonoperating Income (Expense) Commitments and Contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Other Receivables Other Receivables [Member] Other Receivables Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Term Loan B due 2027 Term B Loan Facility [Member] Term B Loan Facility Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Equity Equity [Text Block] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Concentration Risk [Line Items] Concentration Risk [Line Items] Debt component Sale Of Stock, Debt Component, Percent Sale Of Stock, Debt Component, Percent Customer [Axis] Customer [Axis] Current Liabilities Liabilities, Current [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted (usd per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Goodwill [Roll Forward] Goodwill [Roll Forward] Cash flow hedges, net of taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Line of Credit Credit Facility Line of Credit [Member] Noncurrent Assets Assets, Noncurrent [Abstract] Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Investments with readily determinable fair value Investments, Fair Value Disclosure Product Return Concentration Risk Product Return Concentration Risk [Member] Product Return Concentration Risk [Member] Net loss Net loss Net income (loss) Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Liabilities and Equity Liabilities and Equity [Abstract] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Equity Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Beginning balance Ending balance Contract with Customer, Liability Total Inventory, Gross Other intangible assets Other Intangible Assets [Member] NutriQuest, LLC NutriQuest, LLC [Member] NutriQuest, LLC Schedule of Basic And Diluted Weighted-average Shares Outstanding Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Refund within next three months Tax Incremental Financing, Expect To Refund Within Next Three Months Tax Incremental Financing, Expect To Refund Within Next Three Months Fair value of contingent consideration Business Combination, Consideration Transferred, Contingent Consideration Business Combination, Consideration Transferred, Contingent Consideration Executive Category: Executive Category [Axis] Weighted average useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Cross-currency fixed interest rate swap Foreign Exchange Contract [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Defined benefit pension and retiree health benefit plans, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Name Forgone Recovery, Individual Name Carrying Amount Reported Value Measurement [Member] Goodwill Goodwill Balance as of December 31, 2022 Balance as of September 30, 2023 Goodwill Equity Components [Axis] Equity Components [Axis] Proceeds from interest rate swap settlements Proceeds From Derivative Instrument, Operating Activities Proceeds From Derivative Instrument, Operating Activities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivative assets (liabilities) Derivative Assets (Liabilities), at Fair Value, Net Decrease to LIFO cost Inventory, LIFO Reserve Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Notional amount Derivative, Notional Amount Payments Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Incremental Term Facility due 2029 Incremental Term Facility Due April 19, 2029 [Member] Incremental Term Facility Due April 19, 2029 Measurement Frequency [Axis] Measurement Frequency [Axis] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt maturity term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Speke Site Speke Site [Member] Speke Site Proceeds from site divestitures Proceeds from Divestiture of Businesses and Interests in Affiliates Total expense Restructuring, Settlement and Impairment Provisions Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Assumed conversion of dilutive common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Repayments of long-term borrowings Repayments of Senior Debt Schedule of Purchase Consideration Schedule of Business Acquisitions, by Acquisition [Table Text Block] Incremental Term Facility due 2025 Incremental Term Facility Due June 30, 2025 [Member] Incremental Term Facility Due June 30, 2025 TEUs issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Balance at beginning of period Balance at end of period Restructuring Reserve Long-term debt, including current portion Notes Payable, Fair Value Disclosure Acquisition related charges Business Combination, Acquisition Related Costs Award Type Award Type [Axis] Antidilutive shares not included in calculating diluted loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Interest expense, net of capitalized interest Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Derivative amount restructured Derivative, Notional Amount, Amount Restructured Derivative, Notional Amount, Amount Restructured Hedging Designation [Axis] Hedging Designation [Axis] Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Provision for Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Farm Animal Farm Animal [Member] Farm Animal Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Senior Notes due 2028 Senior Notes Due 2028 [Member] Senior Notes Due 2028 [Member] Reduction of revenue Contract with Customer, Liability, Revenue Recognized Including Current Year Additions Contract with Customer, Liability, Revenue Recognized Including Current Year Additions Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Finite-lived intangible assets Finite-Lived Intangible Assets, Net Implementation of New Financial Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date New corporate headquarters, estimated total incentive to be funded by TIF Tax Incremental Financing, Estimated Total Incentive To Be Funded Tax Incremental Financing, Estimated Total Incentive To Be Funded Schedule of Gains (Losses) , Net of Tax Offsetting Liabilities [Table Text Block] Tax incremental financing, commitment amount Tax Incremental Financing, Commitment Amount Tax Incremental Financing, Commitment Amount Lessee, operating lease, lease not yet commenced, term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and cash equivalents – beginning of period Cash and cash equivalents – end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Offering price (usd per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Determination of shares: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Total purchase consideration Total purchase consideration Business Combination, Consideration Transferred Sales rebates and discounts Contract with Customer, Liability, Current Security Exchange Name Security Exchange Name Total debt Long-Term Debt Proceeds after underwriting discounts and commissions Sale of Stock, Consideration Received on Transaction Marketing, selling and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Costs, expenses and other Costs and Expenses Other financing activities, net Proceeds from (Payments for) Other Financing Activities Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Asset Impairment, Restructuring and Other Special Charges Restructuring and Related Costs [Table Text Block] Document Type Document Type Additions related to acquisitions Goodwill, Acquired During Period Swine Swine [Member] Swine Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Customer Concentration Risk Customer Concentration Risk [Member] Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] NutriQuest Brazil NutriQuest Nutricao Animal Ltda [Member] NutriQuest Nutricao Animal Ltda Costs, expenses and other: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Schedule of Activity in Reserves Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Contingent consideration Nonfinancial Liabilities Fair Value Disclosure Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Equity method investments Equity Method Investments Inventories Inventories Inventory, Net Range [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Product Sales Product [Member] Changes in operating assets and liabilities, net of acquisitions Increase (Decrease) in Operating Capital Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Asset impairment, restructuring and other special charges Restructuring Costs and Asset Impairment Charges Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Acquisitions, Divestitures and Other Arrangements Mergers, Acquisitions and Dispositions Disclosures [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Accrual charge Loss Contingency Accrual, Provision Debt instrument, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Microbiome R&D Platform Carve-Out Microbiome R&D Platform Carve-Out [Member] Microbiome R&D Platform Carve-Out Current Assets Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Disposal Group Name [Domain] Disposal Group Name [Domain] PEO PEO [Member] 4.272% Senior Notes due 2023 4.272% Senior Notes due 2023 [Member] 4.272% Senior Notes due 2023 Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Foreign currency translation, net of taxes Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Class of Stock [Domain] Class of Stock [Domain] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Interest Rate Swap Interest Rate Swap [Member] Duration over which proceeds will be received Divestiture Of Business, Duration Over Which Proceeds Will Be Received Divestiture Of Business, Duration Over Which Proceeds Will Be Received Securitization Facility Securitization Facility [Member] Securitization Facility Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Percentage of long term debt bearing fixed interest Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Loss per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Basis of Accounting [Text Block] Proceeds from issuance of long-term debt Proceeds from Issuance of Senior Long-Term Debt Common stock, no par value, 5,000,000,000 shares authorized, 492,683,420 and 474,237,738 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Settlement rate Tangible Equity Unit, Settlement Rate Tangible Equity Unit, Settlement Rate Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Commitments and Contingencies Legal Matters and Contingencies [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Schedule of Description of Accounting Standards Adopted and Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Table Text Block] Schedule of Fair Value Information Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Contingent consideration liability Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Litigation Case [Domain] Litigation Case [Domain] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Other comprehensive income (loss), net investment hedge, gain (loss), net of tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Implementation of New Financial Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] PEO Name PEO Name Concentration risk Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Incremental Term Facility due 2028 Incremental Term Facility Due August 12, 2028 [Member] Incremental Term Facility Due August 12, 2028 Schedule of Goodwill Schedule of Goodwill [Table Text Block] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Contract with customer, asset, before allowance for credit loss Contract with Customer, Asset, before Allowance for Credit Loss Shawnee and Speke Shawnee And Speke [Member] Shawnee And Speke Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Depreciation and amortization Depreciation, Depletion and Amortization Interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Pet Health Pet Health [Member] Pet Health Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Business Combination and Asset Acquisition [Abstract] Total equity Balance at beginning of period Balance at end of period Equity, Attributable to Parent Goodwill impairment Impairment charge Impairment charge Goodwill, Impairment Loss Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Cash Flow Hedge Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Purchases of intangible assets Payments to Acquire Intangible Assets Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Hedging Designation [Domain] Hedging Designation [Domain] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Net Investment Hedging Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Unamortized debt issuance costs Debt Issuance Costs, Net Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Other noncurrent assets Other Noncurrent Assets [Member] Finished products Inventory, Finished Goods, Gross Disposal Group Classification [Domain] Disposal Group Classification [Domain] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Total identifiable assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Operating lease, lease not yet commenced liability Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid Definite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Asset Impairment, Restructuring and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] BexCaFe, LLC BexCaFe, LLC [Member] BexCaFe, LLC Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Schedule of Revenue Disaggregated by Geographic Area Revenue from External Customers by Geographic Areas [Table Text Block] Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earning Per Share Earnings Per Share [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Foreign currency translation adjustments Contract With Customer, Liability, Foreign Currency Translation Contract With Customer, Liability, Foreign Currency Translation Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Weighted-average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Other investing activities, net Payments for (Proceeds from) Other Investing Activities Accumulated Deficit Retained Earnings [Member] Current portion of long-term debt Less current portion of long-term debt Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and equity Liabilities and Equity Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (usd per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Gain on disposal Gain (Loss) on Disposition of Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Arrangement Duration Trading Arrangement Duration Acquired in-process research and development (IPR&D) In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Release of stranded tax benefits Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net Increase in derivative notional amount during period Derivative, Notional Amount, Increase (Decrease) In Period Derivative, Notional Amount, Increase (Decrease) In Period Restructuring charges (credits) Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Repayments of facility Repayment of revolving credit facility Repayments of Lines of Credit Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Number of employees transferred Disposal Group, Including Discontinued Operation, Number of Employees Transferred Disposal Group, Including Discontinued Operation, Number of Employees Transferred Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Long-Term Debt, Gross Adjustments to reconcile net loss to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Deferred cash consideration due January 4, 2024 Deferred Payments To Acquire Businesses, Gross Deferred Payments To Acquire Businesses, Gross Unrealized gains to be reclassified during next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Future Milestone Payments And Sales Royalties Future Milestone Payments And Sales Royalties [Member] Future Milestone Payments And Sales Royalties All Adjustments to Compensation All Adjustments to Compensation [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Shares issued upon conversion of prepaid stock purchase contracts (in shares) Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion TEU Amortizing Notes due 2023 5.00% Tangible Equity Units [Member] 5.00% Tangible Equity Units Additional paid-in capital Additional Paid in Capital Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Prepaid expenses and other Prepaid Expense and Other Assets, Current Work in process Inventory, Work in Process, Gross Equity component Sale Of Stock, Equity Component, Percent Sale Of Stock, Equity Component, Percent Insider Trading Arrangements [Line Items] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Stock-based compensation activity, net (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Marketed products Marketed Products [Member] Marketed Products Adjustment to Compensation, Amount Adjustment to Compensation Amount Cash paid Payments for Restructuring Document Period End Date Document Period End Date Proceeds from facility Proceeds from Revolving Credit Facility Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Net revenue Revenue from Contract with Customer Benchmark [Member] Entity Central Index Key Entity Central Index Key Loss contingency accrual Loss Contingency Accrual Foreign exchange forward contracts Derivative, Gain (Loss) on Derivative, Net Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax (benefit) expense Income tax (benefit) expense Income Tax Expense (Benefit) International Non-US [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Fair Value Fair Value Disclosures [Text Block] Revenue Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Reclassification of gain (loss) from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other comprehensive loss, net of taxes Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Asset impairments and other items Impairment of Long-Lived Assets to be Disposed of Schedule of Revenue Disaggregated by Product Category Disaggregation of Revenue [Table Text Block] Cattle Cattle [Member] Cattle Equity [Abstract] Equity [Abstract] Inventories Inventory Disclosure [Text Block] Total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other receivables Other Receivables, Net, Current Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Net purchases of property and equipment and software Payments To Acquire Property, Plant, Equipment, And Software Payments To Acquire Property, Plant, Equipment, And Software Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash paid for acquisitions Payments to Acquire Businesses, Net of Cash Acquired Credit Facility [Domain] Credit Facility [Domain] Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing [Member] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Goodwill Goodwill Disclosure [Text Block] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Global Customers Global Customers [Member] Global Customers Diluted (in shares) Diluted weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Activity in Sales Rebates and Discounts Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Revenue Revenue from Contract with Customer [Text Block] Company Selected Measure Amount Company Selected Measure Amount Unrealized gain (loss) on investments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Additional Paid-in Capital Additional Paid-in Capital [Member] Single Customer Customer A [Member] Customer A [Member] Conversion of tangible equity units (TEUs) into common stock (in shares) Stock Issued During Period, Shares, Conversion of Units Asset impairment and write-down charges Asset Impairment Charges, Including Inventory Write-Down Asset Impairment Charges, Including Inventory Write-Down Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss Contingencies [Line Items] Loss Contingencies [Line Items] Tangible Equity Unit Tangible Equity Unit [Member] Tangible Equity Unit Cover [Abstract] Stock-based compensation activity, net APIC, Share-Based Payment Arrangement, Increase for Cost Recognition United States UNITED STATES Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Other noncurrent liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Cash Flow Hedging Cash Flow Hedging [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Seresto Class Action Lawsuits Seresto Class Action Lawsuits [Member] Seresto Class Action Lawsuits Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Consolidated Entities [Domain] Consolidated Entities [Domain] Payment on agreement Payments For License Fees Payment On Agreement Aqua Aqua [Member] Aqua Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Concentration Risk [Table] Concentration Risk [Table] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Poultry Poultry [Member] Poultry EX-101.PRE 9 elan-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 elan-20230930_g1.jpg ELANCO LOGO begin 644 elan-20230930_g1.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2023
Nov. 02, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-38661  
Entity Registrant Name Elanco Animal Health Inc  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 82-5497352  
Entity Address, Address Line One 2500 INNOVATION WAY  
Entity Address, City or Town GREENFIELD  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46140  
City Area Code 877  
Local Phone Number 352-6261  
Title of 12(b) Security Common stock, no par value  
Trading Symbol ELAN  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   492,798,113
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001739104  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenue $ 1,068 $ 1,026 $ 3,382 $ 3,426
Costs, expenses and other:        
Cost of sales 487 472 1,415 1,465
Research and development 86 78 248 241
Marketing, selling and administrative 313 298 993 963
Amortization of intangible assets 140 128 410 398
Asset impairment, restructuring and other special charges 16 26 91 152
Goodwill impairment 1,042 0 1,042 0
Interest expense, net of capitalized interest 72 60 210 179
Other expense, net 9 8 41 11
Costs, expenses and other 2,165 1,070 4,450 3,409
(Loss) income before income taxes (1,097) (44) (1,068) 17
Income tax (benefit) expense (1) 21 22 41
Net loss $ (1,096) $ (65) $ (1,090) $ (24)
Loss per share:        
Basic (usd per share) $ (2.22) $ (0.13) $ (2.21) $ (0.05)
Diluted (usd per share) $ (2.22) $ (0.13) $ (2.21) $ (0.05)
Weighted-average shares outstanding:        
Basic (in shares) 492.7 488.4 492.1 488.3
Diluted (in shares) 492.7 488.4 492.1 488.3
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (1,096) $ (65) $ (1,090) $ (24)
Other comprehensive loss:        
Cash flow hedges, net of taxes 0 62 (19) 179
Foreign currency translation, net of taxes (197) (418) (65) (973)
Defined benefit pension and retiree health benefit plans, net of taxes (4) (2) (6) (4)
Other comprehensive loss, net of taxes (201) (358) (90) (798)
Comprehensive loss $ (1,297) $ (423) $ (1,180) $ (822)
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 369 $ 345
Accounts receivable, net 911 797
Other receivables 224 205
Inventories 1,690 1,538
Prepaid expenses and other 371 394
Total current assets 3,565 3,279
Noncurrent Assets    
Goodwill 4,902 5,993
Other intangibles, net 4,475 4,842
Other noncurrent assets 410 378
Property and equipment, net 992 999
Total assets 14,344 15,491
Current Liabilities    
Accounts payable 296 390
Sales rebates and discounts 356 324
Current portion of long-term debt 39 388
Other current liabilities 574 600
Total current liabilities 1,265 1,702
Noncurrent Liabilities    
Long-term debt 5,870 5,448
Deferred taxes 643 662
Other noncurrent liabilities 432 390
Total liabilities 8,210 8,202
Commitments and Contingencies
Equity    
Common stock, no par value, 5,000,000,000 shares authorized, 492,683,420 and 474,237,738 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 0 0
Additional paid-in capital 8,763 8,738
Accumulated deficit (2,147) (1,057)
Accumulated other comprehensive loss (482) (392)
Total equity 6,134 7,289
Total liabilities and equity $ 14,344 $ 15,491
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, shares authorized (in shares) 5,000,000,000 5,000,000,000
Common stock, shares issued (in shares) 492,683,420 474,237,738
Common stock, shares outstanding (in shares) 492,683,420 474,237,738
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Cash Flow Hedge
Foreign Currency Translation
Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2021   473,100,000            
Balance at beginning of period at Dec. 31, 2021 $ 7,508 $ 0 $ 8,696 $ (979) $ (209) $ 25 $ (253) $ 19
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 51     51        
Other comprehensive income (loss), net of tax 23       23 109 (85) (1)
Stock-based compensation activity, net (in shares)   1,000,000.0            
Stock-based compensation activity, net 3   3          
Balance at end of period (in shares) at Mar. 31, 2022   474,100,000            
Balance at end of period at Mar. 31, 2022 7,585 $ 0 8,699 (928) (186) 134 (338) 18
Balance at beginning of period (in shares) at Dec. 31, 2021   473,100,000            
Balance at beginning of period at Dec. 31, 2021 7,508 $ 0 8,696 (979) (209) 25 (253) 19
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (24)              
Other comprehensive income (loss), net of tax (798)              
Balance at end of period (in shares) at Sep. 30, 2022   474,100,000            
Balance at end of period at Sep. 30, 2022 6,714 $ 0 8,724 (1,003) (1,007) 204 (1,226) 15
Balance at beginning of period (in shares) at Mar. 31, 2022   474,100,000            
Balance at beginning of period at Mar. 31, 2022 7,585 $ 0 8,699 (928) (186) 134 (338) 18
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (10)     (10)        
Other comprehensive income (loss), net of tax (463)       (463) 8 (470) (1)
Stock-based compensation activity, net 13   13          
Balance at end of period (in shares) at Jun. 30, 2022   474,100,000            
Balance at end of period at Jun. 30, 2022 7,125 $ 0 8,712 (938) (649) 142 (808) 17
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (65)     (65)        
Other comprehensive income (loss), net of tax (358)       (358) 62 (418) (2)
Stock-based compensation activity, net 12   12          
Balance at end of period (in shares) at Sep. 30, 2022   474,100,000            
Balance at end of period at Sep. 30, 2022 $ 6,714 $ 0 8,724 (1,003) (1,007) 204 (1,226) 15
Balance at beginning of period (in shares) at Dec. 31, 2022 474,237,738 474,200,000            
Balance at beginning of period at Dec. 31, 2022 $ 7,289 $ 0 8,738 (1,057) (392) 182 (672) 98
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 103     103        
Other comprehensive income (loss), net of tax 82       82 (48) 130  
Stock-based compensation activity, net (in shares)   1,000,000.0            
Stock-based compensation activity, net 6   6          
Conversion of tangible equity units (TEUs) into common stock (in shares)   17,200,000            
Balance at end of period (in shares) at Mar. 31, 2023   492,400,000            
Balance at end of period at Mar. 31, 2023 $ 7,480 $ 0 8,744 (954) (310) 134 (542) 98
Balance at beginning of period (in shares) at Dec. 31, 2022 474,237,738 474,200,000            
Balance at beginning of period at Dec. 31, 2022 $ 7,289 $ 0 8,738 (1,057) (392) 182 (672) 98
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (1,090)              
Other comprehensive income (loss), net of tax $ (90)              
Balance at end of period (in shares) at Sep. 30, 2023 492,683,420 492,700,000            
Balance at end of period at Sep. 30, 2023 $ 6,134 $ 0 8,763 (2,147) (482) 163 (737) 92
Balance at beginning of period (in shares) at Mar. 31, 2023   492,400,000            
Balance at beginning of period at Mar. 31, 2023 7,480 $ 0 8,744 (954) (310) 134 (542) 98
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (97)     (97)        
Other comprehensive income (loss), net of tax 29       29 29 2 (2)
Stock-based compensation activity, net (in shares)   200,000            
Stock-based compensation activity, net 8   8          
Balance at end of period (in shares) at Jun. 30, 2023   492,600,000            
Balance at end of period at Jun. 30, 2023 7,420 $ 0 8,752 (1,051) (281) 163 (540) 96
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (1,096)     (1,096)        
Other comprehensive income (loss), net of tax (201)       (201)   (197) (4)
Stock-based compensation activity, net (in shares)   100,000            
Stock-based compensation activity, net $ 11   11          
Balance at end of period (in shares) at Sep. 30, 2023 492,683,420 492,700,000            
Balance at end of period at Sep. 30, 2023 $ 6,134 $ 0 $ 8,763 $ (2,147) $ (482) $ 163 $ (737) $ 92
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows from Operating Activities    
Net loss $ (1,090) $ (24)
Adjustments to reconcile net loss to cash flows from operating activities:    
Depreciation and amortization 523 514
Goodwill impairment 1,042 0
Stock-based compensation expense 31 44
Asset impairment and write-down charges 5 81
Proceeds from interest rate swap settlements 57 207
Changes in operating assets and liabilities, net of acquisitions (446) (385)
Other non-cash operating activities, net (8) 2
Net Cash Provided by Operating Activities 114 439
Cash Flows from Investing Activities    
Net purchases of property and equipment and software (99) (94)
Cash paid for acquisitions (19) 0
Purchases of intangible assets (14) (11)
Other investing activities, net (2) 2
Net Cash Used for Investing Activities (134) (103)
Cash Flows from Financing Activities    
Proceeds from issuance of long-term debt 0 425
Repayments of long-term borrowings (388) (607)
Other financing activities, net (6) (33)
Net Cash Provided by (Used for) Financing Activities 56 (465)
Effect of exchange rate changes on cash and cash equivalents (12) (49)
Net increase (decrease) in cash and cash equivalents 24 (178)
Cash and cash equivalents – beginning of period 345 638
Cash and cash equivalents – end of period 369 460
Revolving Credit Facility    
Cash Flows from Financing Activities    
Proceeds from facility 350 563
Repayments of facility (53) (813)
Securitization Facility    
Cash Flows from Financing Activities    
Proceeds from facility 250 0
Repayments of facility $ (97) $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Note 1. Basis of Presentation and Summary of Significant Accounting Policies
We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our 2022 Form 10-K. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period.
In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.
The significant accounting policies set forth in Note 4 to the consolidated financial statements in our 2022 Form 10-K appropriately represent, in all material respects, the current status of our accounting policies.
Revision of Previously Issued Consolidated Financial Statements
In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified and corrected relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. In conjunction with making these corrections, we made other adjustments to the prior years to revise uncorrected errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. Further information is included in Note 2 and Note 21 to the consolidated financial statements in our 2022 Form 10-K.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Implementation of New Financial Accounting Pronouncements
 9 Months Ended
Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]  
Implementation of New Financial Accounting Pronouncements
Note 2. Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:
StandardDescriptionEffective DateEffect on the Financial Statements or Other Significant Matters
ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope; ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.
Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3. Revenue
We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligations, which is
generally once the goods have been shipped and the customer has assumed title. For contract manufacturing organization (CMO) arrangements, we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services.
We have a single customer that accounted for approximately 10% and 11% of revenue for the nine months ended September 30, 2023 and 2022, respectively. Product sales with this customer resulted in accounts receivable of $96 million and $73 million at September 30, 2023 and December 31, 2022, respectively.
Provisions for sales rebates and discounts are recorded as a reduction to revenue in the period the related sales are recognized and are based on specific agreements. In determining the appropriate accrual amount, we consider our historical experience with similar incentive programs, current sales data and estimates of inventory levels at our channel distributors. The following table summarizes the activity in our global sales rebates and discounts liability:
Nine Months Ended September 30,
20232022
Beginning balance$324 $319 
Reduction of revenue558 524 
Payments(522)(521)
Foreign currency translation adjustments(4)(18)
Ending balance$356 $304 
Adjustments to revenue recognized as a result of changes in estimates during the nine months ended September 30, 2023 and 2022 for product shipped in previous periods were not material. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2023 and 2022.
Disaggregation of Revenue
The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Pet Health$495 $469 $1,688 $1,718 
Farm Animal:
Cattle242 227 700 722 
Poultry184 176 545 529 
Swine93 95 284 284 
Aqua42 47 132 132 
Total Farm Animal561 545 1,661 1,667 
Contract Manufacturing (1)
12 12 33 41 
Revenue$1,068 $1,026 $3,382 $3,426 
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party.
The following table summarizes our revenue disaggregated by geographic area:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
United States$479 $475 $1,522 $1,536 
International589 551 1,860 1,890 
Revenue$1,068 $1,026 $3,382 $3,426 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions, Divestitures and Other Arrangements
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions, Divestitures and Other Arrangements
Note 4. Acquisitions, Divestitures and Other Arrangements
NutriQuest U.S. Acquisition
On January 3, 2023, we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest). NutriQuest is a provider of swine, poultry and cattle nutritional health products to animal producers. The acquisition allows us to expand our existing nutritional health offerings and furthers our efforts to explore innovative antibiotic alternatives.
The composition of the purchase price was as follows:
Up-front cash consideration$16 
Deferred cash consideration due January 4, 20245 
Fair value of contingent consideration37 
Total purchase consideration$58 
The NutriQuest acquisition was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date, with the excess of the purchase price over the fair value of the acquired assets recorded as goodwill. The determination of estimated fair value requires management to make significant estimates and assumptions. Contingent consideration for this acquisition includes up to $85 million of cash consideration payable if specific development, sales and geographic expansion milestones are achieved, as outlined in the asset purchase agreement. The initial fair value of this contingent consideration liability of $37 million was estimated at the acquisition date using a Monte Carlo simulation model, which represented a Level 3 measurement under the fair value measurement hierarchy (see Note 10. Fair Value for further information).
The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:
Inventories$3 
Intangible assets:
Marketed products29 
Acquired in-process research and development (IPR&D)10 
Other intangible assets15 
Total identifiable assets57 
Goodwill1 
Total consideration transferred$58 
Other intangible assets consist of customer relationships and trade names. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk and competitive trends impacting the asset and each cash flow stream, as well as other factors.
The accounting for this acquisition has not been finalized as of September 30, 2023. The purchase price allocation is preliminary and subject to change, including the valuation of the contingent consideration and intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. Revenue attributable to the NutriQuest acquisition for the nine months ended September 30, 2023, was approximately $16 million.
NutriQuest Brazil Acquisition
On August 1, 2023, we acquired certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil) for total purchase consideration of $19 million. The composition of the purchase price included cash paid on the closing date of approximately $3 million, with consideration payable through 2026 valued at approximately $16 million, a portion of which is contingent upon the continuation of certain terms and conditions set forth in the asset purchase agreement. The NutriQuest Brazil acquisition was accounted for as a business combination under the acquisition method of accounting.
The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:
Inventories$3 
Definite-lived intangible assets15 
Total identifiable assets18 
Goodwill1 
Total consideration transferred$19 
The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately nine years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach. The purchase price allocation for this acquisition is preliminary as of September 30, 2023, and subject to change, including the valuation of the intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. Neither revenue nor income before taxes included within our condensed consolidated statements of operations from NutriQuest Brazil were material for the three and nine months ended September 30, 2023.
Divestitures
Microbiome R&D platform carve-out
In April 2022, we signed an agreement to transfer assets associated with our microbiome R&D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retained a non-voting, minority stake in the company. In addition, we entered into transitional services agreements with the company for certain services. Assets transferred included intellectual property and laboratory equipment. The book values of those assets were not material. We recorded a gain on disposal of the assets of approximately $3 million during the year ended December 31, 2022.
Shawnee and Speke
During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx began manufacturing existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which was included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets.
Based on the terms of the agreements and cash proceeds received to date, as of September 30, 2023, we had a net receivable balance from TriRx of $73 million from the sales of Shawnee and Speke, which was included within other receivables on the condensed consolidated balance sheets. In May 2023, we entered into amendments to the agreements which effectively restructured the payment schedule related to the remaining amount owed. Under the terms of the amendments we expect to receive approximately $67 million of this receivable balance upon the earlier of the date on which certain conditions are met or in equal installments over a twelve-month period beginning January 31, 2024, with the remainder due within the next 12 months. We continue to assess the collectibility of these receivables from TriRx and continue to believe amounts owed are collectible. Further, we have rights to certain collateral in the event of a default and we continue to monitor the value of this collateral.
BexCaFe Arrangement
In June 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to Bexacat, an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, Consolidation, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. There is no minimum payout due on the contingent consideration and the maximum payout related to sales royalties is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&D asset because we concluded that it did not have an alternative future use.
During the nine months ended September 30, 2023, we paid $13 million to BexCaFe in connection with development/regulatory milestones achieved upon U.S. Food and Drug Administration (FDA) approval of the original new animal drug application for Bexacat in December 2022. Remaining contingent consideration liabilities of $35 million were included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2023.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Asset Impairment, Restructuring and Other Special Charges
 9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring and Other Special Charges
Note 5. Asset Impairment, Restructuring and Other Special Charges
In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash impairment charges can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions.
Components of asset impairment, restructuring and other special charges were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Restructuring charges (credits)(1)
$— $— $— $(7)
Acquisition related charges(2)
11 27 86 77 
Asset impairments and other items (3)
5 (1)5 82 
Total expense$16 $26 $91 $152 
(1)Restructuring credits in 2022 related to adjustments resulting from the reversal of severance accruals associated with 2021 restructuring programs, resulting from final negotiations and certain restructured employees filling open positions.
(2)Acquisition related charges included transaction costs directly related to acquiring businesses, such as expenditures for banking, legal, accounting, consulting and other similar services, integration charges inclusive of system and process integration and product transfers, and independent company stand-up costs related to the implementation of new systems, programs and processes.
(3)Asset impairments during the third quarter of 2023 primarily related to the write-down of certain indefinite-lived intangible assets due to increases in the relevant discount rates. Asset impairments during 2022 included a charge of $59 million related to the write-off of an IPR&D asset with no alternative future use licensed from BexCaFe and a $22 million charge related to the finalization of the write-down upon sale of the Speke site (see Note 4. Acquisitions, Divestitures and Other Arrangements for further discussion on each of these items).
The changes in our restructuring reserves during the nine months ended September 30, 2023, were as follows:
Balance at December 31, 2022$36 
Cash paid(29)
Balance at September 30, 2023$7 
These reserves were included within other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain country-specific negotiations and regulations.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventories
Note 6. Inventories
Inventories are stated at the lower of cost and net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted-average cost method.
Inventories consisted of the following:
September 30, 2023December 31, 2022
Finished products$831 $783 
Work in process772 683 
Raw materials and supplies145 130 
Total1,748 1,596 
Decrease to LIFO cost(58)(58)
Inventories$1,690 $1,538 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Equity
Note 7. Equity
Tangible Equity Unit (TEU) Offering
In January 2020, we issued 11 million in TEUs at the stated amount of $50 per unit. Total proceeds, net of issuance costs, were $528 million. The gross proceeds and deferred finance costs from the issuance of the TEUs were allocated 86% to equity (prepaid stock purchase contracts) and 14% to debt (TEU amortizing notes) based on the
relative fair value of the respective components of each TEU. The TEU prepaid stock purchase contracts were converted into shares of our common stock on February 1, 2023. Holders of our TEUs received 1.5625 shares of our common stock based on the maximum settlement rate for the applicable market value being below $32.00. In total, we issued approximately 17 million shares to holders in connection with the settlement.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Debt
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Debt
Note 8. Debt
Long-term debt consisted of the following:
September 30, 2023December 31, 2022
Incremental Term Facility due 2025$175 $175 
Incremental Term Facility due 2028490 494 
Incremental Term Facility due 2029247 249 
Term Loan B due 20273,849 3,881 
Revolving Credit Facility (1)
297 — 
Securitization Facility (2)
153 — 
4.272% Senior Notes due 2023 (3)
— 344 
4.900% Senior Notes due 2028 (4)
750 750 
TEU Amortizing Notes due 2023 (5)
— 7 
Unamortized debt issuance costs(52)(64)
5,909 5,836 
Less current portion of long-term debt39 388 
Total long-term debt$5,870 $5,448 
(1)During the nine months ended September 30, 2023, we drew $350 million on our Revolving Credit Facility (subsequently repaying $53 million), both to fund working capital needs and to partially fund the repayment of the 4.272% Senior Notes due 2023 (see below for further information). Our Revolving Credit Facility provides up to $750 million in borrowing capacity (with incremental capacity if certain conditions are met), bears interest at Term SOFR plus 2.10% and matures in August 2025.
(2)In August 2023, we entered into a new secured term facility that is secured and collateralized by our U.S. Net Eligible Receivables Balance (see below for further information).
(3)We redeemed the 4.272% Senior Notes due 2023 in full in August 2023 (see below for further information).
(4)Subsequent to issuance in August 2018, the 4.900% Senior Notes due 2028 have been subject to interest rate increases related to credit rating agency downgrades. As of September 30, 2023, these notes bear interest at a rate of 6.650%.
(5)The TEU Amortizing Notes due 2023 matured on February 1, 2023 (see Note 7. Equity for further information).
2023 Financing
On August 3, 2023, we entered into a new secured term facility (the "Securitization Facility") that is secured and collateralized by our U.S. accounts receivable subject to certain adjustments (defined as the Net Eligible Receivables Balance within the applicable agreement). Of the maximum borrowing capacity under the Securitization Facility of $300 million, $250 million was drawn on August 3, 2023, based on our borrowing capacity on that date. Our borrowing capacity under the Securitization Facility is subject to fluctuation monthly based on the level of our borrowing base as reported to the lender, which is correlated to our U.S. Net Eligible Receivables Balances. The Securitization Facility requires monthly interest payments over its three-year term at a variable rate based on Term SOFR plus 125 basis points. The full, outstanding balance of the Securitization Facility is due on July 31, 2026. During the three months ended September 30, 2023, we utilized the proceeds from the Securitization Facility, in addition to a $100 million draw on our Revolving Credit Facility, to redeem in full the 4.272% Senior Notes due 2023. The early redemption of the 4.272% Senior Notes due 2023 satisfied all obligations and commitments thereunder. Subsequent to our initial $250 million draw on the Securitization Facility, $97 million was repaid, resulting in a balance of $153 million outstanding as of September 30, 2023. The Securitization Facility includes various covenants specific to the underlying composition of our U.S. accounts receivables portfolio.
As of September 30, 2023, approximately 76% of our long-term indebtedness bears interest at a fixed rate, including variable-rate converted to fixed-rate through the use of interest rate swaps (see Note 9. Financial Instruments for further information). We were in compliance with all of our debt covenants as of September 30, 2023.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
Note 9. Financial Instruments
To manage our exposure to market risks, such as changes in foreign currency exchange rates and interest rates, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at
inception. We also assess at least quarterly thereafter whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Further, we do not offset derivative assets and liabilities on the condensed consolidated balance sheets. Our outstanding positions are discussed below.
Derivatives not designated as hedges
We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. As of September 30, 2023 and December 31, 2022, we had outstanding foreign exchange contracts with aggregate notional amounts of $864 million and $784 million, respectively.
The amounts of net gains (losses) on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Foreign exchange forward contracts (1)
$1 $(5)$2 $(20)
(1)These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.
Derivatives designated as hedges
To manage our exposure to variable interest rate risk, we utilize interest rate swap contracts to effectively convert our variable-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated our interest rate swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2 in the fair value hierarchy (see Note 10. Fair Value for further information).
Our outstanding forward-starting interest rate swaps had maturities ranging between 2023 and 2028, with aggregate notional amounts of $3,800 million and $3,050 million as of September 30, 2023 and December 31, 2022, respectively. In March 2023, we entered into new interest rate swap agreements with a combined notional amount of $1,000 million, which became effective on October 1, 2023, following the maturity of certain swaps with the same combined notional amount. Additionally, on May 1, 2023, we entered into new interest rate swap agreements with a combined notional amount of $750 million, which became effective on June 1, 2023, and mature in August 2028. Also, in September 2023, we took advantage of market opportunities to further restructure our interest rate swap portfolio (see below for further details). As of September 30, 2023, when factoring in the $3,800 million of variable rate debt converted to fixed-rate through the use of interest rate swaps (excluding the expected future reclassifications to interest expense, net of capitalized interest related to past interest rate swap settlements), the weighted-average effective interest rate on our outstanding indebtedness was 6.34%.
Additionally, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a series of cross-currency fixed interest rate swaps in September 2023 with a 1 billion CHF notional amount with tenors in 2027. These instruments were determined to be, and were designated as, effective economic hedges of net investments in our CHF denominated net assets. The fair values of these instruments were estimated based on quoted market values of similar hedges and is classified as Level 2 in the fair value hierarchy. Over the life of these instruments, gains or losses due to spot rate fluctuations will be recorded as cumulative translation adjustments, as a component of other comprehensive income (loss). Gains and losses within accumulated other comprehensive income (loss) will remain in accumulated other comprehensive income (loss) until either the sale or substantial liquidation of the hedged subsidiary.
The amounts of gains (losses) on derivatives designated as cash flow hedges and net investment hedges, net of tax, recorded in other comprehensive loss were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Forward-starting interest rate swaps$— $62 $(19)$179 
Cross-currency fixed interest rate swaps9 — 9 — 
During the three months ended September 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive loss included gains of $24 million and a gain of $75 million, net of tax, respectively, related to mark-to-market adjustments. During the nine months ended September 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive loss included gains of $57 million and $218 million, net of tax, respectively, related to mark-to-market adjustments.
As noted above, in September 2023, we took advantage of market opportunities to restructure $3,050 million of our interest rate swap portfolio by unwinding existing swaps and simultaneously entering into new agreements with the same notional amounts and tenors extending through 2026. As a result, we received cash settlements of $57 million in the aggregate. Also, in April 2022 and September 2022, we settled certain existing interest rate swaps and simultaneously entered into new agreements with the same notional amount and covering the same tenor. As a result, we received cash settlements of $207 million in the aggregate. The cash proceeds from these interest rate swap settlements were included in net cash from operating activities in the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022.
During the three months ended September 30, 2023 and 2022, we reclassified $35 million and $11 million of net gains, respectively, into interest expense, net of capitalized interest. During the nine months ended September 30, 2023 and 2022, we reclassified $94 million of net gains and $10 million of net losses, respectively, into interest expense, net of capitalized interest. Over the next 12 months, we expect to reclassify a gain of $120 million to interest expense, net of capitalized interest related to our derivatives designated as hedges.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value
Note 10. Fair Value
Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a framework that utilizes the inputs market participants use to determine the fair value of an asset or liability and establishes a fair value hierarchy to prioritize those inputs. Level 1 fair value measurements are based on quoted prices in active markets for identical assets or liabilities. We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. Our Level 3 fair value measurements, which include the value of contingent consideration as of September 30, 2023, are based on unobservable inputs based on little or no market activity.
The following table summarizes the fair value information at September 30, 2023 and December 31, 2022 for assets and liabilities measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt, for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2023
Recurring fair value measurements
Prepaid expenses and other - derivative instruments$64 $— $64 $— $64 
Other noncurrent assets - derivative instruments32 — 32 — 32 
Other noncurrent assets - investments with readily determinable fair value8 8 — — 8 
Other current liabilities - derivative instruments(61)— (61)— (61)
Other current liabilities - contingent consideration(16)— — (16)(16)
Other noncurrent liabilities - contingent consideration(33)— — (33)(33)
Financial instruments not carried at fair value
Long-term debt, including current portion(5,961)— (5,877)— (5,877)
December 31, 2022
Recurring fair value measurements
Prepaid expenses and other - derivative instruments$90 $— $90 $— $90 
Other noncurrent assets - derivative instruments10 — 10 — 10 
Other noncurrent assets - investments with readily determinable fair value7 7 — — 7 
Other current liabilities - derivative instruments(64)— (64)— (64)
Financial instruments not carried at fair value
Long-term debt, including current portion(5,900)— (5,711)— (5,711)
We also had investments without readily determinable fair values and equity method investments, which were classified as other noncurrent assets on our condensed consolidated balance sheets totaling $28 million and $27 million as of September 30, 2023 and December 31, 2022, respectively. These investments are not recorded at fair value on a recurring basis, and as such, are not included in the fair value table above.
Of the total value of the contingent consideration liabilities at September 30, 2023, $42 million related to our acquisition of certain assets from NutriQuest during the first quarter of 2023 (see Note 4. Acquisitions, Divestitures and Other Arrangements for further information). We may pay up to $85 million in cash consideration related to this acquisition, which is contingent upon the achievement of specific development, sales and geographic expansion milestones, as outlined in the asset purchase agreement. The fair values of these liabilities at September 30, 2023, were estimated using the Monte Carlo simulation model, consisting of Level 3 inputs not observable in the market, including estimates relating to revenue forecasts, discount rates and volatility.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
Note 11. Goodwill
The following table summarizes the changes in the carrying amount of goodwill:
Balance as of December 31, 2022$5,993 
     Additions related to acquisitions2 
     Impairment charge(1,042)
     Foreign currency translation adjustments(51)
Balance as of September 30, 2023$4,902 
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. Goodwill is not amortized, but is reviewed for
impairment at least annually on October 1, or more frequently if certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment.
Given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. Accordingly, we performed an interim quantitative goodwill impairment test, which resulted in a $1,042 million pre-tax impairment charge. The fair value of our single reporting unit was determined using the income approach, based on a discounted cash flow model. Significant management judgment was required in estimating our reporting unit’s fair value, including, but not limited to, estimates and assumptions regarding future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these judgments based on historical experience, relevant market size, historical pricing and expected industry trends. While we believe our estimates and assumptions underlying the September 30, 2023, interim goodwill impairment test were reasonable in view of all available information, future changes in our discount rate, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on the estimated fair value of our reporting unit, exposing us to further goodwill impairment losses.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
Note 12. Income Taxes
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Income tax (benefit) expense$(1)$21 $22 $41 
Effective tax rate0.2 %(47.7)%(2.0)%234.3 %
For the three and nine months ended September 30, 2023, we recognized an income tax benefit of $1 million and income tax expense of $22 million, respectively. Our effective tax rates of 0.2% and (2.0)%, respectively, differ from the statutory income tax rates primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions.
For the three and nine months ended September 30, 2022, we recognized income tax expense of $21 million and $41 million, respectively. Our effective tax rates of (47.7)% and 234.3%, respectively, differ from the statutory income tax rate primarily due to the mix of earnings between periods resulting in projected losses in the U.S. and for various other foreign affiliates for which there was no tax benefit, as valuation allowances had been established in those jurisdictions. Income tax expense for the nine months ended September 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps.
We were included in Eli Lilly and Company's (Lilly's) U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in 2019 and remains ongoing.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 13. Commitments and Contingencies
Legal Matters
We are party to various legal actions that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded when it is deemed probable that we will incur a loss and we can formulate a reasonable estimate of that loss.
Seresto Class Action Lawsuits and EPA Safety Review
Claims seeking actual damages, injunctive relief and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the Seresto collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. In June 2023, the parties agreed on the monetary terms of a potential settlement of the consolidated class action lawsuits, and as a result, a charge of $15 million was recorded during the three months ended June 30, 2023. The parties must still reach agreement on non-monetary terms, and any settlement, if reached, is subject to approval by the court, and likely will be subject to other conditions. This $15 million provision was included within other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2023.
Also, in January 2023, a lawsuit seeking damages for alleged negligence, breach of statutory regulations, breach of statutory duties and deceptive marketing was filed in Israel against Elanco and other parties, arising out of the use of Seresto and Foresto™ flea and tick collars for cats and dogs that are marketed and sold in Europe and in Israel. We intend to defend our position vigorously, and as of the date of this filing, we are unable to estimate the probability of loss or range of loss, if any.
Seresto is a pesticide registered with the U.S. Environmental Protection Agency (the EPA). In April 2021, a non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. In response to the EPA's request for comments from the public on the petition, we submitted a comment to the EPA supporting the safety profile of Seresto and engaged in discussions with the EPA. On July 13, 2023, the EPA announced their completion of a comprehensive, multi-year review, with support from the FDA, of the Seresto flea and tick collar and confirmed the continued registration of the collar, denying the citizen's petition. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA registered pet products. Based on comprehensive data from the review, the EPA concluded that Seresto continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose unreasonable risk of harm.
Additional Legal Matters
For the litigation matters discussed below we either believe loss is not probable or are unable to estimate the possible loss or range of loss, if any. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolutions cannot be predicted. As of September 30, 2023 and December 31, 2022, we had no material liabilities established related to the litigation matters mentioned below.
On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives and other individuals. The lawsuit alleged, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit sought unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. On January 13, 2021, we filed a motion to dismiss, and on August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint. On December 7, 2022, we filed an opposition to the plaintiffs' motion, and on September 27, 2023, the Court denied the plaintiffs' motion for leave, issuing final judgment in favor of Elanco. On October 25, 2023, the plaintiffs filed a notice of appeal to the United Stated Court of Appeals for the Seventh Circuit. We continue to believe the claims made in the case are meritless, and we intend to continue to vigorously defend our position.
On October 16, 2020, a shareholder class action lawsuit captioned Saffron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives and other individuals and entities. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or TEUs issued in connection with the public offering. From February 2021 to August 2022, this case was stayed in deference to Hunter v. Elanco Animal Health Inc. On October 24, 2022, we filed a motion to dismiss. On December 23, 2022, the plaintiffs filed their opposition to the motion to dismiss. Prior to the ruling on the motion to dismiss, on June 8, 2023, the plaintiffs filed a motion for leave to file a second amended complaint, which is now the operative complaint. We filed a motion to dismiss the complaint on August 7, 2023, to which the plaintiff filed their opposition on October 13, 2023. We continue to believe the claims made in the case are meritless, and we intend to vigorously defend our position.
In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful, exclusive dealing and tying of its flea and tick products Advantage, Advantix and Seresto and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive
dealing related to Advantage and Advantix and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. The trial is scheduled for July 2024. We intend to defend our position vigorously.
Regulatory Matters
On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. We have recently engaged in discussions with the SEC about a possible resolution or settlement of potential disclosure claims, but there can be no assurance that a resolution or settlement will be reached. Management continues to believe that its actions were appropriate. We are unable to estimate the range of any reasonably possible loss associated with this matter.
Other Commitments
As of September 30, 2023, we had a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025.
The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. During 2022, we refunded approximately $15 million of the TIF proceeds to the developer. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive was included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning on the commencement date and offset future rent expense.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Earning Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earning Per Share
Note 14. Earnings Per Share
We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted-average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements. We also had variable common stock equivalents related to the TEU prepaid stock purchase contracts during the three and nine months ended September 30, 2022, and in the first quarter of 2023 through the settlement date of February 1, 2023 (see Note 7. Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards converted their holdings into common stock and that could have occurred if holders of unsettled TEUs had converted their holdings into common stock prior to the February 1, 2023 settlement date. The weighted-average number of potentially dilutive shares outstanding was calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) were considered to be anti-dilutive and as such, these shares were not included in the calculation of diluted loss per share.
Basic and diluted weighted-average shares outstanding were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Determination of shares:
Basic weighted-average common shares outstanding (1)
492.7 488.4492.1 488.3
Assumed conversion of dilutive common stock equivalents (2)
— — — — 
Diluted weighted-average shares outstanding492.7 488.4492.1 488.3
(1)The TEU prepaid stock purchase contracts were convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares. The minimum 14.3 million shares were included in the calculation of basic weighted-average shares from January 22, 2020 to February 1, 2023. The 17.2 million shares that were ultimately issued were included in the calculation of basic weighted-average shares subsequent to the settlement date of February 1, 2023.
(2)For the three months ended September 30, 2023 and 2022, approximately 2.7 million and 4.4 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2023 and 2022, approximately 2.7 million and 2.6 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure                
Net loss $ (1,096) $ (97) $ 103 $ (65) $ (10) $ 51 $ (1,090) $ (24)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our 2022 Form 10-K. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period.
In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:
StandardDescriptionEffective DateEffect on the Financial Statements or Other Significant Matters
ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope; ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.
Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Implementation of New Financial Accounting Pronouncements (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]  
Schedule of Description of Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:
StandardDescriptionEffective DateEffect on the Financial Statements or Other Significant Matters
ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope; ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.
Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Activity in Sales Rebates and Discounts Liability The following table summarizes the activity in our global sales rebates and discounts liability:
Nine Months Ended September 30,
20232022
Beginning balance$324 $319 
Reduction of revenue558 524 
Payments(522)(521)
Foreign currency translation adjustments(4)(18)
Ending balance$356 $304 
Schedule of Revenue Disaggregated by Product Category
The following table summarizes our revenue disaggregated by product category:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Pet Health$495 $469 $1,688 $1,718 
Farm Animal:
Cattle242 227 700 722 
Poultry184 176 545 529 
Swine93 95 284 284 
Aqua42 47 132 132 
Total Farm Animal561 545 1,661 1,667 
Contract Manufacturing (1)
12 12 33 41 
Revenue$1,068 $1,026 $3,382 $3,426 
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party.
Schedule of Revenue Disaggregated by Geographic Area
The following table summarizes our revenue disaggregated by geographic area:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
United States$479 $475 $1,522 $1,536 
International589 551 1,860 1,890 
Revenue$1,068 $1,026 $3,382 $3,426 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions, Divestitures and Other Arrangements (Tables)
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Purchase Consideration
The composition of the purchase price was as follows:
Up-front cash consideration$16 
Deferred cash consideration due January 4, 20245 
Fair value of contingent consideration37 
Total purchase consideration$58 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:
Inventories$3 
Intangible assets:
Marketed products29 
Acquired in-process research and development (IPR&D)10 
Other intangible assets15 
Total identifiable assets57 
Goodwill1 
Total consideration transferred$58 
The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:
Inventories$3 
Definite-lived intangible assets15 
Total identifiable assets18 
Goodwill1 
Total consideration transferred$19 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Asset Impairment, Restructuring and Other Special Charges (Tables)
 9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Asset Impairment, Restructuring and Other Special Charges
Components of asset impairment, restructuring and other special charges were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Restructuring charges (credits)(1)
$— $— $— $(7)
Acquisition related charges(2)
11 27 86 77 
Asset impairments and other items (3)
5 (1)5 82 
Total expense$16 $26 $91 $152 
(1)Restructuring credits in 2022 related to adjustments resulting from the reversal of severance accruals associated with 2021 restructuring programs, resulting from final negotiations and certain restructured employees filling open positions.
(2)Acquisition related charges included transaction costs directly related to acquiring businesses, such as expenditures for banking, legal, accounting, consulting and other similar services, integration charges inclusive of system and process integration and product transfers, and independent company stand-up costs related to the implementation of new systems, programs and processes.
(3)Asset impairments during the third quarter of 2023 primarily related to the write-down of certain indefinite-lived intangible assets due to increases in the relevant discount rates. Asset impairments during 2022 included a charge of $59 million related to the write-off of an IPR&D asset with no alternative future use licensed from BexCaFe and a $22 million charge related to the finalization of the write-down upon sale of the Speke site (see Note 4. Acquisitions, Divestitures and Other Arrangements for further discussion on each of these items).
Schedule of Activity in Reserves
The changes in our restructuring reserves during the nine months ended September 30, 2023, were as follows:
Balance at December 31, 2022$36 
Cash paid(29)
Balance at September 30, 2023$7 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of the following:
September 30, 2023December 31, 2022
Finished products$831 $783 
Work in process772 683 
Raw materials and supplies145 130 
Total1,748 1,596 
Decrease to LIFO cost(58)(58)
Inventories$1,690 $1,538 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt consisted of the following:
September 30, 2023December 31, 2022
Incremental Term Facility due 2025$175 $175 
Incremental Term Facility due 2028490 494 
Incremental Term Facility due 2029247 249 
Term Loan B due 20273,849 3,881 
Revolving Credit Facility (1)
297 — 
Securitization Facility (2)
153 — 
4.272% Senior Notes due 2023 (3)
— 344 
4.900% Senior Notes due 2028 (4)
750 750 
TEU Amortizing Notes due 2023 (5)
— 7 
Unamortized debt issuance costs(52)(64)
5,909 5,836 
Less current portion of long-term debt39 388 
Total long-term debt$5,870 $5,448 
(1)During the nine months ended September 30, 2023, we drew $350 million on our Revolving Credit Facility (subsequently repaying $53 million), both to fund working capital needs and to partially fund the repayment of the 4.272% Senior Notes due 2023 (see below for further information). Our Revolving Credit Facility provides up to $750 million in borrowing capacity (with incremental capacity if certain conditions are met), bears interest at Term SOFR plus 2.10% and matures in August 2025.
(2)In August 2023, we entered into a new secured term facility that is secured and collateralized by our U.S. Net Eligible Receivables Balance (see below for further information).
(3)We redeemed the 4.272% Senior Notes due 2023 in full in August 2023 (see below for further information).
(4)Subsequent to issuance in August 2018, the 4.900% Senior Notes due 2028 have been subject to interest rate increases related to credit rating agency downgrades. As of September 30, 2023, these notes bear interest at a rate of 6.650%.
(5)The TEU Amortizing Notes due 2023 matured on February 1, 2023 (see Note 7. Equity for further information).
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Gains (Losses) , Net of Tax
The amounts of net gains (losses) on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Foreign exchange forward contracts (1)
$1 $(5)$2 $(20)
(1)These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.
The amounts of gains (losses) on derivatives designated as cash flow hedges and net investment hedges, net of tax, recorded in other comprehensive loss were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Forward-starting interest rate swaps$— $62 $(19)$179 
Cross-currency fixed interest rate swaps9 — 9 — 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Information The following table summarizes the fair value information at September 30, 2023 and December 31, 2022 for assets and liabilities measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt, for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2023
Recurring fair value measurements
Prepaid expenses and other - derivative instruments$64 $— $64 $— $64 
Other noncurrent assets - derivative instruments32 — 32 — 32 
Other noncurrent assets - investments with readily determinable fair value8 8 — — 8 
Other current liabilities - derivative instruments(61)— (61)— (61)
Other current liabilities - contingent consideration(16)— — (16)(16)
Other noncurrent liabilities - contingent consideration(33)— — (33)(33)
Financial instruments not carried at fair value
Long-term debt, including current portion(5,961)— (5,877)— (5,877)
December 31, 2022
Recurring fair value measurements
Prepaid expenses and other - derivative instruments$90 $— $90 $— $90 
Other noncurrent assets - derivative instruments10 — 10 — 10 
Other noncurrent assets - investments with readily determinable fair value7 7 — — 7 
Other current liabilities - derivative instruments(64)— (64)— (64)
Financial instruments not carried at fair value
Long-term debt, including current portion(5,900)— (5,711)— (5,711)
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill (Tables)
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table summarizes the changes in the carrying amount of goodwill:
Balance as of December 31, 2022$5,993 
     Additions related to acquisitions2 
     Impairment charge(1,042)
     Foreign currency translation adjustments(51)
Balance as of September 30, 2023$4,902 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of Provision for Taxes on Income
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Income tax (benefit) expense$(1)$21 $22 $41 
Effective tax rate0.2 %(47.7)%(2.0)%234.3 %
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Earning Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Basic And Diluted Weighted-average Shares Outstanding
Basic and diluted weighted-average shares outstanding were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Determination of shares:
Basic weighted-average common shares outstanding (1)
492.7 488.4492.1 488.3
Assumed conversion of dilutive common stock equivalents (2)
— — — — 
Diluted weighted-average shares outstanding492.7 488.4492.1 488.3
(1)The TEU prepaid stock purchase contracts were convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares. The minimum 14.3 million shares were included in the calculation of basic weighted-average shares from January 22, 2020 to February 1, 2023. The 17.2 million shares that were ultimately issued were included in the calculation of basic weighted-average shares subsequent to the settlement date of February 1, 2023.
(2)For the three months ended September 30, 2023 and 2022, approximately 2.7 million and 4.4 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2023 and 2022, approximately 2.7 million and 2.6 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Concentration Risk [Line Items]      
Accounts receivable, net $ 911   $ 797
Product Sales      
Concentration Risk [Line Items]      
Accounts receivable, net $ 96   $ 73
Customer Concentration Risk | Revenue | Single Customer      
Concentration Risk [Line Items]      
Concentration risk 10.00% 11.00%  
Product Return Concentration Risk | Net revenue | Global Customers      
Concentration Risk [Line Items]      
Concentration risk 1.00% 1.00%  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Activity in Sales Rebates and Discounts Liability (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Change In Contract With Customer, Liability [Roll Forward]    
Beginning balance $ 324 $ 319
Reduction of revenue 558 524
Payments (522) (521)
Foreign currency translation adjustments (4) (18)
Ending balance $ 356 $ 304
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Revenue $ 1,068 $ 1,026 $ 3,382 $ 3,426
United States        
Disaggregation of Revenue [Line Items]        
Revenue 479 475 1,522 1,536
International        
Disaggregation of Revenue [Line Items]        
Revenue 589 551 1,860 1,890
Pet Health        
Disaggregation of Revenue [Line Items]        
Revenue 495 469 1,688 1,718
Farm Animal        
Disaggregation of Revenue [Line Items]        
Revenue 561 545 1,661 1,667
Cattle        
Disaggregation of Revenue [Line Items]        
Revenue 242 227 700 722
Poultry        
Disaggregation of Revenue [Line Items]        
Revenue 184 176 545 529
Swine        
Disaggregation of Revenue [Line Items]        
Revenue 93 95 284 284
Aqua        
Disaggregation of Revenue [Line Items]        
Revenue 42 47 132 132
Contract Manufacturing        
Disaggregation of Revenue [Line Items]        
Revenue $ 12 $ 12 $ 33 $ 41
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions, Divestitures and Other Arrangements - Schedule of The Composition of The Purchase Consideration (Details) - NutriQuest, LLC
$ in Millions
Jan. 03, 2023
USD ($)
Business Acquisition [Line Items]  
Up-front cash consideration $ 16
Deferred cash consideration due January 4, 2024 5
Fair value of contingent consideration 37
Total purchase consideration $ 58
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions, Divestitures and Other Arrangements - NutriQuest US Acquisition & NutriQuest Brazil Acquisition (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Aug. 01, 2023
Jan. 03, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Business Acquisition [Line Items]            
Revenue     $ 1,068 $ 1,026 $ 3,382 $ 3,426
NutriQuest, LLC            
Business Acquisition [Line Items]            
Contingent consideration liability     $ 42   42  
Fair value of contingent consideration   $ 37        
Weighted average useful life   12 years        
Total purchase consideration   $ 58        
Up-front cash consideration   16        
NutriQuest, LLC | NutriQuest, LLC            
Business Acquisition [Line Items]            
Revenue         $ 16  
NutriQuest Brazil            
Business Acquisition [Line Items]            
Contingent consideration liability $ 16          
Weighted average useful life 9 years          
Total purchase consideration $ 19          
Up-front cash consideration $ 3          
Maximum | NutriQuest, LLC            
Business Acquisition [Line Items]            
Contingent consideration liability   $ 85        
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Aug. 01, 2023
Jan. 03, 2023
Dec. 31, 2022
Business Acquisition [Line Items]        
Goodwill $ 4,902     $ 5,993
NutriQuest, LLC        
Business Acquisition [Line Items]        
Inventories     $ 3  
Total identifiable assets     57  
Goodwill     1  
Total consideration transferred     58  
NutriQuest, LLC | Marketed products        
Business Acquisition [Line Items]        
Definite-lived intangible assets     29  
NutriQuest, LLC | Acquired in-process research and development (IPR&D)        
Business Acquisition [Line Items]        
Definite-lived intangible assets     10  
NutriQuest, LLC | Other intangible assets        
Business Acquisition [Line Items]        
Definite-lived intangible assets     $ 15  
NutriQuest Brazil        
Business Acquisition [Line Items]        
Inventories   $ 3    
Definite-lived intangible assets   15    
Total identifiable assets   18    
Goodwill   1    
Total consideration transferred   $ 19    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions, Divestitures and Other Arrangements - Divestitures and BexCaFe Arrangement (Details)
$ in Millions
 1 Months Ended 9 Months Ended 12 Months Ended 26 Months Ended
May 31, 2023
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Feb. 01, 2022
USD ($)
Dec. 31, 2021
employee
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Contract with customer, asset, before allowance for credit loss           $ 55  
Liabilities   $ 8,210 $ 8,202 $ 8,210      
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Liabilities         $ 59    
Payment on agreement   13          
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC | Future Milestone Payments And Sales Royalties              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Liabilities   $ 35   35 49    
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC | Acquired in-process research and development (IPR&D)              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Finite-lived intangible assets         $ 59    
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Number of employees transferred | employee             600
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Microbiome R&D Platform Carve-Out              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gain on disposal     $ 3        
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Shawnee and Speke              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Proceeds from site divestitures       73      
Duration over which proceeds will be received 12 months            
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Shawnee and Speke | Other Receivables              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Proceeds from site divestitures       $ 67      
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]          
Restructuring charges (credits) $ 0 $ 0 $ 0 $ (7)  
Acquisition related charges 11 27 86 77  
Asset impairments and other items 5 (1) 5 82  
Total expense $ 16 $ 26 $ 91 $ 152  
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Speke Site          
Restructuring Cost and Reserve [Line Items]          
Asset impairments and other items         $ 22
Variable Interest Entity, Primary Beneficiary | BexCaFe, LLC | Acquired in-process research and development (IPR&D)          
Restructuring Cost and Reserve [Line Items]          
Asset impairments and other items         $ 59
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Restructuring Reserve [Roll Forward]  
Balance at beginning of period $ 36
Cash paid (29)
Balance at end of period $ 7
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Finished products $ 831 $ 783
Work in process 772 683
Raw materials and supplies 145 130
Total 1,748 1,596
Decrease to LIFO cost (58) (58)
Inventories $ 1,690 $ 1,538
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Equity (Details) - Tangible Equity Unit - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended
Jan. 31, 2020
Feb. 01, 2023
Class of Stock [Line Items]    
TEUs issued (in shares) 11,000,000  
Offering price (usd per share) $ 50  
Proceeds after underwriting discounts and commissions $ 528  
Equity component 86.00%  
Debt component 14.00%  
Settlement rate   156.25%
Shares issued upon conversion of prepaid stock purchase contracts (in shares)   17,000,000
Maximum    
Class of Stock [Line Items]    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share)   $ 32.00
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Long-term Debt (Details) - USD ($)
$ in Millions
 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 03, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Aug. 31, 2023
Dec. 31, 2022
Aug. 31, 2018
Debt Instrument [Line Items]                
Unamortized debt issuance costs   $ (52) $ (52) $ (52)     $ (64)  
Total debt   5,909 5,909 5,909     5,836  
Less current portion of long-term debt   39 39 39     388  
Total long-term debt   5,870 5,870 5,870     5,448  
Securitization Facility                
Debt Instrument [Line Items]                
Proceeds from Revolving Credit Facility       250 $ 0      
Repayment of revolving credit facility       97 $ 0      
Line of Credit | Secured Debt | Incremental Term Facility due 2025                
Debt Instrument [Line Items]                
Long-term debt, gross   175 175 175     175  
Line of Credit | Secured Debt | Incremental Term Facility due 2028                
Debt Instrument [Line Items]                
Long-term debt, gross   490 490 490     494  
Line of Credit | Secured Debt | Incremental Term Facility due 2029                
Debt Instrument [Line Items]                
Long-term debt, gross   247 247 247     249  
Line of Credit | Secured Debt | Securitization Facility                
Debt Instrument [Line Items]                
Long-term debt, gross   153 153 153     0  
Proceeds from Revolving Credit Facility $ 250              
Repayment of revolving credit facility   97            
Line of Credit | Secured Debt | Securitization Facility | Secured Overnight Financing Rate (SOFR)                
Debt Instrument [Line Items]                
Basis spread on variable rate 1.25%              
Line of Credit | Term Loan B due 2027                
Debt Instrument [Line Items]                
Long-term debt, gross   3,849 3,849 3,849     3,881  
Line of Credit | Revolving Credit Facility                
Debt Instrument [Line Items]                
Long-term debt, gross   297 297 297     0  
Proceeds from Revolving Credit Facility     100 350        
Repayment of revolving credit facility       53        
Credit facility, maximum borrowing capacity   750 750 $ 750        
Line of Credit | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR)                
Debt Instrument [Line Items]                
Basis spread on variable rate       2.10%        
Senior Notes | 4.272% Senior Notes due 2023                
Debt Instrument [Line Items]                
Long-term debt, gross   $ 0 $ 0 $ 0     344  
Interest rate   4.272% 4.272% 4.272%   4.272%    
Senior Notes | Senior Notes due 2028                
Debt Instrument [Line Items]                
Long-term debt, gross   $ 750 $ 750 $ 750     750  
Interest rate   4.90% 4.90% 4.90%       4.90%
Effective interest rate   6.65% 6.65% 6.65%        
Senior Notes | TEU Amortizing Notes due 2023                
Debt Instrument [Line Items]                
Long-term debt, gross   $ 0 $ 0 $ 0     $ 7  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Narrative (Details) - USD ($)
$ in Millions
 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 03, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Aug. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]              
Percentage of long term debt bearing fixed interest   76.00% 76.00% 76.00%      
Credit Facility | Revolving Credit Facility              
Debt Instrument [Line Items]              
Proceeds from Revolving Credit Facility     $ 100 $ 350      
Repayment of revolving credit facility       53      
Long-term debt, gross   $ 297 297 $ 297     $ 0
Credit Facility | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR)              
Debt Instrument [Line Items]              
Basis spread on variable rate       2.10%      
Securitization Facility              
Debt Instrument [Line Items]              
Proceeds from Revolving Credit Facility       $ 250 $ 0    
Repayment of revolving credit facility       97 $ 0    
Securitization Facility | Credit Facility | Secured Debt              
Debt Instrument [Line Items]              
Debt instrument, face amount $ 300            
Proceeds from Revolving Credit Facility $ 250            
Repayment of revolving credit facility   97          
Long-term debt, gross   $ 153 $ 153 $ 153     0
Securitization Facility | Credit Facility | Secured Debt | Secured Overnight Financing Rate (SOFR)              
Debt Instrument [Line Items]              
Debt maturity term 3 years            
Basis spread on variable rate 1.25%            
4.272% Senior Notes due 2023 | Senior Notes              
Debt Instrument [Line Items]              
Interest rate   4.272% 4.272% 4.272%   4.272%  
Long-term debt, gross   $ 0 $ 0 $ 0     $ 344
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments - Narrative (Details)
$ in Millions, SFr in Billions
 1 Months Ended 3 Months Ended 9 Months Ended
May 01, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
CHF (SFr)
Dec. 31, 2022
USD ($)
Derivative Instruments, Gain (Loss) [Line Items]                
Proceeds from interest rate swap settlements         $ 57 $ 207    
Reclassification of gain (loss) from AOCI     $ 35 $ 11 94 (10)    
Unrealized gains to be reclassified during next 12 months     $ 120   $ 120      
Weighted Average                
Derivative Instruments, Gain (Loss) [Line Items]                
Effective interest rate     6.34%   6.34%   6.34%  
Designated as Hedging Instrument                
Derivative Instruments, Gain (Loss) [Line Items]                
Unrealized gain (loss) on investments     $ 24 $ 75 $ 57 $ 218    
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument                
Derivative Instruments, Gain (Loss) [Line Items]                
Notional amount     864   864     $ 784
Cross-currency fixed interest rate swap | Designated as Hedging Instrument | Net Investment Hedging                
Derivative Instruments, Gain (Loss) [Line Items]                
Notional amount | SFr             SFr 1  
Interest Rate Swap | Designated as Hedging Instrument                
Derivative Instruments, Gain (Loss) [Line Items]                
Notional amount     3,800   3,800     $ 3,050
Increase in derivative notional amount during period $ 750 $ 1,000            
Derivative amount restructured     $ 3,050   $ 3,050      
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments - Net Losses/Gains on Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Interest Rate Swap | Designated as Hedging Instrument | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Other comprehensive income (loss), net investment hedge, gain (loss), net of tax $ 0 $ 62 $ (19) $ 179
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Foreign exchange forward contracts 1 (5) 2 (20)
Cross-currency fixed interest rate swap | Designated as Hedging Instrument | Net Investment Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Other comprehensive income (loss), net investment hedge, gain (loss), net of tax $ 9 $ 0 $ 9 $ 0
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Schedule of Fair Value Information (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion $ 0 $ 0
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion (5,877) (5,711)
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion 0 0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion (5,961) (5,900)
Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, including current portion (5,877) (5,711)
Prepaid expenses and other | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Prepaid expenses and other | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 64 90
Prepaid expenses and other | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Prepaid expenses and other | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 64 90
Prepaid expenses and other | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 64 90
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Investments with readily determinable fair value 8 7
Other noncurrent assets | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 32 10
Investments with readily determinable fair value 0 0
Other noncurrent assets | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Investments with readily determinable fair value 0 0
Other noncurrent assets | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 32 10
Investments with readily determinable fair value 8 7
Other noncurrent assets | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 32 10
Investments with readily determinable fair value 8 7
Other current liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Contingent consideration 0  
Other current liabilities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (61) (64)
Contingent consideration 0  
Other current liabilities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Contingent consideration (16)  
Other current liabilities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (61) (64)
Contingent consideration (16)  
Other current liabilities | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (61) $ (64)
Contingent consideration (16)  
Other noncurrent liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0  
Other noncurrent liabilities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0  
Other noncurrent liabilities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (33)  
Other noncurrent liabilities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (33)  
Other noncurrent liabilities | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ (33)  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Jan. 03, 2023
Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Equity method investments $ 28   $ 27
NutriQuest, LLC      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration liability $ 42    
NutriQuest, LLC | Maximum      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration liability   $ 85  
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill - Goodwill Activity (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Goodwill [Roll Forward]        
Balance as of December 31, 2022     $ 5,993  
Additions related to acquisitions     2  
Impairment charge $ (1,042) $ 0 (1,042) $ 0
Foreign currency translation adjustments     (51)  
Balance as of September 30, 2023 $ 4,902   $ 4,902  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]        
Impairment charge $ 1,042 $ 0 $ 1,042 $ 0
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes - Provision for Taxes on Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ (1) $ 21 $ 22 $ 41
Effective tax rate 0.20% (47.70%) (2.00%) 234.30%
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ (1) $ 21 $ 22 $ 41
Effective tax rate 0.20% (47.70%) (2.00%) 234.30%
Release of stranded tax benefits       $ 17
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Details) - USD ($)
$ in Millions
 3 Months Ended
Jun. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Loss Contingencies [Line Items]        
Operating lease, lease not yet commenced liability   $ 378    
Lessee, operating lease, lease not yet commenced, term of contract   25 years    
New corporate headquarters, estimated total incentive to be funded by TIF   $ 64    
Tax incremental financing, commitment amount       $ 64
Refund within next three months     $ 15  
Seresto Class Action Lawsuits        
Loss Contingencies [Line Items]        
Accrual charge $ 15      
Loss contingency accrual   $ 15    
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Earning Per Share (Details) - shares
shares in Millions
 3 Months Ended 8 Months Ended 9 Months Ended 36 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Jan. 31, 2023
Determination of shares:            
Basic weighted-average common shares outstanding (in shares) 492.7 488.4   492.1 488.3  
Assumed conversion of dilutive common stock equivalents (in shares) 0.0 0.0   0.0 0.0  
Diluted weighted-average shares outstanding (in shares) 492.7 488.4   492.1 488.3  
Antidilutive shares not included in calculating diluted loss per share (in shares) 2.7 4.4   2.7 2.6  
Tangible Equity Unit            
Determination of shares:            
Conversion of tangible equity units (TEUs) into common stock (in shares)     17.2      
Minimum | Tangible Equity Unit            
Determination of shares:            
Conversion of tangible equity units (TEUs) into common stock (in shares)       14.3   14.3
Maximum | Tangible Equity Unit            
Determination of shares:            
Conversion of tangible equity units (TEUs) into common stock (in shares)       17.2    
XML 69 elan-20230930_htm.xml IDEA: XBRL DOCUMENT 0001739104 2023-01-01 2023-09-30 0001739104 2023-11-02 0001739104 2023-07-01 2023-09-30 0001739104 2022-07-01 2022-09-30 0001739104 2022-01-01 2022-09-30 0001739104 2023-09-30 0001739104 2022-12-31 0001739104 us-gaap:CommonStockMember 2021-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001739104 us-gaap:RetainedEarningsMember 2021-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001739104 2021-12-31 0001739104 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001739104 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001739104 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001739104 us-gaap:CommonStockMember 2022-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001739104 us-gaap:RetainedEarningsMember 2022-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001739104 2022-03-31 0001739104 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001739104 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-04-01 2022-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001739104 us-gaap:CommonStockMember 2022-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001739104 us-gaap:RetainedEarningsMember 2022-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001739104 2022-06-30 0001739104 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001739104 us-gaap:CommonStockMember 2022-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001739104 us-gaap:RetainedEarningsMember 2022-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001739104 2022-09-30 0001739104 us-gaap:CommonStockMember 2022-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001739104 us-gaap:RetainedEarningsMember 2022-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001739104 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001739104 2023-01-01 2023-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001739104 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001739104 us-gaap:CommonStockMember 2023-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001739104 us-gaap:RetainedEarningsMember 2023-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001739104 2023-03-31 0001739104 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001739104 2023-04-01 2023-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 2023-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001739104 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001739104 us-gaap:CommonStockMember 2023-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001739104 us-gaap:RetainedEarningsMember 2023-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001739104 2023-06-30 0001739104 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2023-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001739104 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001739104 us-gaap:CommonStockMember 2023-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001739104 us-gaap:RetainedEarningsMember 2023-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-09-30 0001739104 elan:SecuritizationFacilityMember 2023-01-01 2023-09-30 0001739104 elan:SecuritizationFacilityMember 2022-01-01 2022-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001739104 us-gaap:ProductMember 2023-09-30 0001739104 us-gaap:ProductMember 2022-12-31 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2023-01-01 2023-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2022-01-01 2022-09-30 0001739104 elan:PetHealthMember 2023-07-01 2023-09-30 0001739104 elan:PetHealthMember 2022-07-01 2022-09-30 0001739104 elan:PetHealthMember 2023-01-01 2023-09-30 0001739104 elan:PetHealthMember 2022-01-01 2022-09-30 0001739104 elan:CattleMember 2023-07-01 2023-09-30 0001739104 elan:CattleMember 2022-07-01 2022-09-30 0001739104 elan:CattleMember 2023-01-01 2023-09-30 0001739104 elan:CattleMember 2022-01-01 2022-09-30 0001739104 elan:PoultryMember 2023-07-01 2023-09-30 0001739104 elan:PoultryMember 2022-07-01 2022-09-30 0001739104 elan:PoultryMember 2023-01-01 2023-09-30 0001739104 elan:PoultryMember 2022-01-01 2022-09-30 0001739104 elan:SwineMember 2023-07-01 2023-09-30 0001739104 elan:SwineMember 2022-07-01 2022-09-30 0001739104 elan:SwineMember 2023-01-01 2023-09-30 0001739104 elan:SwineMember 2022-01-01 2022-09-30 0001739104 elan:AquaMember 2023-07-01 2023-09-30 0001739104 elan:AquaMember 2022-07-01 2022-09-30 0001739104 elan:AquaMember 2023-01-01 2023-09-30 0001739104 elan:AquaMember 2022-01-01 2022-09-30 0001739104 elan:FarmAnimalMember 2023-07-01 2023-09-30 0001739104 elan:FarmAnimalMember 2022-07-01 2022-09-30 0001739104 elan:FarmAnimalMember 2023-01-01 2023-09-30 0001739104 elan:FarmAnimalMember 2022-01-01 2022-09-30 0001739104 elan:ContractManufacturingMember 2023-07-01 2023-09-30 0001739104 elan:ContractManufacturingMember 2022-07-01 2022-09-30 0001739104 elan:ContractManufacturingMember 2023-01-01 2023-09-30 0001739104 elan:ContractManufacturingMember 2022-01-01 2022-09-30 0001739104 country:US 2023-07-01 2023-09-30 0001739104 country:US 2022-07-01 2022-09-30 0001739104 country:US 2023-01-01 2023-09-30 0001739104 country:US 2022-01-01 2022-09-30 0001739104 us-gaap:NonUsMember 2023-07-01 2023-09-30 0001739104 us-gaap:NonUsMember 2022-07-01 2022-09-30 0001739104 us-gaap:NonUsMember 2023-01-01 2023-09-30 0001739104 us-gaap:NonUsMember 2022-01-01 2022-09-30 0001739104 elan:NutriQuestLLCMember 2023-01-03 2023-01-03 0001739104 srt:MaximumMember elan:NutriQuestLLCMember 2023-01-03 0001739104 elan:NutriQuestLLCMember 2023-01-03 0001739104 elan:NutriQuestLLCMember elan:MarketedProductsMember 2023-01-03 0001739104 elan:NutriQuestLLCMember us-gaap:InProcessResearchAndDevelopmentMember 2023-01-03 0001739104 elan:NutriQuestLLCMember us-gaap:OtherIntangibleAssetsMember 2023-01-03 0001739104 elan:NutriQuestLLCMember elan:NutriQuestLLCMember 2023-01-01 2023-09-30 0001739104 elan:NutriQuestNutricaoAnimalLtdaMember 2023-08-01 2023-08-01 0001739104 elan:NutriQuestNutricaoAnimalLtdaMember 2023-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:MicrobiomeRDPlatformCarveOutMember 2022-01-01 2022-12-31 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2021-12-31 0001739104 2022-02-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeAndSpekeMember 2021-08-01 2023-09-30 0001739104 elan:OtherReceivablesMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeAndSpekeMember 2021-08-01 2023-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeAndSpekeMember 2023-05-01 2023-05-31 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember us-gaap:InProcessResearchAndDevelopmentMember 2022-06-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember 2022-06-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember elan:FutureMilestonePaymentsAndSalesRoyaltiesMember 2022-06-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember 2023-01-01 2023-09-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember elan:FutureMilestonePaymentsAndSalesRoyaltiesMember 2023-09-30 0001739104 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember elan:BexCaFeLLCMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:SpekeSiteMember 2022-01-01 2022-12-31 0001739104 elan:TangibleEquityUnitMember 2020-01-01 2020-01-31 0001739104 elan:TangibleEquityUnitMember 2020-01-31 0001739104 elan:TangibleEquityUnitMember 2023-02-01 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember 2023-02-01 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDueJune302025Member us-gaap:LineOfCreditMember 2023-09-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDueJune302025Member us-gaap:LineOfCreditMember 2022-12-31 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDueAugust122028Member us-gaap:LineOfCreditMember 2023-09-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDueAugust122028Member us-gaap:LineOfCreditMember 2022-12-31 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDueApril192029Member us-gaap:LineOfCreditMember 2023-09-30 0001739104 us-gaap:SecuredDebtMember elan:IncrementalTermFacilityDueApril192029Member us-gaap:LineOfCreditMember 2022-12-31 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001739104 us-gaap:SecuredDebtMember elan:SecuritizationFacilityMember us-gaap:LineOfCreditMember 2023-09-30 0001739104 us-gaap:SecuredDebtMember elan:SecuritizationFacilityMember us-gaap:LineOfCreditMember 2022-12-31 0001739104 elan:A4272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-09-30 0001739104 elan:A4272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2022-12-31 0001739104 elan:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2023-09-30 0001739104 elan:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2022-12-31 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2023-09-30 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2022-12-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember elan:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001739104 elan:A4272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2023-08-31 0001739104 elan:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2018-08-31 0001739104 us-gaap:SecuredDebtMember elan:SecuritizationFacilityMember us-gaap:LineOfCreditMember 2023-08-03 0001739104 us-gaap:SecuredDebtMember elan:SecuritizationFacilityMember us-gaap:LineOfCreditMember 2023-08-03 2023-08-03 0001739104 us-gaap:SecuredDebtMember elan:SecuritizationFacilityMember us-gaap:LineOfCreditMember elan:SecuredOvernightFinancingRateSOFRMember 2023-08-03 2023-08-03 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-07-01 2023-09-30 0001739104 us-gaap:SecuredDebtMember elan:SecuritizationFacilityMember us-gaap:LineOfCreditMember 2023-08-04 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-07-01 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0001739104 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001739104 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001739104 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-01 2023-03-31 0001739104 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-05-01 2023-05-01 0001739104 srt:WeightedAverageMember 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0001739104 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0001739104 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001739104 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001739104 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0001739104 us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001739104 elan:NutriQuestLLCMember 2023-09-30 0001739104 elan:SerestoClassActionLawsuitsMember 2023-04-01 2023-06-30 0001739104 elan:SerestoClassActionLawsuitsMember 2023-09-30 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember 2023-01-01 2023-09-30 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember 2023-01-01 2023-09-30 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember 2020-01-22 2023-01-31 0001739104 elan:TangibleEquityUnitMember 2023-02-01 2023-09-30 shares iso4217:USD iso4217:USD shares pure elan:employee iso4217:CHF false 2023 Q3 0001739104 --12-31 10-Q true 2023-09-30 false 001-38661 Elanco Animal Health Inc IN 82-5497352 2500 INNOVATION WAY GREENFIELD IN 46140 877 352-6261 Common stock, no par value ELAN NYSE Yes Yes Large Accelerated Filer false false false 492798113 1068000000 1026000000 3382000000 3426000000 487000000 472000000 1415000000 1465000000 86000000 78000000 248000000 241000000 313000000 298000000 993000000 963000000 140000000 128000000 410000000 398000000 16000000 26000000 91000000 152000000 1042000000 0 1042000000 0 72000000 60000000 210000000 179000000 -9000000 -8000000 -41000000 -11000000 2165000000 1070000000 4450000000 3409000000 -1097000000 -44000000 -1068000000 17000000 -1000000 21000000 22000000 41000000 -1096000000 -65000000 -1090000000 -24000000 -2.22 -0.13 -2.21 -0.05 -2.22 -0.13 -2.21 -0.05 492700000 488400000 492100000 488300000 492700000 488400000 492100000 488300000 -1096000000 -65000000 -1090000000 -24000000 0 62000000 -19000000 179000000 -197000000 -418000000 -65000000 -973000000 4000000 2000000 6000000 4000000 -201000000 -358000000 -90000000 -798000000 -1297000000 -423000000 -1180000000 -822000000 369000000 345000000 911000000 797000000 224000000 205000000 1690000000 1538000000 371000000 394000000 3565000000 3279000000 4902000000 5993000000 4475000000 4842000000 410000000 378000000 992000000 999000000 14344000000 15491000000 296000000 390000000 356000000 324000000 39000000 388000000 574000000 600000000 1265000000 1702000000 5870000000 5448000000 643000000 662000000 432000000 390000000 8210000000 8202000000 5000000000 5000000000 492683420 492683420 474237738 474237738 0 0 8763000000 8738000000 -2147000000 -1057000000 -482000000 -392000000 6134000000 7289000000 14344000000 15491000000 473100000 0 8696000000 -979000000 25000000 -253000000 19000000 -209000000 7508000000 51000000 51000000 109000000 -85000000 -1000000 23000000 23000000 1000000.0 3000000 3000000 474100000 0 8699000000 -928000000 134000000 -338000000 18000000 -186000000 7585000000 -10000000 -10000000 8000000 -470000000 -1000000 -463000000 -463000000 13000000 13000000 474100000 0 8712000000 -938000000 142000000 -808000000 17000000 -649000000 7125000000 -65000000 -65000000 62000000 -418000000 -2000000 -358000000 -358000000 12000000 12000000 474100000 0 8724000000 -1003000000 204000000 -1226000000 15000000 -1007000000 6714000000 474200000 0 8738000000 -1057000000 182000000 -672000000 98000000 -392000000 7289000000 103000000 103000000 -48000000 130000000 82000000 82000000 1000000.0 6000000 6000000 17200000 492400000 0 8744000000 -954000000 134000000 -542000000 98000000 -310000000 7480000000 -97000000 -97000000 29000000 2000000 -2000000 29000000 29000000 200000 8000000 8000000 492600000 0 8752000000 -1051000000 163000000 -540000000 96000000 -281000000 7420000000 -1096000000 -1096000000 -197000000 -4000000 -201000000 -201000000 100000 11000000 11000000 492700000 0 8763000000 -2147000000 163000000 -737000000 92000000 -482000000 6134000000 -1090000000 -24000000 523000000 514000000 1042000000 0 31000000 44000000 5000000 81000000 57000000 207000000 446000000 385000000 -8000000 2000000 114000000 439000000 99000000 94000000 19000000 0 14000000 11000000 2000000 -2000000 -134000000 -103000000 350000000 563000000 53000000 813000000 250000000 0 97000000 0 0 425000000 388000000 607000000 -6000000 -33000000 56000000 -465000000 -12000000 -49000000 24000000 -178000000 345000000 638000000 369000000 460000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. Basis of Presentation and Summary of Significant Accounting Policies</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies set forth in Note 4 to the consolidated financial statements in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> appropriately represent, in all material respects, the current status of our accounting policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:117%">Revision of Previously Issued Consolidated Financial Statements</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified and corrected relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. In conjunction with making these corrections, we made other adjustments to the prior years to revise uncorrected errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. Further information is included in Note 2 and Note 21 to the consolidated financial statements in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span>. <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div> <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Implementation of New Financial Accounting Pronouncements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial Statements or Other Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2022-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements. </span></div></td></tr></table></div> <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial Statements or Other Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2022-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements. </span></div></td></tr></table></div> <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was adopted during the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial Statements or Other Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2022-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements. </span></div></td></tr></table></div> <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. Revenue </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligations, which is </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally once the goods have been shipped and the customer has assumed title. For contract manufacturing organization (CMO) arrangements, we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a single customer that accounted for approximately 10% and 11% of revenue for the nine months ended September 30, 2023 and 2022, respectively. Product sales with this customer resulted in accounts receivable of $96 million and $73 million at September 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for sales rebates and discounts are recorded as a reduction to revenue in the period the related sales are recognized and are based on specific agreements. In determining the appropriate accrual amount, we consider our historical experience with similar incentive programs, current sales data and estimates of inventory levels at our channel distributors. The following table summarizes the activity in our global sales rebates and discounts liability:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to revenue recognized as a result of changes in estimates during the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023 and 2022 for product shipped in previous periods were not material. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2023 and 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by product category:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cattle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poultry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swine</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aqua</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Farm Animal</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents revenue from arrangements in which we manufacture products on behalf of a third party. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by geographic area: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.10 0.11 96000000 73000000 The following table summarizes the activity in our global sales rebates and discounts liability:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 324000000 319000000 558000000 524000000 522000000 521000000 4000000 18000000 356000000 304000000 0.01 0.01 <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by product category:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cattle</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poultry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swine</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aqua</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Farm Animal</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party. 495000000 469000000 1688000000 1718000000 242000000 227000000 700000000 722000000 184000000 176000000 545000000 529000000 93000000 95000000 284000000 284000000 42000000 47000000 132000000 132000000 561000000 545000000 1661000000 1667000000 12000000 12000000 33000000 41000000 1068000000 1026000000 3382000000 3426000000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue disaggregated by geographic area: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 479000000 475000000 1522000000 1536000000 589000000 551000000 1860000000 1890000000 1068000000 1026000000 3382000000 3426000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. Acquisitions, Divestitures and Other Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NutriQuest U.S. Acquisition</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest). NutriQuest is a provider of swine, poultry and cattle nutritional health products to animal producers. The acquisition allows us to expand our existing nutritional health offerings and furthers our efforts to explore innovative antibiotic alternatives.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of the purchase price was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front cash consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cash consideration due January 4, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NutriQuest acquisition was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date, with the excess of the purchase price over the fair value of the acquired assets recorded as goodwill. The determination of estimated fair value requires management to make significant estimates and assumptions. Contingent consideration for this acquisition includes up to $85 million of cash consideration payable if specific development, sales and geographic expansion milestones are achieved, as outlined in the asset purchase agreement. The initial fair value of this contingent consideration liability of $37 million was estimated at the acquisition date using a Monte Carlo simulation model, which represented a Level 3 measurement under the fair value measurement hierarchy (see Note 10. Fair Value for further information). </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consist of customer relationships and trade names. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&amp;D expenses, marketing, selling and administrative expenses and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk and competitive trends impacting the asset and each cash flow stream, as well as other factors.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for this acquisition has not been finalized as of September 30, 2023. The purchase price allocation is preliminary and subject to change, including the valuation of the contingent consideration and intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. Revenue attributable to the NutriQuest acquisition for the nine months ended September 30, 2023, was approximately $16 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NutriQuest Brazil Acquisition</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, we acquired certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil) for total purchase consideration of $19 million. The composition of the purchase price included cash paid on the closing date of approximately $3 million, with consideration payable through 2026 valued at approximately $16 million, a portion of which is contingent upon the continuation of certain terms and conditions set forth in the asset purchase agreement. The NutriQuest Brazil acquisition was accounted for as a business combination under the acquisition method of accounting. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately nine years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach. The purchase price allocation for this acquisition is preliminary as of September 30, 2023, and subject to change, including the valuation of the intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. Neither revenue nor income before taxes included within our condensed consolidated statements of operations from NutriQuest Brazil were material for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Microbiome R&amp;D platform carve-out</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we signed an agreement to transfer assets associated with our microbiome R&amp;D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retained a non-voting, minority stake in the company. In addition, we entered into transitional services agreements with the company for certain services. Assets transferred included intellectual property and laboratory equipment. The book values of those assets were not material. We recorded a gain on disposal of the assets of approximately $3 million during the year ended December 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shawnee and Speke</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx began manufacturing existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which was included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the terms of the agreements and cash proceeds received to date, as of September 30, 2023, we had a net receivable balance from TriRx of $73 million from the sales of Shawnee and Speke, which was included within other receivables on the condensed consolidated balance sheets. In May 2023, we entered into amendments to the agreements which effectively restructured the payment schedule related to the remaining amount owed. Under the terms of the amendments we expect to receive approximately $67 million of this receivable balance upon the earlier of the date on which certain conditions are met or in equal installments over a twelve-month period beginning January 31, 2024, with the remainder due within the next 12 months. We continue to assess the collectibility of these receivables from TriRx and continue to believe amounts owed are collectible. Further, we have rights to certain collateral in the event of a default and we continue to monitor the value of this collateral.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BexCaFe Arrangement</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bexacat, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&amp;D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. There is no minimum payout due on the contingent consideration and the maximum payout related to sales royalties is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&amp;D asset because we concluded that it did not have an alternative future use. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, we paid $13 million to BexCaFe in connection with development/regulatory milestones achieved upon U.S. Food and Drug Administration (FDA) approval of the original new animal drug application for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bexacat</span> in December 2022. Remaining contingent consideration liabilities of $35 million were included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2023. <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of the purchase price was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front cash consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred cash consideration due January 4, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 16000000 5000000 37000000 58000000 85000000 37000000 <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000000 29000000 10000000 15000000 57000000 1000000 58000000 P12Y 16000000 19000000 3000000 16000000 3000000 15000000 18000000 1000000 19000000 P9Y 3000000 600 55000000 73000000 67000000 P12M 59000000 59000000 49000000 13000000 35000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. Asset Impairment, Restructuring and Other Special Charges </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash impairment charges can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of asset impairment, restructuring and other special charges were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges (credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related charges</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and other items </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Restructuring credits in 2022 related to adjustments resulting from the reversal of severance accruals associated with 2021 restructuring programs, resulting from final negotiations and certain restructured employees filling open positions.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Acquisition related charges included transaction costs directly related to acquiring businesses, such as expenditures for banking, legal, accounting, consulting and other similar services, integration charges inclusive of system and process integration and product transfers, and independent company stand-up costs related to the implementation of new systems, programs and processes.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Asset impairments during the third quarter of 2023 primarily related to the write-down of certain indefinite-lived intangible assets due to increases in the relevant discount rates. Asset impairments during 2022 included a charge of $59 million related to the write-off of an IPR&amp;D asset with no alternative future use licensed from BexCaFe and a $22 million charge related to the finalization of the write-down upon sale of the Speke site (see Note 4. Acquisitions, Divestitures and Other Arrangements for further discussion on each of these items).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our restructuring reserves during the nine months ended September 30, 2023, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>These reserves were included within other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain country-specific negotiations and regulations. <div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of asset impairment, restructuring and other special charges were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges (credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related charges</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and other items </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Restructuring credits in 2022 related to adjustments resulting from the reversal of severance accruals associated with 2021 restructuring programs, resulting from final negotiations and certain restructured employees filling open positions.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Acquisition related charges included transaction costs directly related to acquiring businesses, such as expenditures for banking, legal, accounting, consulting and other similar services, integration charges inclusive of system and process integration and product transfers, and independent company stand-up costs related to the implementation of new systems, programs and processes.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Asset impairments during the third quarter of 2023 primarily related to the write-down of certain indefinite-lived intangible assets due to increases in the relevant discount rates. Asset impairments during 2022 included a charge of $59 million related to the write-off of an IPR&amp;D asset with no alternative future use licensed from BexCaFe and a $22 million charge related to the finalization of the write-down upon sale of the Speke site (see Note 4. Acquisitions, Divestitures and Other Arrangements for further discussion on each of these items).</span></div> 0 0 0 -7000000 11000000 27000000 86000000 77000000 5000000 -1000000 5000000 82000000 16000000 26000000 91000000 152000000 59000000 22000000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our restructuring reserves during the nine months ended September 30, 2023, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 36000000 29000000 7000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. Inventories </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted-average cost method. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 831000000 783000000 772000000 683000000 145000000 130000000 1748000000 1596000000 58000000 58000000 1690000000 1538000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. Equity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tangible Equity Unit (TEU) Offering</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we issued 11 million in TEUs at the stated amount of $50 per unit. Total proceeds, net of issuance costs, were $528 million. The gross proceeds and deferred finance costs from the issuance of the TEUs were allocated 86% to equity (prepaid stock purchase contracts) and 14% to debt (TEU amortizing notes) based on the </span></div>relative fair value of the respective components of each TEU. The TEU prepaid stock purchase contracts were converted into shares of our common stock on February 1, 2023. Holders of our TEUs received 1.5625 shares of our common stock based on the maximum settlement rate for the applicable market value being below $32.00. In total, we issued approximately 17 million shares to holders in connection with the settlement. 11000000 50 528000000 0.86 0.14 1.5625 32.00 17000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. Debt </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2025</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2029</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B due 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securitization Facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU Amortizing Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,909 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,836 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,870 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">During the nine months ended September 30, 2023, we drew $350 million on our Revolving Credit Facility (subsequently repaying $53 million), both to fund working capital needs and to partially fund the repayment of the 4.272% Senior Notes due 2023 (see below for further information). Our Revolving Credit Facility provides up to $750 million in borrowing capacity (with incremental capacity if certain conditions are met), bears interest at Term SOFR plus 2.10% and matures in August 2025.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In August 2023, we entered into a new secured term facility that is secured and collateralized by our U.S. Net Eligible Receivables Balance (see below for further information). </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">We redeemed the 4.272% Senior Notes due 2023 in full in August 2023 (see below for further information).</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Subsequent to issuance in August 2018, the 4.900% Senior Notes due 2028 have been subject to interest rate increases related to credit rating agency downgrades. As of September 30, 2023, these notes bear interest at a rate of 6.650%.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">The TEU Amortizing Notes due 2023 matured on February 1, 2023 (see Note 7. Equity for further information).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Financing</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2023, we entered into a new secured term facility (the "Securitization Facility") that is secured and collateralized by our U.S. accounts receivable subject to certain adjustments (defined as the Net Eligible Receivables Balance within the applicable agreement). Of the maximum borrowing capacity under the Securitization Facility of $300 million, $250 million was drawn on August 3, 2023, based on our borrowing capacity on that date. Our borrowing capacity under the Securitization Facility is subject to fluctuation monthly based on the level of our borrowing base as reported to the lender, which is correlated to our U.S. Net Eligible Receivables Balances. The Securitization Facility requires monthly interest payments over its three-year term at a variable rate based on Term SOFR plus 125 basis points. The full, outstanding balance of the Securitization Facility is due on July 31, 2026. During the three months ended September 30, 2023, we utilized the proceeds from the Securitization Facility, in addition to a $100 million draw on our Revolving Credit Facility, to redeem in full the 4.272% Senior Notes due 2023. The early redemption of the 4.272% Senior Notes due 2023 satisfied all obligations and commitments thereunder. Subsequent to our initial $250 million draw on the Securitization Facility, $97 million was repaid, resulting in a balance of $153 million outstanding as of September 30, 2023. The Securitization Facility includes various covenants specific to the underlying composition of our U.S. accounts receivables portfolio. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, approximately 76% of our long-term indebtedness bears interest at a fixed rate, including variable-rate converted to fixed-rate through the use of interest rate swaps (see Note 9. Financial Instruments for further information). We were in compliance with all of our debt covenants as of September 30, 2023.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2025</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility due 2029</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B due 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securitization Facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU Amortizing Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,909 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,836 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,870 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">During the nine months ended September 30, 2023, we drew $350 million on our Revolving Credit Facility (subsequently repaying $53 million), both to fund working capital needs and to partially fund the repayment of the 4.272% Senior Notes due 2023 (see below for further information). Our Revolving Credit Facility provides up to $750 million in borrowing capacity (with incremental capacity if certain conditions are met), bears interest at Term SOFR plus 2.10% and matures in August 2025.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In August 2023, we entered into a new secured term facility that is secured and collateralized by our U.S. Net Eligible Receivables Balance (see below for further information). </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">We redeemed the 4.272% Senior Notes due 2023 in full in August 2023 (see below for further information).</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Subsequent to issuance in August 2018, the 4.900% Senior Notes due 2028 have been subject to interest rate increases related to credit rating agency downgrades. As of September 30, 2023, these notes bear interest at a rate of 6.650%.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">The TEU Amortizing Notes due 2023 matured on February 1, 2023 (see Note 7. Equity for further information).</span></div> 175000000 175000000 490000000 494000000 247000000 249000000 3849000000 3881000000 297000000 0 153000000 0 0.04272 0 344000000 0.04900 750000000 750000000 0 7000000 52000000 64000000 5909000000 5836000000 39000000 388000000 5870000000 5448000000 350000000 53000000 0.04272 750000000 0.0210 0.04272 0.04900 0.06650 300000000 250000000 P3Y 0.0125 100000000 0.04272 0.04272 250000000 97000000 153000000 0.76 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Financial Instruments </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our exposure to market risks, such as changes in foreign currency exchange rates and interest rates, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception. We also assess at least quarterly thereafter whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Further, we do not offset derivative assets and liabilities on the condensed consolidated balance sheets. Our outstanding positions are discussed below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. As of September 30, 2023 and December 31, 2022, we had outstanding foreign exchange contracts with aggregate notional amounts of $864 million and $784 million, respectively. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gains (losses) on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives designated as hedges</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our exposure to variable interest rate risk, we utilize interest rate swap contracts to effectively convert our variable-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated our interest rate swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2 in the fair value hierarchy (see Note 10. Fair Value for further information). </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding forward-starting interest rate swaps had maturities ranging between 2023 and 2028, with aggregate notional amounts of $3,800 million and $3,050 million as of September 30, 2023 and December 31, 2022, respectively. In March 2023, we entered into new interest rate swap agreements with a combined notional amount of $1,000 million, which became effective on October 1, 2023, following the maturity of certain swaps with the same combined notional amount. Additionally, on May 1, 2023, we entered into new interest rate swap agreements with a combined notional amount of $750 million, which became effective on June 1, 2023, and mature in August 2028. Also, in September 2023, we took advantage of market opportunities to further restructure our interest rate swap portfolio (see below for further details). As of September 30, 2023, when factoring in the $3,800 million of variable rate debt converted to fixed-rate through the use of interest rate swaps (excluding the expected future reclassifications to interest expense, net of capitalized interest related to past interest rate swap settlements), the weighted-average effective interest rate on our outstanding indebtedness was 6.34%. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a series of cross-currency fixed interest rate swaps in September 2023 with a 1 billion CHF notional amount with tenors in 2027. These instruments were determined to be, and were designated as, effective economic hedges of net investments in our CHF denominated net assets. The fair values of these instruments were estimated based on quoted market values of similar hedges and is classified as Level 2 in the fair value hierarchy. Over the life of these instruments, gains or losses due to spot rate fluctuations will be recorded as cumulative translation adjustments, as a component of other comprehensive income (loss). Gains and losses within accumulated other comprehensive income (loss) will remain in accumulated other comprehensive income (loss) until either the sale or substantial liquidation of the hedged subsidiary.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of gains (losses) on derivatives designated as cash flow hedges and net investment hedges, net of tax, recorded in other comprehensive loss were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency fixed interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive loss included gains of $24 million and a gain of $75 million, net of tax, respectively, related to mark-to-market adjustments. During the nine months ended September 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive loss included gains of $57 million and $218 million, net of tax, respectively, related to mark-to-market adjustments. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, in September 2023, we took advantage of market opportunities to restructure $3,050 million of our interest rate swap portfolio by unwinding existing swaps and simultaneously entering into new agreements with the same notional amounts and tenors extending through 2026. As a result, we received cash settlements of $57 million in the aggregate. Also, in April 2022 and September 2022, we settled certain existing interest rate swaps and simultaneously entered into new agreements with the same notional amount and covering the same tenor. As a result, we received cash settlements of $207 million in the aggregate. The cash proceeds from these interest rate swap settlements were included in net cash from operating activities in the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023 and 2022, we reclassified $35 million and $11 million of net gains, respectively, into interest expense, net of capitalized interest. During the nine months ended September 30, 2023 and 2022, we reclassified $94 million of net gains and $10 million of net losses, respectively, into interest expense, net of capitalized interest. Over the next 12 months, we expect to reclassify a gain of $120 million to interest expense, net of capitalized interest related to our derivatives designated as hedges.</span></div> 864000000 784000000 <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gains (losses) on derivative instruments not designated as hedging instruments, recorded in other expense, net were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of gains (losses) on derivatives designated as cash flow hedges and net investment hedges, net of tax, recorded in other comprehensive loss were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency fixed interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1000000 -5000000 2000000 -20000000 3800000000 3050000000 1000000000 750000000 3800000000 0.0634 1000000000 0 62000000 -19000000 179000000 9000000 0 9000000 0 24000000 75000000 57000000 218000000 3050000000 57000000 207000000 35000000 11000000 94000000 -10000000 120000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. Fair Value </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a framework that utilizes the inputs market participants use to determine the fair value of an asset or liability and establishes a fair value hierarchy to prioritize those inputs. Level 1 fair value measurements are based on quoted prices in active markets for identical assets or liabilities. We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. Our Level 3 fair value measurements, which include the value of contingent consideration as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023, are based on unobservable inputs based on little or no market activity.</span></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2023 and December 31, 2022 for assets and liabilities measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt, for which fair value is disclosed on a recurring basis: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - derivative instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments with readily determinable fair value</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial instruments not carried at fair value</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - derivative instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments with readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - derivative instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial instruments not carried at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,900)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,711)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,711)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also had investments without readily determinable fair values and equity method investments, which were classified as other noncurrent assets on our condensed consolidated balance sheets totaling $28 million and $27 million as of September 30, 2023 and December 31, 2022, respectively. These investments are not recorded at fair value on a recurring basis, and as such, are not included in the fair value table above. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total value of the contingent consideration liabilities at September 30, 2023, $42 million related to our acquisition of certain assets from NutriQuest during the first quarter of 2023 (see Note 4. Acquisitions, Divestitures and Other Arrangements for further information). We may pay up to $85 million in cash consideration related to this acquisition, which is contingent upon the achievement of specific development, sales and geographic expansion milestones, as outlined in the asset purchase agreement. The fair values of these liabilities at September 30, 2023, were estimated using the Monte Carlo simulation model, consisting of Level 3 inputs not observable in the market, including estimates relating to revenue forecasts, discount rates and volatility.</span></div> The following table summarizes the fair value information at September 30, 2023 and December 31, 2022 for assets and liabilities measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt, for which fair value is disclosed on a recurring basis: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - derivative instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments with readily determinable fair value</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial instruments not carried at fair value</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - derivative instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments with readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - derivative instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial instruments not carried at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,900)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,711)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,711)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 64000000 0 64000000 0 64000000 32000000 0 32000000 0 32000000 8000000 8000000 0 0 8000000 -61000000 0 -61000000 0 -61000000 16000000 0 0 16000000 16000000 33000000 0 0 33000000 33000000 5961000000 0 5877000000 0 5877000000 90000000 0 90000000 0 90000000 10000000 0 10000000 0 10000000 7000000 7000000 0 0 7000000 -64000000 0 -64000000 0 -64000000 5900000000 0 5711000000 0 5711000000 28000000 27000000 42000000 85000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Additions related to acquisitions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Impairment charge</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Foreign currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,902 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. Goodwill is not amortized, but is reviewed for </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">impairment at least annually on October 1, or more frequently if certain qualitative impairment indicators are present. When required, a comparison of fair value to the carrying amount of our single reporting unit is performed to determine the amount of any impairment. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. Accordingly, we performed an interim quantitative goodwill impairment test, which resulted in a $1,042 million pre-tax impairment charge. The fair value of our single reporting unit was determined using the income approach, based on a discounted cash flow model. Significant management judgment was required in estimating our reporting unit’s fair value, including, but not limited to, estimates and assumptions regarding future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these judgments based on historical experience, relevant market size, historical pricing and expected industry trends. While we believe our estimates and assumptions underlying the September 30, 2023, interim goodwill impairment test were reasonable in view of all available information, future changes in our discount rate, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on the estimated fair value of our reporting unit, exposing us to further goodwill impairment losses.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Additions related to acquisitions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Impairment charge</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Foreign currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,902 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5993000000 2000000 1042000000 -51000000 4902000000 1042000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. Income Taxes</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, we recognized an income tax benefit of $1 million and income tax expense of $22 million, respectively. Our effective tax rates of 0.2% and (2.0)%, respectively, differ from the statutory income tax rates primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, we recognized income tax expense of $21 million and $41 million, respectively. Our effective tax rates of (47.7)% and 234.3%, respectively, differ from the statutory income tax rate primarily due to the mix of earnings between periods resulting in projected losses in the U.S. and for various other foreign affiliates for which there was no tax benefit, as valuation allowances had been established in those jurisdictions. Income tax expense for the nine months ended September 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps.</span></div>We were included in Eli Lilly and Company's (Lilly's) U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in 2019 and remains ongoing. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -1000000 21000000 22000000 41000000 0.002 -0.477 -0.020 2.343 -1000000 22000000 0.002 -0.020 21000000 41000000 -0.477 2.343 17000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. Commitments and Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various legal actions that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded when it is deemed probable that we will incur a loss and we can formulate a reasonable estimate of that loss. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto Class Action Lawsuits and EPA Safety Review</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims seeking actual damages, injunctive relief and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Seresto™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. In June 2023, the parties agreed on the monetary terms of a potential settlement of the consolidated class action lawsuits, and as a result, a charge of $15 million was recorded during the three months ended June 30, 2023. The parties must still reach agreement on non-monetary terms, and any settlement, if reached, is subject to approval by the court, and likely will be subject to other conditions. This $15 million provision was included within other noncurrent liabilities on our condensed consolidated balance sheet as of September 30, 2023.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in January 2023, a lawsuit seeking damages for alleged negligence, breach of statutory regulations, breach of statutory duties and deceptive marketing was filed in Israel against Elanco and other parties, arising out of the use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foresto™ </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flea and tick collars for cats and dogs that are marketed and sold in Europe and in Israel. We intend to defend our position vigorously, and as of the date of this filing, we are unable to estimate the probability of loss or range of loss, if any. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a pesticide registered with the U.S. Environmental Protection Agency (the EPA). In April 2021, a non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto’s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pesticide registration and suspend the registration pending cancellation. In response to the EPA's request for comments from the public on the petition, we submitted a comment to the EPA supporting the safety profile of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and engaged in discussions with the EPA. On July 13, 2023, the EPA announced their completion of a comprehensive, multi-year review, with support from the FDA, of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> flea and tick collar and confirmed the continued registration of the collar, denying the citizen's petition. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA registered pet products. Based on comprehensive data from the review, the EPA concluded that</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose unreasonable risk of harm.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Legal Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the litigation matters discussed below we either believe loss is not probable or are unable to estimate the possible loss or range of loss, if any. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolutions cannot be predicted. As of September 30, 2023 and December 31, 2022, we had no material liabilities established related to the litigation matters mentioned below.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hunter v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives and other individuals. The lawsuit alleged, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit sought unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. On January 13, 2021, we filed a motion to dismiss, and on August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint. On December 7, 2022, we filed an opposition to the plaintiffs' motion, and on September 27, 2023, the Court denied the plaintiffs' motion for leave, issuing final judgment in favor of Elanco. On October 25, 2023, the plaintiffs filed a notice of appeal to the United Stated Court of Appeals for the Seventh Circuit. We continue to believe the claims made in the case are meritless, and we intend to continue to vigorously defend our position. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Saffron Capital Corporation v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the Marion Superior Court of Indiana against Elanco, certain executives and other individuals and entities. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or TEUs issued in connection with the public offering. From February 2021 to August 2022, this case was stayed in deference to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hunter v. Elanco Animal Health Inc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On October 24, 2022, we filed a motion to dismiss. On December 23, 2022, the plaintiffs filed their opposition to the motion to dismiss. Prior to the ruling on the motion to dismiss, on June 8, 2023, the plaintiffs filed a motion for leave to file a second amended complaint, which is now the operative complaint. We filed a motion to dismiss the complaint on August 7, 2023, to which the plaintiff filed their opposition on October 13, 2023. We continue to believe the claims made in the case are meritless, and we intend to vigorously defend our position.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful, exclusive dealing and tying of its flea and tick products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dealing related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantix </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. The trial is scheduled for July 2024. We intend to defend our position vigorously.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. We have recently engaged in discussions with the SEC about a possible resolution or settlement of potential disclosure claims, but there can be no assurance that a resolution or settlement will be reached. Management continues to believe that its actions were appropriate. We are unable to estimate the range of any reasonably possible loss associated with this matter.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. During 2022, we refunded approximately $15 million of the TIF proceeds to the developer. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive was included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning on the commencement date and offset future rent expense.</span></div> 15000000 15000000 378000000 P25Y 64000000 64000000 15000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. Earnings Per Share</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted-average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements. We also had variable common stock equivalents related to the TEU prepaid stock purchase contracts during the three and nine months ended September 30, 2022, and in the first quarter of 2023 through the settlement date of February 1, 2023 (see Note 7. Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards converted their holdings into common stock and that could have occurred if holders of unsettled TEUs had converted their holdings into common stock prior to the February 1, 2023 settlement date. The weighted-average number of potentially dilutive shares outstanding was calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) were considered to be anti-dilutive and as such, these shares were not included in the calculation of diluted loss per share. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted-average shares outstanding were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Determination of shares:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed conversion of dilutive common stock equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The TEU prepaid stock purchase contracts were convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares. The minimum 14.3 million shares were included in the calculation of basic weighted-average shares from January 22, 2020 to February 1, 2023. The 17.2 million shares that were ultimately issued were included in the calculation of basic weighted-average shares subsequent to the settlement date of February 1, 2023.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the three months ended September 30, 2023 and 2022, approximately 2.7 million and 4.4 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2023 and 2022, approximately 2.7 million and 2.6 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.</span></div> <div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted-average shares outstanding were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Determination of shares:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed conversion of dilutive common stock equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">The TEU prepaid stock purchase contracts were convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares. The minimum 14.3 million shares were included in the calculation of basic weighted-average shares from January 22, 2020 to February 1, 2023. The 17.2 million shares that were ultimately issued were included in the calculation of basic weighted-average shares subsequent to the settlement date of February 1, 2023.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the three months ended September 30, 2023 and 2022, approximately 2.7 million and 4.4 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2023 and 2022, approximately 2.7 million and 2.6 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.</span></div> 492700000 488400000 492100000 488300000 0 0 0 0 492700000 488400000 492100000 488300000 14300000 17200000 14300000 17200000 2700000 4400000 2700000 2600000 false false false false EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 286 217 1 false 73 0 false 6 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.elanco.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited Condensed Consolidated Statements of Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Sheet http://www.elanco.com/role/Revenue Revenue Notes 10 false false R11.htm 0000011 - Disclosure - Acquisitions, Divestitures and Other Arrangements Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements Acquisitions, Divestitures and Other Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Asset Impairment, Restructuring and Other Special Charges Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges Asset Impairment, Restructuring and Other Special Charges Notes 12 false false R13.htm 0000013 - Disclosure - Inventories Sheet http://www.elanco.com/role/Inventories Inventories Notes 13 false false R14.htm 0000014 - Disclosure - Equity Sheet http://www.elanco.com/role/Equity Equity Notes 14 false false R15.htm 0000015 - Disclosure - Debt Sheet http://www.elanco.com/role/Debt Debt Notes 15 false false R16.htm 0000016 - Disclosure - Financial Instruments Sheet http://www.elanco.com/role/FinancialInstruments Financial Instruments Notes 16 false false R17.htm 0000017 - Disclosure - Fair Value Sheet http://www.elanco.com/role/FairValue Fair Value Notes 17 false false R18.htm 0000018 - Disclosure - Goodwill Sheet http://www.elanco.com/role/Goodwill Goodwill Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.elanco.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.elanco.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Earning Per Share Sheet http://www.elanco.com/role/EarningPerShare Earning Per Share Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables Implementation of New Financial Accounting Pronouncements (Tables) Tables http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements 25 false false R26.htm 9954473 - Disclosure - Revenue (Tables) Sheet http://www.elanco.com/role/RevenueTables Revenue (Tables) Tables http://www.elanco.com/role/Revenue 26 false false R27.htm 9954474 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables Acquisitions, Divestitures and Other Arrangements (Tables) Tables http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements 27 false false R28.htm 9954475 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables Asset Impairment, Restructuring and Other Special Charges (Tables) Tables http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges 28 false false R29.htm 9954476 - Disclosure - Inventories (Tables) Sheet http://www.elanco.com/role/InventoriesTables Inventories (Tables) Tables http://www.elanco.com/role/Inventories 29 false false R30.htm 9954477 - Disclosure - Debt (Tables) Sheet http://www.elanco.com/role/DebtTables Debt (Tables) Tables http://www.elanco.com/role/Debt 30 false false R31.htm 9954478 - Disclosure - Financial Instruments (Tables) Sheet http://www.elanco.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.elanco.com/role/FinancialInstruments 31 false false R32.htm 9954479 - Disclosure - Fair Value (Tables) Sheet http://www.elanco.com/role/FairValueTables Fair Value (Tables) Tables http://www.elanco.com/role/FairValue 32 false false R33.htm 9954480 - Disclosure - Goodwill (Tables) Sheet http://www.elanco.com/role/GoodwillTables Goodwill (Tables) Tables http://www.elanco.com/role/Goodwill 33 false false R34.htm 9954481 - Disclosure - Income Taxes (Tables) Sheet http://www.elanco.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.elanco.com/role/IncomeTaxes 34 false false R35.htm 9954482 - Disclosure - Earning Per Share (Tables) Sheet http://www.elanco.com/role/EarningPerShareTables Earning Per Share (Tables) Tables http://www.elanco.com/role/EarningPerShare 35 false false R36.htm 9954483 - Disclosure - Revenue - Narrative (Details) Sheet http://www.elanco.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 36 false false R37.htm 9954484 - Disclosure - Revenue - Activity in Sales Rebates and Discounts Liability (Details) Sheet http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails Revenue - Activity in Sales Rebates and Discounts Liability (Details) Details 37 false false R38.htm 9954485 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 38 false false R39.htm 9954486 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Schedule of The Composition of The Purchase Consideration (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails Acquisitions, Divestitures and Other Arrangements - Schedule of The Composition of The Purchase Consideration (Details) Details 39 false false R40.htm 9954487 - Disclosure - Acquisitions, Divestitures and Other Arrangements - NutriQuest US Acquisition & NutriQuest Brazil Acquisition (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails Acquisitions, Divestitures and Other Arrangements - NutriQuest US Acquisition & NutriQuest Brazil Acquisition (Details) Details 40 false false R41.htm 9954488 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Details 41 false false R42.htm 9954489 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Divestitures and BexCaFe Arrangement (Details) Sheet http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails Acquisitions, Divestitures and Other Arrangements - Divestitures and BexCaFe Arrangement (Details) Details 42 false false R43.htm 9954490 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details) Details 43 false false R44.htm 9954491 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details) Details 44 false false R45.htm 9954492 - Disclosure - Inventories (Details) Sheet http://www.elanco.com/role/InventoriesDetails Inventories (Details) Details http://www.elanco.com/role/InventoriesTables 45 false false R46.htm 9954493 - Disclosure - Equity (Details) Sheet http://www.elanco.com/role/EquityDetails Equity (Details) Details http://www.elanco.com/role/Equity 46 false false R47.htm 9954494 - Disclosure - Debt - Long-term Debt (Details) Sheet http://www.elanco.com/role/DebtLongtermDebtDetails Debt - Long-term Debt (Details) Details 47 false false R48.htm 9954495 - Disclosure - Debt - Narrative (Details) Sheet http://www.elanco.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 48 false false R49.htm 9954496 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 49 false false R50.htm 9954497 - Disclosure - Financial Instruments - Net Losses/Gains on Derivative Instruments (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails Financial Instruments - Net Losses/Gains on Derivative Instruments (Details) Details 50 false false R51.htm 9954498 - Disclosure - Fair Value - Schedule of Fair Value Information (Details) Sheet http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails Fair Value - Schedule of Fair Value Information (Details) Details 51 false false R52.htm 9954499 - Disclosure - Fair Value - Narrative (Details) Sheet http://www.elanco.com/role/FairValueNarrativeDetails Fair Value - Narrative (Details) Details 52 false false R53.htm 9954500 - Disclosure - Goodwill - Goodwill Activity (Details) Sheet http://www.elanco.com/role/GoodwillGoodwillActivityDetails Goodwill - Goodwill Activity (Details) Details 53 false false R54.htm 9954501 - Disclosure - Goodwill - Narrative (Details) Sheet http://www.elanco.com/role/GoodwillNarrativeDetails Goodwill - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) Sheet http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails Income Taxes - Provision for Taxes on Income (Details) Details 55 false false R56.htm 9954503 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.elanco.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 56 false false R57.htm 9954504 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.elanco.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.elanco.com/role/CommitmentsandContingencies 57 false false R58.htm 9954505 - Disclosure - Earning Per Share (Details) Sheet http://www.elanco.com/role/EarningPerShareDetails Earning Per Share (Details) Details http://www.elanco.com/role/EarningPerShareTables 58 false false All Reports Book All Reports elan-20230930.htm elan-20230930.xsd elan-20230930_cal.xml elan-20230930_def.xml elan-20230930_lab.xml elan-20230930_pre.xml elan-20230930_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "elan-20230930.htm": { "nsprefix": "elan", "nsuri": "http://www.elanco.com/20230930", "dts": { "inline": { "local": [ "elan-20230930.htm" ] }, "schema": { "local": [ "elan-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "elan-20230930_cal.xml" ] }, "definitionLink": { "local": [ "elan-20230930_def.xml" ] }, "labelLink": { "local": [ "elan-20230930_lab.xml" ] }, "presentationLink": { "local": [ "elan-20230930_pre.xml" ] } }, "keyStandard": 193, "keyCustom": 24, "axisStandard": 29, "axisCustom": 0, "memberStandard": 40, "memberCustom": 30, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 286, "entityCount": 1, "segmentCount": 73, "elementCount": 499, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 653, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.elanco.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R3": { "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R4": { "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R7": { "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R8": { "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements", "longName": "0000009 - Disclosure - Implementation of New Financial Accounting Pronouncements", "shortName": "Implementation of New Financial Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.elanco.com/role/Revenue", "longName": "0000010 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements", "longName": "0000011 - Disclosure - Acquisitions, Divestitures and Other Arrangements", "shortName": "Acquisitions, Divestitures and Other Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges", "longName": "0000012 - Disclosure - Asset Impairment, Restructuring and Other Special Charges", "shortName": "Asset Impairment, Restructuring and Other Special Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.elanco.com/role/Inventories", "longName": "0000013 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.elanco.com/role/Equity", "longName": "0000014 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.elanco.com/role/Debt", "longName": "0000015 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.elanco.com/role/FinancialInstruments", "longName": "0000016 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.elanco.com/role/FairValue", "longName": "0000017 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.elanco.com/role/Goodwill", "longName": "0000018 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.elanco.com/role/IncomeTaxes", "longName": "0000019 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.elanco.com/role/CommitmentsandContingencies", "longName": "0000020 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.elanco.com/role/EarningPerShare", "longName": "0000021 - Disclosure - Earning Per Share", "shortName": "Earning Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccounting", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccounting", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables", "longName": "9954472 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables)", "shortName": "Implementation of New Financial Accounting Pronouncements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.elanco.com/role/RevenueTables", "longName": "9954473 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables", "longName": "9954474 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables)", "shortName": "Acquisitions, Divestitures and Other Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables", "longName": "9954475 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables)", "shortName": "Asset Impairment, Restructuring and Other Special Charges (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.elanco.com/role/InventoriesTables", "longName": "9954476 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.elanco.com/role/DebtTables", "longName": "9954477 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.elanco.com/role/FinancialInstrumentsTables", "longName": "9954478 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OffsettingLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OffsettingLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.elanco.com/role/FairValueTables", "longName": "9954479 - Disclosure - Fair Value (Tables)", "shortName": "Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.elanco.com/role/GoodwillTables", "longName": "9954480 - Disclosure - Goodwill (Tables)", "shortName": "Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.elanco.com/role/IncomeTaxesTables", "longName": "9954481 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.elanco.com/role/EarningPerShareTables", "longName": "9954482 - Disclosure - Earning Per Share (Tables)", "shortName": "Earning Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.elanco.com/role/RevenueNarrativeDetails", "longName": "9954483 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-118", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R37": { "role": "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails", "longName": "9954484 - Disclosure - Revenue - Activity in Sales Rebates and Discounts Liability (Details)", "shortName": "Revenue - Activity in Sales Rebates and Discounts Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "longName": "9954485 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "shortName": "Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R39": { "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails", "longName": "9954486 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Schedule of The Composition of The Purchase Consideration (Details)", "shortName": "Acquisitions, Divestitures and Other Arrangements - Schedule of The Composition of The Purchase Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-158", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "elan:DeferredPaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R40": { "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "longName": "9954487 - Disclosure - Acquisitions, Divestitures and Other Arrangements - NutriQuest US Acquisition & NutriQuest Brazil Acquisition (Details)", "shortName": "Acquisitions, Divestitures and Other Arrangements - NutriQuest US Acquisition & NutriQuest Brazil Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R41": { "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954488 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "shortName": "Acquisitions, Divestitures and Other Arrangements - Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-160", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R42": { "role": "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "longName": "9954489 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Divestitures and BexCaFe Arrangement (Details)", "shortName": "Acquisitions, Divestitures and Other Arrangements - Divestitures and BexCaFe Arrangement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-169", "name": "us-gaap:ContractWithCustomerAssetGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-169", "name": "us-gaap:ContractWithCustomerAssetGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails", "longName": "9954490 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details)", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Component of Asset Impairment, Restructuring and Other Special Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails", "longName": "9954491 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details)", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Activity in Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.elanco.com/role/InventoriesDetails", "longName": "9954492 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.elanco.com/role/EquityDetails", "longName": "9954493 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-180", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.elanco.com/role/DebtLongtermDebtDetails", "longName": "9954494 - Disclosure - Debt - Long-term Debt (Details)", "shortName": "Debt - Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R48": { "role": "http://www.elanco.com/role/DebtNarrativeDetails", "longName": "9954495 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R49": { "role": "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9954496 - Disclosure - Financial Instruments - Narrative (Details)", "shortName": "Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "elan:ProceedsFromDerivativeInstrumentOperatingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R50": { "role": "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails", "longName": "9954497 - Disclosure - Financial Instruments - Net Losses/Gains on Derivative Instruments (Details)", "shortName": "Financial Instruments - Net Losses/Gains on Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-223", "name": "elan:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "elan:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails", "longName": "9954498 - Disclosure - Fair Value - Schedule of Fair Value Information (Details)", "shortName": "Fair Value - Schedule of Fair Value Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-256", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-256", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.elanco.com/role/FairValueNarrativeDetails", "longName": "9954499 - Disclosure - Fair Value - Narrative (Details)", "shortName": "Fair Value - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.elanco.com/role/GoodwillGoodwillActivityDetails", "longName": "9954500 - Disclosure - Goodwill - Goodwill Activity (Details)", "shortName": "Goodwill - Goodwill Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R54": { "role": "http://www.elanco.com/role/GoodwillNarrativeDetails", "longName": "9954501 - Disclosure - Goodwill - Narrative (Details)", "shortName": "Goodwill - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails", "longName": "9954502 - Disclosure - Income Taxes - Provision for Taxes on Income (Details)", "shortName": "Income Taxes - Provision for Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "longName": "9954503 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "elan:InterestRateCashFlowHedgeGainLossStrandedTaxBenefitsReclassifiedToEarningsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } }, "R57": { "role": "http://www.elanco.com/role/CommitmentsandContingenciesDetails", "longName": "9954504 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-6", "name": "elan:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "elan:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.elanco.com/role/EarningPerShareDetails", "longName": "9954505 - Disclosure - Earning Per Share (Details)", "shortName": "Earning Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elan-20230930.htm", "unique": true } } }, "tag": { "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r702" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r273", "r274", "r561", "r562", "r563", "r620", "r622", "r625", "r631", "r638", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r654", "r673", "r691", "r836", "r853" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/Equity" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r154", "r216", "r355", "r357", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r371", "r461", "r617", "r618", "r637" ] }, "elan_ShawneeAndSpekeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ShawneeAndSpekeMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shawnee and Speke", "label": "Shawnee And Speke [Member]", "documentation": "Shawnee And Speke" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r751" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r702" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r744" ] }, "elan_TaxIncrementalFinancingCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TaxIncrementalFinancingCommitmentAmount", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax incremental financing, commitment amount", "label": "Tax Incremental Financing, Commitment Amount", "documentation": "Tax Incremental Financing, Commitment Amount" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r273", "r274", "r561", "r562", "r563", "r620", "r622", "r625", "r631", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r654", "r673", "r691", "r836", "r853" ] }, "elan_ChangeInContractWithCustomerLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ChangeInContractWithCustomerLiabilityRollForward", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "documentation": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r744" ] }, "elan_SerestoClassActionLawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SerestoClassActionLawsuitsMember", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seresto Class Action Lawsuits", "label": "Seresto Class Action Lawsuits [Member]", "documentation": "Seresto Class Action Lawsuits" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r744" ] }, "elan_DeferredPaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "DeferredPaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred cash consideration due January 4, 2024", "label": "Deferred Payments To Acquire Businesses, Gross", "documentation": "Deferred Payments To Acquire Businesses, Gross" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r55", "r275" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r739" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r762" ] }, "elan_FutureMilestonePaymentsAndSalesRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "FutureMilestonePaymentsAndSalesRoyaltiesMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future Milestone Payments And Sales Royalties", "label": "Future Milestone Payments And Sales Royalties [Member]", "documentation": "Future Milestone Payments And Sales Royalties" } } }, "auth_ref": [] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r744" ] }, "elan_ContractWithCustomerLiabilityForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ContractWithCustomerLiabilityForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation adjustments", "label": "Contract With Customer, Liability, Foreign Currency Translation", "documentation": "Contract With Customer, Liability, Foreign Currency Translation" } } }, "auth_ref": [] }, "elan_GlobalCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "GlobalCustomersMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Customers", "label": "Global Customers [Member]", "documentation": "Global Customers" } } }, "auth_ref": [] }, "elan_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r763" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r134", "r169", "r257", "r265", "r269", "r271", "r511", "r521", "r663" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of long-term debt", "terseLabel": "Less current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r190" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r745" ] }, "elan_SecuritizationFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SecuritizationFacilityMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securitization Facility", "label": "Securitization Facility [Member]", "documentation": "Securitization Facility" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r789" ] }, "elan_MicrobiomeRDPlatformCarveOutMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "MicrobiomeRDPlatformCarveOutMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Microbiome R&D Platform Carve-Out", "label": "Microbiome R&D Platform Carve-Out [Member]", "documentation": "Microbiome R&D Platform Carve-Out" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r747" ] }, "elan_TaxIncrementalFinancingEstimatedTotalIncentiveToBeFunded": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TaxIncrementalFinancingEstimatedTotalIncentiveToBeFunded", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New corporate headquarters, estimated total incentive to be funded by TIF", "label": "Tax Incremental Financing, Estimated Total Incentive To Be Funded", "documentation": "Tax Incremental Financing, Estimated Total Incentive To Be Funded" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r746" ] }, "elan_AquaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "AquaMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aqua", "label": "Aqua [Member]", "documentation": "Aqua" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r750" ] }, "elan_AssetImpairmentChargesIncludingInventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "AssetImpairmentChargesIncludingInventoryWriteDown", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Asset impairment and write-down charges", "label": "Asset Impairment Charges, Including Inventory Write-Down", "documentation": "Asset Impairment Charges, Including Inventory Write-Down" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r748" ] }, "elan_TangibleEquityUnitSettlementRate": { "xbrltype": "percentItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TangibleEquityUnitSettlementRate", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement rate", "label": "Tangible Equity Unit, Settlement Rate", "documentation": "Tangible Equity Unit, Settlement Rate" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to cash flows from operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r749" ] }, "elan_ContractManufacturingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ContractManufacturingMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract Manufacturing", "label": "Contract Manufacturing [Member]", "documentation": "Contract Manufacturing [Member]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r749" ] }, "elan_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, lease not yet commenced liability", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid", "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid" } } }, "auth_ref": [] }, "elan_PaymentsToAcquirePropertyPlantEquipmentAndSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "PaymentsToAcquirePropertyPlantEquipmentAndSoftware", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net purchases of property and equipment and software", "label": "Payments To Acquire Property, Plant, Equipment, And Software", "documentation": "Payments To Acquire Property, Plant, Equipment, And Software" } } }, "auth_ref": [] }, "elan_DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred": { "xbrltype": "integerItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees transferred", "label": "Disposal Group, Including Discontinued Operation, Number of Employees Transferred", "documentation": "Disposal Group, Including Discontinued Operation, Number of Employees Transferred" } } }, "auth_ref": [] }, "elan_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "CustomerAMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Single Customer", "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21", "r451" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "elan_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "documentation": "Contract With Customer, Liability, Increase From Cash Receipts" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r191" ] }, "elan_SaleOfStockEquityComponentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SaleOfStockEquityComponentPercent", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity component", "label": "Sale Of Stock, Equity Component, Percent", "documentation": "Sale Of Stock, Equity Component, Percent" } } }, "auth_ref": [] }, "elan_IncrementalTermFacilityDueJune302025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "IncrementalTermFacilityDueJune302025Member", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental Term Facility due 2025", "label": "Incremental Term Facility Due June 30, 2025 [Member]", "documentation": "Incremental Term Facility Due June 30, 2025" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtPercentageBearingFixedInterestRate", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of long term debt bearing fixed interest", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": [ "r35" ] }, "elan_TangibleEquityUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TangibleEquityUnitMember", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails", "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tangible Equity Unit", "label": "Tangible Equity Unit [Member]", "documentation": "Tangible Equity Unit" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r54", "r56", "r101", "r102", "r275", "r639" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r12", "r261" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r469", "r475" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r686" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r275", "r674", "r836", "r853", "r854" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r714", "r725", "r735", "r760" ] }, "elan_DerivativeNotionalAmountIncreaseDecreaseInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "DerivativeNotionalAmountIncreaseDecreaseInPeriod", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in derivative notional amount during period", "label": "Derivative, Notional Amount, Increase (Decrease) In Period", "documentation": "Derivative, Notional Amount, Increase (Decrease) In Period" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "elan_SaleOfStockDebtComponentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SaleOfStockDebtComponentPercent", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt component", "label": "Sale Of Stock, Debt Component, Percent", "documentation": "Sale Of Stock, Debt Component, Percent" } } }, "auth_ref": [] }, "elan_SpekeSiteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SpekeSiteMember", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Speke Site", "label": "Speke Site [Member]", "documentation": "Speke Site" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r339", "r387", "r388", "r389", "r390", "r391", "r392", "r497", "r498", "r499", "r667", "r668", "r679", "r680", "r681" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r3", "r85", "r445" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r763" ] }, "elan_IncrementalTermFacilityDueAugust122028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "IncrementalTermFacilityDueAugust122028Member", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental Term Facility due 2028", "label": "Incremental Term Facility Due August 12, 2028 [Member]", "documentation": "Incremental Term Facility Due August 12, 2028" } } }, "auth_ref": [] }, "elan_DerivativeNotionalAmountAmountRestructured": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "DerivativeNotionalAmountAmountRestructured", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative amount restructured", "label": "Derivative, Notional Amount, Amount Restructured", "documentation": "Derivative, Notional Amount, Amount Restructured" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from facility", "terseLabel": "Proceeds from Revolving Credit Facility", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r45", "r798" ] }, "elan_ProceedsFromDerivativeInstrumentOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ProceedsFromDerivativeInstrumentOperatingActivities", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from interest rate swap settlements", "label": "Proceeds From Derivative Instrument, Operating Activities", "documentation": "Proceeds From Derivative Instrument, Operating Activities" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "elan_MarketedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "MarketedProductsMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketed products", "label": "Marketed Products [Member]", "documentation": "Marketed Products" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r751" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.elanco.com/role/DebtLongtermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r26", "r167", "r338", "r353", "r667", "r668", "r852" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt maturity term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation activity, net (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r20", "r122", "r123", "r157" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation, net of taxes", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r10", "r18", "r161" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r470", "r471", "r472", "r473", "r475" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive loss, net of taxes", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r18", "r161", "r203", "r206" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development (IPR&D)", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r372", "r373", "r384" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r124", "r686", "r856" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r12", "r59", "r64" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "Implementation of New Financial Accounting Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r174", "r175", "r177", "r181", "r225", "r226", "r229", "r230", "r239", "r240", "r281", "r282", "r435", "r436", "r437", "r458", "r462", "r466", "r467", "r468", "r479", "r480", "r481", "r491", "r492", "r494", "r504", "r505", "r506", "r536", "r537", "r538", "r539", "r540" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Defined benefit pension and retiree health benefit plans, net of taxes", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r8", "r18", "r133", "r161" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity in Sales Rebates and Discounts Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r835" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r310", "r311", "r312", "r315", "r822", "r823" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r682", "r683" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r61", "r149" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r188" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r296", "r299" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails", "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r179", "r192", "r193", "r194", "r217", "r244", "r245", "r247", "r249", "r255", "r256", "r279", "r316", "r318", "r319", "r320", "r323", "r324", "r356", "r357", "r360", "r363", "r370", "r478", "r543", "r544", "r545", "r546", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r575", "r596", "r614", "r632", "r633", "r634", "r635", "r636", "r777", "r797", "r804" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Taxes on Income", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r158" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r36", "r70" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r310", "r311", "r312", "r315", "r822", "r823" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r90", "r91", "r93", "r94", "r564", "r566", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r626", "r627", "r628", "r629", "r659", "r689", "r691" ] }, "elan_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "OtherReceivablesMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Receivables", "label": "Other Receivables [Member]", "documentation": "Other Receivables" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r682", "r683" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combination and Asset Acquisition [Abstract]", "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains to be reclassified during next 12 months", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r97" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r172", "r176", "r237", "r238", "r262", "r428", "r439", "r525" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total consideration transferred", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r84" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r16", "r22", "r27", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r151" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.elanco.com/role/GoodwillGoodwillActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r160" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r310", "r778" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.elanco.com/role/EarningPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r243", "r249" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.elanco.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r28", "r129", "r130", "r131" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.elanco.com/role/EarningPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed conversion of dilutive common stock equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r805" ] }, "elan_A500TangibleEquityUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "A500TangibleEquityUnitsMember", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "TEU Amortizing Notes due 2023", "label": "5.00% Tangible Equity Units [Member]", "documentation": "5.00% Tangible Equity Units" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation activity, net", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r78", "r79", "r394" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.elanco.com/role/EarningPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r242", "r249" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r15", "r512", "r520", "r686" ] }, "elan_TaxIncrementalFinancingExpectToRefundWithinNextThreeMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TaxIncrementalFinancingExpectToRefundWithinNextThreeMonths", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refund within next three months", "label": "Tax Incremental Financing, Expect To Refund Within Next Three Months", "documentation": "Tax Incremental Financing, Expect To Refund Within Next Three Months" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r701" ] }, "elan_PetHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "PetHealthMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pet Health", "label": "Pet Health [Member]", "documentation": "Pet Health" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from site divestitures", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r223", "r224", "r254", "r502", "r542", "r560", "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r592", "r594", "r597", "r598", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r692" ] }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonfinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contingent consideration", "label": "Nonfinancial Liabilities Fair Value Disclosure", "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.elanco.com/role/FairValue" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r469" ] }, "elan_InterestRateCashFlowHedgeGainLossStrandedTaxBenefitsReclassifiedToEarningsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "InterestRateCashFlowHedgeGainLossStrandedTaxBenefitsReclassifiedToEarningsNet", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Release of stranded tax benefits", "label": "Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net", "documentation": "Interest Rate Cash Flow Hedge Gain (Loss), Stranded Tax Benefits Reclassified to Earnings, Net" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r58", "r62" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Up-front cash consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r44", "r444" ] }, "elan_ProductReturnConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ProductReturnConcentrationRiskMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Return Concentration Risk", "label": "Product Return Concentration Risk [Member]", "documentation": "Product Return Concentration Risk [Member]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r302", "r795" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Gross", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r788" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r743" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r741" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r212", "r231", "r232", "r233", "r234", "r235", "r242", "r244", "r247", "r248", "r249", "r253", "r464", "r465", "r510", "r524", "r661" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r222", "r223", "r224", "r254", "r502", "r542", "r560", "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r592", "r594", "r597", "r598", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r692" ] }, "elan_TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share)", "label": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "documentation": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r742" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares not included in calculating diluted loss per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r250" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss per share:", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.elanco.com/role/GoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r665", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r704" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_ContractWithCustomerAssetGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetGross", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, asset, before allowance for credit loss", "label": "Contract with Customer, Asset, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r173", "r284", "r833", "r834" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r123" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used for) Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r213" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used for Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r213" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r742" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r142", "r143", "r144" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r737" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, no par value, 5,000,000,000 shares authorized, 492,683,420 and 474,237,738 shares issued and outstanding as of September 30, 2023 and December\u00a031, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r123", "r516", "r686" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of tangible equity units (TEUs) into common stock (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r20", "r74", "r122", "r123", "r157" ] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r470", "r471", "r474" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r762" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r743" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r123", "r575" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r285" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r20", "r123", "r575", "r593", "r858", "r859" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments with readily determinable fair value", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r470" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r307", "r308", "r309" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r50" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r743" ] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of long-term debt", "label": "Proceeds from Issuance of Senior Long-Term Debt", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r45" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.elanco.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r178", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r385" ] }, "elan_TermBLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TermBLoanFacilityMember", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan B due 2027", "label": "Term B Loan Facility [Member]", "documentation": "Term B Loan Facility" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r776" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r744" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r743" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Purchase Consideration", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r81", "r82" ] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Long-term debt, including current portion", "label": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net of capitalized interest", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r105", "r171", "r210", "r260", "r489", "r599", "r699", "r857" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r83", "r84" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/GoodwillGoodwillActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Additions related to acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r290", "r665" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.elanco.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r36", "r74", "r77", "r103", "r104", "r106", "r108", "r155", "r156", "r667", "r669", "r800" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definite-lived intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r83", "r84" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r743" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r743" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r83", "r84" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r744" ] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Changes and Error Corrections [Abstract]", "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r705", "r775" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash operating activities, net", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "elan_DivestitureOfBusinessDurationOverWhichProceedsWillBeReceived": { "xbrltype": "durationItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "DivestitureOfBusinessDurationOverWhichProceedsWillBeReceived", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Duration over which proceeds will be received", "label": "Divestiture Of Business, Duration Over Which Proceeds Will Be Received", "documentation": "Divestiture Of Business, Duration Over Which Proceeds Will Be Received" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total purchase consideration", "terseLabel": "Total purchase consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r17" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r786" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r788" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r34", "r185", "r217", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r447", "r449", "r450", "r478", "r686", "r827", "r843", "r844" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.elanco.com/role/EarningPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic And Diluted Weighted-average Shares Outstanding", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r805" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r221", "r446", "r447", "r449", "r450", "r496", "r649", "r826", "r829", "r830" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r21" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r702" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r221", "r446", "r447", "r449", "r450", "r496", "r649", "r826", "r829", "r830" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r762" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r105", "r832" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r564", "r566", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r626", "r627", "r628", "r629", "r689", "r691" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Line of Credit", "terseLabel": "Credit Facility", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r123", "r126", "r127", "r146", "r577", "r593", "r615", "r616", "r686", "r700", "r799", "r807", "r841", "r858" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r35", "r104", "r354", "r490" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r212", "r231", "r232", "r233", "r234", "r235", "r244", "r247", "r248", "r249", "r253", "r464", "r465", "r510", "r524", "r661" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r35", "r327" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r21" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r272", "r502", "r526", "r527", "r528", "r529", "r530", "r531", "r653", "r672", "r687", "r783", "r824", "r825", "r836", "r853" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent Assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/EarningPerShareDetails", "http://www.elanco.com/role/EquityDetails", "http://www.elanco.com/role/FairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r386", "r393", "r417", "r418", "r419", "r500", "r501", "r532", "r565", "r566", "r619", "r621", "r623", "r624", "r630", "r650", "r651", "r664", "r671", "r684", "r688", "r691", "r819", "r831", "r846", "r847", "r848", "r849", "r850" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r32", "r217", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r447", "r449", "r450", "r478", "r573", "r662", "r700", "r827", "r843", "r844" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "elan_SeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SeniorNotesDue2028Member", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2028", "label": "Senior Notes Due 2028 [Member]", "documentation": "Senior Notes Due 2028 [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r24", "r98", "r339", "r667", "r668" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r98", "r99", "r100" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r339", "r667", "r668" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r272", "r502", "r526", "r527", "r528", "r529", "r530", "r531", "r653", "r672", "r687", "r783", "r824", "r825", "r836", "r853" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r765" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/EarningPerShareDetails", "http://www.elanco.com/role/EquityDetails", "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r393", "r501", "r532", "r565", "r566", "r619", "r621", "r623", "r624", "r630", "r650", "r651", "r664", "r671", "r684", "r688", "r831", "r845", "r846", "r847", "r848", "r849", "r850" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/EarningPerShareDetails", "http://www.elanco.com/role/EquityDetails", "http://www.elanco.com/role/FairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r386", "r393", "r417", "r418", "r419", "r500", "r501", "r532", "r565", "r566", "r619", "r621", "r623", "r624", "r630", "r650", "r651", "r664", "r671", "r684", "r688", "r691", "r819", "r831", "r846", "r847", "r848", "r849", "r850" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r451" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r99", "r100" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r21", "r90", "r93" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r652", "r696", "r697" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r21", "r90", "r93", "r94", "r95", "r96", "r451" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r476" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r393", "r501", "r532", "r565", "r566", "r619", "r621", "r623", "r624", "r630", "r650", "r651", "r664", "r671", "r684", "r688", "r831", "r845", "r846", "r847", "r848", "r849", "r850" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r339", "r477", "r667", "r668" ] }, "elan_CattleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "CattleMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cattle", "label": "Cattle [Member]", "documentation": "Cattle" } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r764" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r36", "r221", "r326", "r327", "r328", "r329", "r330", "r332", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r490", "r666", "r667", "r668", "r669", "r670", "r798" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r762" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r650", "r651", "r845", "r847", "r850" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on investments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r199", "r200" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r128", "r168", "r519", "r686", "r799", "r807", "r841" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity in Reserves", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r66", "r69" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r702" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r219", "r220", "r329", "r358", "r495", "r658", "r659" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r137", "r502" ] }, "elan_ContractWithCustomerLiabilityRevenueRecognizedIncludingCurrentYearAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingCurrentYearAdditions", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/RevenueActivityinSalesRebatesandDiscountsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction of revenue", "label": "Contract with Customer, Liability, Revenue Recognized Including Current Year Additions", "documentation": "Contract with Customer, Liability, Revenue Recognized Including Current Year Additions" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r702" ] }, "elan_NutriQuestLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "NutriQuestLLCMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails", "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NutriQuest, LLC", "label": "NutriQuest, LLC [Member]", "documentation": "NutriQuest, LLC" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedge", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r201", "r208", "r209", "r448", "r660", "r790" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r192", "r193", "r194", "r255", "r356", "r357", "r358", "r360", "r363", "r368", "r370", "r543", "r544", "r545", "r546", "r671", "r777", "r797" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r47", "r186", "r655" ] }, "elan_A4272SeniorNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "A4272SeniorNotesDue2023Member", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.272% Senior Notes due 2023", "label": "4.272% Senior Notes due 2023 [Member]", "documentation": "4.272% Senior Notes due 2023" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r182" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r155", "r156", "r157", "r192", "r193", "r194", "r255", "r356", "r357", "r358", "r360", "r363", "r368", "r370", "r543", "r544", "r545", "r546", "r671", "r777", "r797" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r714", "r725", "r735", "r760" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r702" ] }, "elan_PoultryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "PoultryMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Poultry", "label": "Poultry [Member]", "documentation": "Poultry" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r702" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges, net of taxes", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r200" ] }, "elan_IncrementalTermFacilityDueApril192029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "IncrementalTermFacilityDueApril192029Member", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental Term Facility due 2029", "label": "Incremental Term Facility Due April 19, 2029 [Member]", "documentation": "Incremental Term Facility Due April 19, 2029" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "elan_BexCaFeLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "BexCaFeLLCMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BexCaFe, LLC", "label": "BexCaFe, LLC [Member]", "documentation": "BexCaFe, LLC" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r140" ] }, "elan_NutriQuestNutricaoAnimalLtdaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "NutriQuestNutricaoAnimalLtdaMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NutriQuest Brazil", "label": "NutriQuest Nutricao Animal Ltda [Member]", "documentation": "NutriQuest Nutricao Animal Ltda" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "elan_FarmAnimalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "FarmAnimalMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Farm Animal", "label": "Farm Animal [Member]", "documentation": "Farm Animal" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents \u2013 beginning of period", "periodEndLabel": "Cash and cash equivalents \u2013 end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r47", "r142", "r214" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished products", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r785" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r142" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue Disaggregated by Product Category", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r836" ] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in operating assets and liabilities, net of acquisitions", "label": "Increase (Decrease) in Operating Capital", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r482" ] }, "us-gaap_InventoryLIFOReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLIFOReserve", "crdr": "credit", "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease to LIFO cost", "label": "Inventory, LIFO Reserve", "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods." } } }, "auth_ref": [ "r787" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/Goodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r286", "r289", "r293", "r665" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of facility", "terseLabel": "Repayment of revolving credit facility", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r46", "r798" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds after underwriting discounts and commissions", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "TEUs issued (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r383", "r672", "r673", "r674", "r675", "r676", "r677", "r678" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r383", "r672", "r673", "r674", "r675", "r676", "r677", "r678" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r429" ] }, "elan_PaymentsForLicenseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "PaymentsForLicenseFees", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment on agreement", "label": "Payments For License Fees", "documentation": "Payment On Agreement" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccounting", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r145" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r295", "r297", "r298", "r300", "r503", "r507" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Offering price (usd per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.elanco.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r196", "r656", "r686" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r60", "r63" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r219", "r220", "r329", "r358", "r495", "r657", "r659" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r40", "r41", "r133", "r195", "r517", "r537", "r540" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r276", "r277" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/GoodwillGoodwillActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r292" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Marketing, selling and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r139" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash paid for acquisitions", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r44" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Determination of shares:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Asset Impairment, Restructuring and Other Special Charges", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r65", "r67", "r68" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r153", "r215", "r325", "r331", "r332", "r333", "r334", "r335", "r336", "r341", "r348", "r349", "r351" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r20", "r39", "r180", "r207", "r208", "r209", "r222", "r223", "r224", "r228", "r236", "r238", "r254", "r280", "r283", "r371", "r421", "r422", "r423", "r433", "r434", "r453", "r454", "r455", "r456", "r457", "r459", "r463", "r483", "r484", "r485", "r486", "r487", "r488", "r493", "r533", "r534", "r535", "r549", "r614" ] }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets (liabilities)", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments." } } }, "auth_ref": [ "r14" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r26", "r120", "r121", "r166", "r167", "r221", "r326", "r327", "r328", "r329", "r330", "r332", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r490", "r666", "r667", "r668", "r669", "r670", "r798" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r148", "r503" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r421", "r422", "r423", "r549", "r801", "r802", "r803", "r840", "r858" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r326", "r327", "r328", "r329", "r330", "r332", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r490", "r666", "r667", "r668", "r669", "r670", "r798" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r705", "r775" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r36", "r74", "r77", "r103", "r104", "r106", "r108", "r155", "r156", "r221", "r326", "r327", "r328", "r329", "r330", "r332", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r490", "r666", "r667", "r668", "r669", "r670", "r798" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r258", "r259", "r264", "r267", "r268", "r272", "r273", "r275", "r382", "r383", "r502" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 }, "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/GoodwillGoodwillActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "terseLabel": "Goodwill", "periodStartLabel": "Balance as of December 31, 2022", "periodEndLabel": "Balance as of September 30, 2023", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r187", "r287", "r508", "r665", "r686", "r809", "r816" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r222", "r223", "r224", "r228", "r236", "r238", "r280", "r283", "r421", "r422", "r423", "r433", "r434", "r453", "r455", "r456", "r459", "r463", "r533", "r535", "r549", "r858" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Pension and Retiree Health Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r7", "r19", "r41", "r790", "r791", "r792" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.elanco.com/role/EarningPerShareDetails", "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r179", "r192", "r193", "r194", "r217", "r244", "r245", "r247", "r249", "r255", "r256", "r279", "r316", "r318", "r319", "r320", "r323", "r324", "r356", "r357", "r360", "r363", "r370", "r478", "r543", "r544", "r545", "r546", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r575", "r596", "r614", "r632", "r633", "r634", "r635", "r636", "r777", "r797", "r804" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.elanco.com/role/DebtLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r26", "r167", "r352" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r89", "r92" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r307", "r308", "r309" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r88" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r263", "r278", "r784", "r806" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r6", "r19", "r41", "r208", "r209", "r484", "r485", "r486", "r487", "r488", "r790" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Costs, expenses and other", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r136" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r20", "r180", "r207", "r208", "r209", "r222", "r223", "r224", "r228", "r236", "r238", "r254", "r280", "r283", "r371", "r421", "r422", "r423", "r433", "r434", "r453", "r454", "r455", "r456", "r457", "r459", "r463", "r483", "r484", "r485", "r486", "r487", "r488", "r493", "r533", "r534", "r535", "r549", "r614" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r87" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r19", "r41", "r454", "r457", "r493", "r533", "r534", "r790", "r791", "r792", "r801", "r802", "r803" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r162", "r452", "r460" ] }, "elan_BusinessCombinationConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "BusinessCombinationConsiderationTransferredContingentConsideration", "crdr": "credit", "calculation": { "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of contingent consideration", "label": "Business Combination, Consideration Transferred, Contingent Consideration", "documentation": "Business Combination, Consideration Transferred, Contingent Consideration" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r771" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r38", "r107", "r515", "r574" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r86", "r446", "r447", "r449", "r450" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency fixed interest rate swap", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r659", "r679", "r685" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Costs, expenses and other:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r771" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenue", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r275", "r781" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r772" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r104", "r106", "r326", "r490", "r667", "r668" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails", "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r81", "r82", "r443", "r682", "r683" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r771" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r779", "r793" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r773" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails", "http://www.elanco.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r443", "r682", "r683" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r772" ] }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairment, Restructuring and Other Special Charges", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairment, restructuring and other special charges", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r769" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r81", "r82", "r443" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails", "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsScheduleofTheCompositionofThePurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r443" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Concentration risk", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r54", "r56", "r101", "r102", "r275" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r774" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r339", "r387", "r388", "r389", "r390", "r391", "r392", "r471", "r497", "r498", "r499", "r667", "r668", "r679", "r680", "r681" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r705", "r775" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r125", "r157", "r518", "r536", "r540", "r547", "r576", "r686" ] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of long-term borrowings", "label": "Repayments of Senior Debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r46" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r703" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r165", "r189", "r217", "r257", "r266", "r270", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r446", "r449", "r478", "r513", "r587", "r686", "r700", "r827", "r828", "r843" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r339", "r387", "r388", "r389", "r390", "r391", "r392", "r471", "r499", "r667", "r668", "r679", "r680", "r681" ] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions, Divestitures and Other Arrangements", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r110", "r159" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r339", "r387", "r392", "r471", "r497", "r679", "r680", "r681" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r339", "r387", "r392", "r471", "r498", "r667", "r668", "r679", "r680", "r681" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.elanco.com/role/EarningPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earning Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r241", "r250", "r251", "r252" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r426", "r427", "r514" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r275", "r674", "r836", "r853", "r854" ] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r9", "r13", "r22" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsDivestituresandBexCaFeArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on disposal", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r796" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.elanco.com/role/AcquisitionsDivestituresandOtherArrangementsNutriQuestUSAcquisitionNutriQuestBrazilAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r147" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "netLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r135", "r144", "r170", "r183", "r202", "r205", "r209", "r217", "r227", "r231", "r232", "r233", "r234", "r237", "r238", "r246", "r257", "r265", "r269", "r271", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r465", "r478", "r522", "r595", "r612", "r613", "r663", "r699", "r827" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r689", "r690", "r691", "r693", "r694", "r695", "r698", "r801", "r802", "r840", "r855", "r858" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r713", "r724", "r734", "r751", "r759" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue Disaggregated by Geographic Area", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r23" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition related charges", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r80" ] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, lease not yet commenced, term of contract", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r842" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r780", "r794" ] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual charge", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": [ "r821" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r42", "r204", "r206", "r211", "r509", "r523" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r639" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r739" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r739" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r766" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r54", "r56", "r101", "r102", "r275", "r639", "r782" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r741" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r768" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r53", "r54", "r56", "r57", "r101", "r164", "r639" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r740" ] }, "elan_TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion", "presentation": [ "http://www.elanco.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued upon conversion of prepaid stock purchase contracts (in shares)", "label": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "documentation": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion" } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of gain (loss) from AOCI", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r25", "r41", "r208", "r483", "r487", "r488", "r790" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r275", "r781" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r740" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r751" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r33", "r686" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Implementation of New Financial Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r769" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 8.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/GoodwillGoodwillActivityDetails", "http://www.elanco.com/role/GoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill impairment", "negatedTerseLabel": "Impairment charge", "terseLabel": "Impairment charge", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r12", "r288", "r291", "r294", "r665" ] }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains (Losses) , Net of Tax", "label": "Offsetting Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r132", "r198" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r751" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r37" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Description of Accounting Standards Adopted and Not Yet Adopted", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items." } } }, "auth_ref": [ "r48", "r49", "r51", "r52" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r716", "r724", "r734", "r751", "r759", "r763", "r771" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r716", "r724", "r734", "r751", "r759", "r763", "r771" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNetLossesGainsonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange forward contracts", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r839" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r152" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r706", "r717", "r727", "r752" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r767" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r109", "r424", "r851" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.elanco.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r218", "r425", "r430", "r431", "r432", "r438", "r440", "r441", "r442", "r548" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments and other items", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r12", "r150" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r54", "r56", "r101", "r102", "r275", "r639" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges (credits)", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12", "r305", "r307", "r820" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r706", "r717", "r727", "r752" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r54", "r56", "r101", "r102", "r275", "r541", "r639" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r860", "r861", "r862", "r863" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r837", "r838" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r712", "r723", "r733", "r758" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "elan_SwineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elanco.com/20230930", "localname": "SwineMember", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swine", "label": "Swine [Member]", "documentation": "Swine" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesActivityinReservesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r302", "r306" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r184", "r197", "r217", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r446", "r449", "r478", "r686", "r827", "r828", "r843" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.elanco.com/role/FairValueScheduleofFairValueInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r470", "r471", "r474" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.elanco.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Information", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r98", "r163" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.elanco.com/role/DebtLongtermDebtDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r711", "r722", "r732", "r757" ] }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringSettlementAndImpairmentProvisions", "crdr": "debit", "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesComponentofAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total expense", "label": "Restructuring, Settlement and Impairment Provisions", "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss." } } }, "auth_ref": [ "r138" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r713", "r724", "r734", "r759" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Sales rebates and discounts", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r372", "r373", "r384" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r672" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r769" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20,22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r777": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 76 0001739104-23-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739104-23-000023-xbrl.zip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Ý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

WD!K@763)$WC+6:]\<>@A,O;B_!.X@* MKH?!TT]3IX2)K?QSPYW-FUA.2?&3C'%J;YD>6'^[9^NU])W@S?,JC7S$@HA# M#\<.1 F-88H#66B/^L(@=P./*1'(^>:71ACM46TM(FAEU#VV/H)/]>#:%)1Y MCJ[5\# XO#ZG]@7'UT?-S7R ?4Z5TR/LLT]=EM&_DW:[_K%@NTC-D'H)9W$ MD\3U(:+$A6DJ=M:^1PBCD1>&>H=2HSTN;3KO$\YW)&X3S@N9#<-BQW%7,P2L MHCDQ#UP*I''&_E%P+"?J[^_O5?+SCZK?EY9__$7#)%;9)JO8I^Q)[FJ.[8[/ MK%JQ%",:> GTD.]"Y/L!C ,40V$[<()82%,]QAGN;FETTT@+UU+<2_<:(T"K M48P]^";FEQ:Y6M+3C<85$-):S#^EA(JMA%/#GU?&[^/-RUPPRGKLLQ=!,D;!J.,4R0$T(_=M.8 M)3S!B=+Q@*D 2^.">]64TGT&O[?_G^3BHREZUFI_:W8_<^5O,W!.ZWX;MJ.?^T'F M:\)5W?8[)F]'M865WHE?JF: &&IC:=S5D14<"0NDM.H)( 9Q&SFXQ3\^;DB3G1.OV\5Z<_>^K+*' MNJIJ+GXMGA#_+,RNV_P-^[#=4$97.&8NIF$$?<=#LBQT#&.<\$%*#>X;I/YMD[&(99CME0"6UD=64&G7$WT'* *\U M JE8H3]^T#AX-Q[!$3J::UPFYBJ9!**C ]@K<07V:H!:#[!71/P=O&&@T66. MH= (>)AC2&:*;IAN:/0"&2Z%=#!JP;CQ^4(4+M7_*![AXL;,=N]?."]9)0WC M7?##[G;.82-(4^ZC.*#R_$%LV)E,PY'$#O1(2#%U"'/5LC]K]+FT!:I[+^)7 MG&U*\).\T\3*GT'MVI*_%R.HMR-7P5YM$VX9T8F7EH.TH"/NI F&- "RM+56 MZ7'6W;0&!"\WT#JOVK.EW^8/#UDE?]E6IHP\[$6QSV$2R4"&D*408P]#@HD? M^T[HQ4RIH(9.ITLC(KGV9YVUGQ_6?K(7O&!3O*/S[GU7^Q2O;&A)Y49O"2*>>:>%QW17@8A$$00I]@#Z)$9LYD M022XGJ,XE.73N%;=)$,YEL;\C1I7(-\I M92B:OF?W6AZ6=AB)*=.E>@SB$G M2ZZU*FDF@S CB^JY@-8>_E6S- MBD=<5,^?Q2?;!K%%.$JCP,'0#5DL-N^^!^. Q]!W7"_V6.+B0"D%L5:O2Z/- MKI1 BJD9,Z@'^3#Y30;DQ%1G@*$RA1EA,D18HL$.68F_'8A*KZ]9:,E(_1T) MF;UL<*J]73/720-7%D>@^6/%Z( /:S4T=GUR*.7ILTZ%!>3 M=4\V]*O8'(H^WN9EU69^2Q"BGC 3('$<84&DG$,LK H8A)'O>2%G*?7- !P)7Y=9;<4'M?R7)K(:'Q>U/=9$:$_,,#:!OB"UE#)DUO-&C??\ M2DFAE"'IS_BDWH09N;W%Y;W\[_T_M]D37LL0O[K+C,A>Q#_4?79_T7ER15 < M,88Y1,21V4/C&"9![,,XBESD)\@A"5F)K5Z6TV^5L*[42.\BF70FYDO))MP0 M""'KZ4CD#^P@+OB__T?LN>[_"U)VEVUDMBXYC1O!].CPLI$,4^1Q%V'(G32$ M]>%U(FNO1T[@I"3"*,%1.Y+O-W21X[B3ZS5'D8E_?)7Q4UO@9AN1J??70K(K M4 ]'1\ K<) =-(\T*^#1+[MOV%L'K2!K:66\3)99UTHKL+UTT:KA9P'+5 M_E;EY(\;T3[;I5Y<18R&CN\XT',= A&-'9@Z@5@OL<_2R'>#V(E73ZQ(<^6] M04]7.O.TV^&D\2NL-D@?I9S@IVU))46"4HK[LZ;5WP>PHHEO ;2I[7G@%O.0'=:BZ3X"A2T[O:^;>8WR$65/+/"QY_6=@M\JT13Y4MR611NDF.6; MWUAUG]-#^)JBAU"EK<4Y!"28[>'6?H1*:XPY$VT!.S0T* M&(I-OLV(0%V4C+R,2AW,YG+44;?K?]1ZS\R^^#O+[NZ%U7(M5FY\UY8&$40E MN:G\LJW*2IB\L@ZZS!+-Z+NL).N\W!;L8\4>RNNTK(]35W&*?.P@'[HL"2"2 M)DGLI1Z,:8I0C$./!EI)"^R(M33&.KYR)I;DVF I%4NF6QXR-?MF_H&8F/%V M"H%6H[:<4&T@U4J!CE9US#6=$K=CEV4_N[&M#:'6$C MY!5HQ+3HPQK&P99WJJ>7>?U.PZJ>>)1&'K\LFYUH/6V-C+?YILQH'1N7;VX+ MO"DY*PI&W14A.$9ADD)!#C%$#B40^RB%@<\B'@6NYR9H55_X52,,GDE Q8H MY:R8? CFN%;S.D.@1NA3 3LQR^\S#G;DEK<].I*#CNCV,P_JX&4Y":%2UZ^2 MCU 'E+[4A%IMF)J: ^G9VR3L*R]Q$\I3!'TD4Z.[8CG!">?0==/$PWZ"8T_K M8K)*ITMC+NG9+4'!4BSKZ\@#0BIL?QD!JID?3 EQ50O4+HZ3FZ.CU2):H6T: MI^H06;-4%;JEN.[OG]#V$1;,2&6WP_*Y>P%%$WAK&+ MJ$R$X$!!-X[8]K*$"=6'U.EF5A]\SK1 ^.9.7KIZQ])JE<2)PQAF,"8R MZ9:',4Q3AL4\3IR0H(1ZQ-?9;78;7^9ND@K)=(M_=P!36^=-89AX@DJQ8'W9 M\MT0"@;%O4_5M5;2N]/TS(6\3Y4Z+=]]YIF+ XJ.M@Y?&6$R/_&79A.!Z[IX M*R] 81"&8MXFL0\11CZ,F1= WPD3+R$D(L0SCC(:[W]Y[N:;(B>,46'H&2;DJT0\0.&J0.C.'(AXA3+F/408A)[.'#<( D3K*[*DVG#YNY#7TN@*,,*K^PNB=O(XN]GI/=6K;0_3DX>Z%XS@ACE@* MG93*,MP\@BDF$62A'S@)#PF/M79GEPBS-'XYU*KJZ*+'+Q>-C1H%S87XQ"QU M4*.+=KVK:S4!!U7 01?+]VALHFJ)[RX2959*M ':2]:TTN;%.\C::[:N76G7 M]!_;LDXGVUH*KI^&H9LBR&3]&Q0$+DRP%T,W]+#KHX!@5XM"U;I='%GF!)\X!+OV]M 2F#/N"D\P/<@-KJNJR-)M51<7J')P@V5HR 1F MG1Z"]K>&0YV^UHY0 8B!C:#*VZ;AA65-CJT'K5RY.$*^&P8P2N5)8^)3F,24 M0QHE08*25%AYB4Z$P,L.EA8E4,MW!5@K7FT^U-XKW:#!%SBJDB^9F#^G8A_$ +=X.?:ZA'+0>U# MVF>V/Q@_JR")J,N2",9QBB%*B8SADT5$" L=+PVC@'DZ1HAF_TNS1AI_ZKZ* M",![2:_ 9J!DMY6Q4".+"1&>F$OVT1IRMH"?=L(#GA<_MY[LO0*=39L]PC&$ MSA(?Z?8^*UT90O.2S4R;T<_[_AO^D3UL'UJCGCA.PN,H@7%$9:I"APE")QDY:7AI!M<*I)VL_QFF88B[2?F+R:.6RN%'IU?:"=.K'[%[@NA!1+X1I0'SHN4@=WZ%Z M^X;>OI:WA;CLF'L(5M5MA!6P)M]1*!U67_5X*JQ>B!^#R]ZE^-Z>YKX8/Z;R MF,G43 M@U^7I9@X'Q\><59(F^OJ3*KPQL#^]LCJDZFW][BX&["MK8R8&FU-. X34YE: M/O9I2K@:HC9O>O;7.4XRA,8P3?N%AT;ROM>[MNCDK7AU%8:!F_J(09>[!"*" M!,UQY$#LNRYC#A=B3S[[V:&QZ]Y3K]GZ_4U^>AV+>P,$D@"F,,$X^*B9A@)XU2Z@>IYAVKH>YT/LEYKE1=4YK)$R:91*%9 MRX3IC:7H9?-[/9-A$&LU^\ 6?A-/Z9V88N/2"@H:2<'-<+T [:5?!1!+Z_Q@ M5[,NZBI*OUS!E=XQJ-#^[7NV83O/8Y P[,50X_]^_ZJ>/%+G&[QL6GK*SJ#:-VOOC>!I9&(JV@ M0$IZ!6I9U7/"]\,TPB^V$)J8;+K@3.(Z4 +"*,%[?ZNS974?5:R;RGW\8?U- M_/M-E57/PGP6WT39_N^3H =WQ2(7N3SQH!>S0&PD4K&EH(X+Q88"1S&A$<=* M-P0'>UG:5&\$!:V(5[L?@!06?%$U)8:!'=_^6X%KXGEOC)26>V 4"2-?07^K MLSD.1A7K>A'&'S9,]HO+K/S"KTF="&U!-T "-$'8@B MCF#L!AB25/!#'"+?9;%6CEFE;I=&#;74\MCB1K2Z,ULUT\JJX:WF8+"/XL2, ML0?P(/(5:,0%O[?_G^3000\I6TEDU3J=-WVL%A GB6/UWKXL__CUP7=W_2,K M5QC'41 E"0R"6#HLO!@FD9= Z?;D08+<$&GE*^CI9W&DLTN_W)$3_"XEU2Q, MW8>K(M=??MG+JV2:[E&U+ZETW^-F9/ !9\7?\'K+ MWF QV(1]NV>L^K7(MX^"??;W5;^)I9A)1]);7%\SKDVCNF+*2I@JOB=3SXG/ MQY&!7:ZP7!B&E$78\3D-P]C788U+!5H:O4A]0*W0%6A5 K5.8*?4%3C<"][K M!7:*@=]K<[_639.0+AY;->::<\0FIKAY!DN;%&TA;(D]+Q9G5IJU!=Y+/K;6 MKF&P;9O+^ZU$85.U6?FR\H_V<,$G)/:#P(-QFOH0$<>'<>2G$%/?3R*"6>!K M52T9Z6]IM+L3%QS)"Z3 FM&W(SBK<:1%]":FP '@)K@+K(B+K7#;D=[F#;E5 M4_TD[%;Q-3-6J6-!=^4!,E;N*X@PXOMIX$!&A&TG$X'#- X]F+CBMYX?^WX0 MZK!)3S]+8Y$F-)8TPH'U05X]#NE#58T[+& U,6,,/:X&1/\#1>9/ '[*NR7VHV!, ]3Y"%( QQ"Y,FR /+$BG,4.P%B MF!.M(D(O.UC:W-_)!Z2 1@ZA$PC5YOLEP$P\T;4PT9[B?8I;FMLGS<\ZJ?N4 M>SF;>Y\SF\;-Q9S]+F1?5IK[/ XC1TS?6-Z9P:Z8S8$O=@LN)@Y-0B=)M2J! M]_2SM$G=WBH[[-P52D5KX:HVQ2V@-?%,-P%*>\*/P&!IWO?U,NOT'U'U)0N, M/6X0F_IY6Q79?VY96=4_$9Q?;[('O/Y44;SS&2!*7.X+*S]P*43(QS!%C$/B MISSAW(MB-5)0[&]IY'"0&+PI\']G:XVX3@5TAZEA LPFIH@.7#MI02,ND/*: M1,2JZW04JJOQFIT<:GM;(7%\ M1EB:0C=R&42A'\'4<1P88M^EU ^1XRE=Z!OK:&D\VYM3[<^7)573-,)LP#6U M,_8DR=HD=M@8$A/E77L=2VQ,V;$\;!?:8MTRCJZ7WF;5FJW2$#M>DHC=6.1Q MB&A$(/9E&@,'DXAP)TH=I2Q%YQI?VNROA9(Q:J[W4_HSV(FK7RUUC][P=+\4 MDXFGN"X<1F527^I]48G4?6.SET=]J<:YTJ@GSY@MVD1)'8*L4",LB)D[@^QX'K:47,J72ZM.E\G.I""MWFNZC% MOB!Z16D$U%9ZV[A.3 DV(-6V 70PLF0/*'4YJVV@ \)+.T'K7?V[@!^;XHNW M!:VC@3-6RI2*US1_K!C]L,9WJG<"1QM:&L.T LO\[[2^-=^*74^*.J\DW8K^ M0*N"^KW!<4A'7#:VT9SJ$R3D;7#,=;G^VZH;*BW6N'ZB]9 MS:C6TM.;9YD[Y0N7I-6YDA0['O5H #W&'&GA8(A#GL+4#<,DB%'B>5I7D@QD M6!H3'656:W+5/H-LLUN9[21-&QP4-7MG8J@GIJDNRL>FT,X"2I_K]$CR@=HZ M>H5T:BI83IM2;5""):154X%(,;6:4E/Z-M7UW5WUOJA+*'[.J_]BU3LF:.1! M6&M4.]6"2EM+XS,A<\'N9"B'D#S?L'Q;UB5#V:9LHCZ%)D"H @ZZJ%M72N". M&UBV<9V8O P@M5QP3!DGGJ? MMW4\N>-Z:>2&$?1YP"'"&,$TX!QB)K9A+DK3T%(@J>Y.<=>N*SDA["F M6':W:>Y.D^=.1?5?<;:11>A6:4@119X/"7$=B-R(P=1+&.0TI(X3Q:Z+F5D! MD/'.=6;!/.5 6IG;Y CD&50'J0'>5Z$WK JB,!QJ%LXT$$],-(>*(3N4=W*# MCN! 2MX62+1?0T0=,,L5110Z?I7Z(NJ ]%4;T6C!C,S>_W,KB/(W5MWG]./F MB;53<$4"%GB.&\#$KZ\7D C&)_6AJD9 %K":VJQI8&I$!!\58-(FE1$0+#%(7R^STL6(JB^Y8>QQTX.G M)]%*7CQ_9M4*>8$?M!F MAL/D)VNM6'69:9OG:*?J6CLXZS0]\TG9J5*G1V-GGM%C,EF;_JL8I"9Q4ARF M+$QP# GR9?5X/X1QZE#H<">@D4PU3)4J/!^UNC3NJ@732C1U#-+P'#16?>+) M)W.<9&4E]O1K88)@Z>MK\\W822YU5N^A62A>Z,Q \;?#[#MN:Y9I=U;\W7P[ M_X^FA4H.66P_Y8V'Y5W^(#8F*QQ[/O)Y K%'(WD[F<'8"5W(@E#\G]+ Y42O M.$E?5TN;DLR@M\;:77K _0CK+9\VL%MXOEL"IE!R9$Q-*R5&>GM:.;2 M(F,*GY83&7W#]#CEXT;,/RSOP+!WN,+[/+%.ZKM1B"%B)(6(.SY,'(?#A!/' M=ZC'L*>TUQCK:&E$T1X-=(0%4MK1-*AZZ*H>I5R.V3PG*=IP&1RD#&-QP3E* M3\,S'Z,,JW=ZBC+RO)GM\"XK<7OO03",O+LC[/\MJV]EK0(>Q@FF#":A3)+ M8L$&R,,P23$*"<,HU7,^#G6V-%HXEK6YT%9+VUY9T[0@!G%6LR%LH3D6.!U$PJW!\OLGYRAL/JG14 MVWCX2;.E_Z;(Z994N^2<,0^I&\M/VI] M:9.Z%0Y\PVM=W_DQ:FHKMS$6$T_<'0SVB\.>A%/H^$_OVA$?"7/<)I"SU M""(I][EC$+<]WK/2A_P*\=KWTJU:RN0>^4YB@,N2M>DXU]U:)QM620L5'PHS M:A^EC0Z0Z@&;%;QGN]!6"PE^VHG[L\1[+S%H1;9ZL4T1'GOWV\8ZG/N:FR( M9VZ[J;YIZE)\FS\\Y)OZ FYMI91?ME59B=DF^E@EJ1\07Y:;">.@/HB'.$A# M&)'802Y+HEBTI>58'.IN::9&ZR]K1&ZNAE\UMG().F*#G\3\*>M?]T<$FJ"O MZGBTA>D\[LRW><"/K$\U*/LM#QM&NG44H)L M+^85*(ZR<>W3MH/RD=67L4BCR(5Y7@=&1\T*F@CSB4GI-.MK8VHVPW"0'+P= M0?GRU*_C>$V5 7:@Y]=-!#L.R6@^6(4F#%*8T7_BJ4./>5:)S?;^T3%)VD+1D_A@*,:LE M=!E0+XVB"UN[\#;,F0QA04HXI[X/62 CRQV40K$!Q#"):,"1ZP8>U:R#VMO7 MTHAP+ZJ=+&S]&*OZKJT@-[G3V@PT\\LC,R1AZ^_I=:Z6Z"1A&W_%C#3V.4C> M/.]__$O&"M'0_?,G]B20D)U3]?_\VH=+HB^FK,8A_3B4GF$CBUB48/'4NZ5&451W1-K&;W/_<" MV MTH*?NDBV EO,-**.CC5O\VB',SN950$X]2TKOZGO4FYO8=8+K*(;N?/*TMB@ M%4VQM/!+_W.Q(ZQT*.ID3^WV\YL/MPSPG?]MN?^V;3:]\-# MUB3QN-[0?=Y/6=/KS-;80SR)HB2%//1#B(+0@]A+.,0)$_]/4H\CI8OM1KTO M;:IVA*^MW2/Q;3@I],9&;8V?#/&)&<(FV 8%QPU LU:%7*?OF4N3&\!R6J_< MI)'_G[UW;8X;Q](&_PHB-M[9Z@AA@A?P-N\G6;:KM>NR%+:J.V;K@P(WRNQ. MD6HR4V7UKU^ 9&8R+R0!)$AQ-C9FVF5+),XY#XB#@X-ST3<3.O$YVQK4MSG[ M*CXY5:NA?X2E:2;)D[H!,8#,N#UA!Y2)E4Y[K.Y$3.ACKV"@C]):V]EO^VN V/8-C#%HU$\,B8!/K M!-U6T'*\FEM=Q?52!LY?GWD9DWQW]$V)/\ M_K'GS6L%T:)\*9J.)[+>&[^1XY9O-P7CCZE+.2*#JF\INF"$)/_^%LF!"!9\G$8NBD&+H,A)!Y,4A)(Y/893Z!(G_N4D<*CDLU.@M3;WL.0;? M_@,_O_SOCV#+.*@YAX)U1=>&(N(C/@[[.$Y]EZ("X7CY R,L64'KW;A>.7-B M>D!XJ9^GNB-)#Z!&793' > M1K5#W\7@3*Q6&_ZNMC4?)[EG&L3 TF'O/(U93WJ#8AX?\X8?-CWC73,F/HZJ M-N[NRMJE)%A_=(+0#>,8P32416%1G$!"F M]H0=HPOR$1DJ^XS%"2UOT[6&D M9;9S#-DRK'N6Z\%7]1!W.6KSG-X, #,XLPVC<<%AK6?@F4]IP^*='L]&GM>_ M&I;9C]=TO<&KU=L]SMC?JC.UY[1SE?5&79I&Z*;@@JT80,H!7JO_!'WE#]5O MG35!'SFE38KWQ+K$$.H)TJ'-(#2ZT-8D-=LEMQD$W8MOPQ'T^\W43BE>ON!R M_2;OU9O6,PE*$Q>',&',A\B/7$AD2>Q#N/0 M[DAS%L9A=6,#G,F5BB8N6AUJAH2_H%G-V6%GZULS)%2WA["V'-22).(1(2[ M;JI68,9.B0%2<]EJTVLO'' M=TXW93WXIY]TM1'T/PM1I9FU6;>U_;>)1?>\K.VL+UG.;]?\N7H4N,41I1@& MOBS$&20I3(A,6TCB*(B(L)9"K6 >6XPM37EVY0)[P)G-I%/><B6P3SQ MNML>WSP[K;?*+\$^<9P@A5Y ,$1A@F#"/1=R'G/D)(&'4?3XRDM2Z*2CV:@' MW"4ZJ=](U@.NFGK 31UE4%Q27ED)]I@Y,2$!@D%"$K&CX@@F%#DPA6&0%>S[6IR1YH7^F/!T\&\[1^(U(/PIR^4"D JUX6 B\$,:^5Z*0V'. M4 \BS!-(/)]"XL<.3WA$A('3@O\I9^\!_9;L+,!S6=-W8LC5S(G_(:7$S]40 MO[);1%P'$8LYDN];3EQ'Z',9D!.5$F\JU>'5KV6Q>:EN<[E]BU%E8F6=5['A MK#W#%7DE?5EM@]^((D9E<2AQ.F(018$#XY0%XNB$L.O%W!.;@&831!,^EG9( MVHH!:CE:MZI1,D+:I)?B)3C9:[-HQ,7<'1@O@>I,<\:+ MAM._Y+_G11NDJGA_OWMA:5KH_M.=^C7[7NSQ&W0CB2=6!+(E-+J_ MWH\RV]7T">/=6^?37QKD)UPC+_*^\SPKRJ_%FE#&,:!Q"[/ H2#P4>\953$P9)+6W%H?\4S/XOT+ +:GX!VW @.=8(H!^& M=V1]6@5MXD4[A)=)YL$P(3YD@N4)#G( M*U![P^SH51?F/W-!)N_1Y"5U';XH/Z%'A%'@T-"%%-, (B](8AVLMS)4'>OU#MJJ4^$VN%J$G@G5L@-LN=N MYJ_ +FP"[#BW=\+2!LO2F4J=[JRG*&TXCL]-^@-9..0=\>2IQ7P MQ0!T0*@K*'9@ 'L;6XUL_$^_W8U M][2]R6H^]&[DABWT?IBB4!>X]!@F5]6)"XC@>\@ER ME;PF_226M@'5'$H54O-H>$%R!DG%B]B+\)GZ^E43&OU+UU[I;5VUGA*8]X*U M5\"3:]7^)ZT&Z/M6A-?[(0TJC( TA\YD+D>O(*BX801+)P/Q(&+0H?ES+ MM""U1:].6DL9[!B8[HO?!8O7\>%I48(=T[;#\L]-A)K.F ;>B77)2!B^%LRV M8N\'$)LVYOX=@?.M43*H9!Y/T1]9%RY(UHDQV5EM$%XQC2T3[?=,^QV)M M"]OF&U[S[W_BE_8ZWW%#AQ,N5)$3IQ#%E,*$!2&,D5!0%(6R_;%>B^-S9):F M@K9< LDFD'SJ-C0^"Z::KKDW0"AI#G$NA%B$+$? P)$G^$7DQB'L2$<*6&H1=SLC0-LF4;R%XKX$_) M.'AI.0=_"M8!X:!LF=<(OKIHMH;USZQS,+&*ZH@![E*P%>0*[.9%R@)J8@SIMDJ6[^UQEB8^@[S$(-BH_(AXIA"''DA Q#?5O"[F9U+ONIZ:GKU7 M&-3'@P/,IV]5Y#C0ITHOV.C#55??2QW7=^(X@&X4(XCQ- UYU$]*JXCA )!JQ__+X)G:KM9#YL(>6ZJ%#(V[:\U7TG!4-3SJ_WG]]+3^5-8Q7-?/:X-VNX<#+&WM=KO+"DY+_B2=5(+?(N?%I@*' M]7TUVND-PSAB]=A"<.+E;1,\TT:]Y\&YM$_OT:COT:;WO& ]77I['C;;U#^E M*9?Q"FVLY@/^^:UNHU7G=@MB^^3NQS@0>SW!#DP3GT(41![$B%'((C_VB# # M(D_)H:=/>FF*9,>Y#,\'@DG-]KT:H*L9!M- .;%&V:/81L0+MIM[ ]F'.I>6 M:YL+<<\%29MA[/IX6;(Q- C/:GOH W)LDQB,8!BZ77*6K;!V_Y-F2_M+AHD<2P8$L]2AM0\V%:L;HCC" M,/%B!OTP24*&Q+J.?)W([,[86HMYAM#KIG'(:L^@WCKNHN:%B#NQ%PKS+'8@ M\B(.":<.C%(:8C>F 4FU'#*FJ,V@ K_8P$M-X1FB,+&F4P% 6[V=$=627NN. M/*M".R/2L28[]XB^)^5,^YB_5?>RC[?WX3?%, MLKP^3_9NS6R:.R%F:R?3S.':G;,N\_, MQ.IR*Q_H"'@%]B*"KHQMXV2PE;*NM="1$[2"7NU#Y.V969/.A"6#;1H>9S7] M)H7YV(BQY*-\^;%5YSUE>>85LTD@:NP\4IVW-E^0.>!A"'$8%.C-S8 M<^+$\SVM_CNJE)>FV3N,@W/E6V39%LV&.C8+/EAVQ('U* /MT(+%QA/,&D-@,7#@ MO:(%QD,$K,8%?,99^3>\VHAUC:M-69-3 $5JM//SFM6]K=B WBJ?:RZ/6$ M&!IC:3I$\ IVS((]MQI6P1!B"C:");"FMAAZ<++<=D(%#3/+86C@^>P(!?$. MK J5YR^^[O\J&&\J%^P:=,=N1+F#,.0D<2$*/02)%X20>;'KA,P/8CVW]""U MI>F$/8? QCWW&7BU;[XO VV^N_ KT %OBG;F2IC8OS0_0^N]KM'[Q1ZX6!]X MR5!]%/G3 R^?939$&R&*G_@'CLLL?_J<_91>U'U%A$%R&4$ MDB1RH,=3$M (.8AI.3CUR"]-P>PYED6 5D(6(,@^ R:S>$@C!$BE%"!KQ=#4 M/GJSHZB.)L-\:OTD&(>2#6<$S(G*,QM%_YPD%.JWS8J[#@GDKJ'V%IZDIP M"B6K0/(*72"X%;]N_ 0MV^K'I0'@Q@]+=C";6-THP 7^D#Q;.C.-@V)T8AH8 M=K;STKAHW=.2PM.F-=CD)V)%.\$\&Y3#FQ5U:_7UYN%ZYH)] MLT[%:07 >)<=* TWZ@DPKQ]XIVT@!F(.1) M9Q3STDI[I;SST:>>EWJ$"5T7>T+UX22&)'4IC%SD4\Y1+(X9NN653LDL3\61 M-=BSJ>+#UP%535E=#M74EJ<^2D8EE_I!L%AVZ0R1V4LO]0MZKOS2P-.&A5AP MF0NSJ[KG99U'M%<"POI!E$70\W $$15_Q#ST8!(C["<(<^:$CZ^\)(5RX94> M4CI?=Y?@E&[SJ@+"^ 25Y/._-*NL]"&*HY001!S(PI! A'@*XY!Z,(JC2-B3 MKL^8ED5I \]9RM:T?,JKA2:IT%BW]F*KIEUM(#:Q?C4#2[\2S0@2MNK.])&9 MM\K,B+ G-67&GC=,H\155MVEPL*3$<:"P"-B?A2%Q(-N$E&(?)Q (@O^ADD8 M.8$;>H&KU5_GA,+25$'-H+SYO1>C;HN]UH?([YOG9UR^U;TOLZ<\2S.*Y;%F M)PJX+U89U<][/ %=355/+T^\4YR['H? M-%,%V\+BGP5+MU6UD?ZRN_0[S[.B[%[D/F+*TBA$!+IN(#0$D<7!N>-!/R0X M\D*7\%!+0Z@27IKBV!7:EY,(LI;S;0P)W,60Z"D'Y6E0TQE3@#NQ*CG$];:# M:\,V.(P@L:=9=+&RI'"4R 7R KS@$KPV:3C! ME>,XV_\U!\<*X,WZ1U'*1.PK@!+O*HS]*^0YM<6#(G3E^=%5Y,?;QZ5>:RL" M%)VZM[AI"2X^I-KI!WSG"L@ONW[P(Z?U3__C_W!#YW_[;OTK[PJ(\5Z:RH@K MQ48*O=.LIOTNF;R)M5P[;]^;>6OSIFYKL"U6Z.N1WU9]ON/AYZW.UR/<26V^ MON<,>J4\B"G,R(I_^MK>.UL2+?\LJ:'@%DMDKT(%O M,,S5 #Z-YBDV89RI@+# MQ TQY&E"/.(CCW*EUE56N5J:RNX*=04.Q*I-N0.GF+#X=J*!O6S&KG,[\ZQF M"LX^>Q-O(7--G+;-:15H2X:J'9YFM6ZMPGAL$ML=W#!GC3_AU6]X+;6<(-N4 MQW_BN?2G[TN9.CSUDQ0Q&/AT#)\".=%]A19*ME++E&C.FU&F \-) M(IG6RP9U-O[$):MN5D7%'XK?\I=,QK34 ;[:I:H5AEJ:>FE8!C7/(,O!0_9< MQVO^]O7^MA-755V!6@Z-8AP*L(X<[.TC.K&2406S37X UNM5:\!E5KM#8?SY M2GBH"WM0R4/C-3/KIKGH^%JL=\5GD.-0SHE $R6..([Z#!*7AM#S ]=W@B2. M"=:Q9$XH+$VMM+=U-8=Z1LHI>&H&R4603*P7NFA,$ +?*[HEB^)T_%FMAU[Q MCBV%_@<-,W3J L4W3;6.1XK\%,4X@#B0H0]^Z(O3" ]@%(?<<^,PH*ZKTXGG M8'2M]3M;+YYM^1A=- M/3DGUDEFR=F'#'=<^H.SS8K?I5_YG_NHJ/NRR,5?:>N[$(>''S+_O[K-N\]D MXBCQLNH>@4D:A!$/0^BP6#H>B .)[ R!B$^81QR7Q([6=FV5O<7M]:UTTM/X MD5>TS%ZVCL=.0.!W&3U0F\?;R@OR$"Z4-?AOKEF\8J)95[0SWFTNIU9RY^;J M]Q:VK".[S,UK6DT"[(E=-@V5"RLZ=VJR MM?5;V9WL5"$V)$&XCK#=ZX8 18'C8@Y][D80AI5F*A 0]+4Y5[?@'M,KQK=ZL9$VLR+6J* M.]^9*H0*70;4Q[*3"-^XZ\\ MWW"9VR IR6B(OV?K'S>;:ET\\W(7FH0\)XQ"V4F,I+)@#W5@0GT"J6P.XGD4 M8[U.8HITEZ;Y6K:;A)XMX^!/P3G8LFX<0Z8Z%6J:;P* )]9VEK#55G&:2%E2 M:ZI49U5EFE <8Z:?_0_I[SZ!9%2S M4=@@G,.+V19($R]H;7R4%[0* $-;MWB_LVV+?^V7]N#0LRQO%>&V2USI6;UE MSGCV^$D<0]9OG[,5+]N.06^/B9<2CAF%*) I@I0%D#@>A7&2N&F$_! AI5)V M/>,O;7$W+(*:QVVK*D5/1Q^"PXO: BX3KV<]2)07\XC@ YNS>+-9QN(O^Q7< M-]XLBW=$F.VZ'7O,J)?$/2^^\N+Z]:D.@=%LP]OW_M+6I6R,=L)C$HUE$KB>%G M#2.&MBE-36%_% 8>)<2%81@3L2_'#,8X3B'&)!'_\)&G=[][./S2EO^..[-N M"T?8J7G7S!&9>%FK@Z$?MW)69EMQ)X>#SQLWT$49:MO88"$8&=^^@LUG=8V)U3>_1 M9PUJ[-RM?PA#7NSP)?\A6SJ\\J:9AZR _)6O;_-7WM2;_RMG3_Q7<4!O?W.7 M/N"?C]R/Q"&:8>A[R(&(. B2-!;':Q2ZS(]2&CNI6I%H"]SHK(=YZDC7\@#: M%0ADM43@EY7@_"]7(.=K\:.M7."'%.P*/ G1#AXI4K#&/S6JU%PXL2,'B'DG M:V+EUYIPEC4I#\\W63'6( M9ILUO9)%=G >+&AT(8GYRAW9P>*@&)*E(NP$+J$RC 5WX78 MI1C&OHMHZCFIXVJEIOY_,NGC&+Y?_/ M73G,79DB1'J!N2K_\S)4ILQ+><=L%.G9E&Y-\4VKWBVTCR]--]8>("4Y/,*[#FU66=[' YK-;<'2,U&MV^VW[N4K]NWFG@HS)R"R*'>$N0>1RS'$0>A V?)(=H^+$ZP5D*]"=&F[ M=3>-D+R!EF]0,PZVG)O="BK-@9J&L8WLQ)K&#JCF*9@**-G.N!PB^3X)E@H@ M].93JKQK<)EQF].R<1NL9,>3SYC6^4,UT*:.%NR>-O MF@?U]K MP/F\^29R'OCNC0:XM#[5KT7!_LQ6J[W#UJ,Q]5SD"SN4IA!Y401CB@B,61S% M7AHP'J1FQ:9.:"U-U7<+B&R9-2T!=0JLFJUI":Z)%?@YI&8JN=0+B_7Z2:>4 MWJD84J_(_96-^E\QO=M;W^#JQWU9O&:,LP]OOU>9W+W4V>_YT+5NIU15 M'KG+4!@R#"/B8YE3$L.$Q3[DB8=IR-V(Q(%.84IUTEKZ9(:JE?+V7+(.MKS+ MX]B.;[!G7/=>3GDN5&_?ID!X8A5T%MQ?).<@R_^B![/!79HN8M9NS)0)SWPO MI@O(Z>V7]@@7AMK?K'!5W:5U-[[KGUGUZ#NQ[W&,8!0FPO1A.(()$J=?WV5> M[.,P,+OM-*%[(:\*]E40E[!H5QPDDBSD*. U&XK0'A:E!S@U:KXL_8RBW\" M<8YEV1K(^%SMV\"AF5"^#[2$[_0W@F, O1FDF5_<)6I;;@;[E7#TH\"]F( M$K. UL0J3!DH>]$)8Z@8!3F>'7"VB,"BSIR$4WJ[:?Z\=LM5ES)K2-^,;N M-NM*ALK+L&9>UC][I'[B1+Y'H!,Y!")75D&0%4R)XZ $1X%+8J7Z8^_"_=*4 MU+9$"-Z)"YYK><%K728_YY17%19K;UV(LX=,Q%QM6.U-!70ON'1_L$9T4-6R M@V(O//AE4S'PPLOF=W_1L$QF_[H43,(E?S,3J^JMZ*"1'4CAKW9U9O;R@P: MMM?"'@*PPT#\#710D/F$+0Z@ 0)TD*AC8IN?+_G;T3"8E_P-S62++_A;TC/^ MWVLN!\\5LS,UWY'EO? ^. V]&Q-FWNR/_*7D-*N)B;^ON/R+.,I=/Q?E.OMW MH[&"D"2,>ABZJ6P>R=, QBSPH>-'89+XE'B!5GTI%:)+,XBZ/->>)MQA5L]O MK82YFO?:-I(3FPE==J_ CN$:SVL5/+6=U3H 67)9*Y&;4N:^OB-A?+F5?K;WC-ZSL\ML^T>71]Y*1.$$*&N6Q%33@DC(>0BS.? MCPA/7$>I9)8^Z:7IHRVOH%2NG&6 MZH6F@+%R741D05-MEQ?@1VBDO$KT+ ^ M2=*=/E[65),RX9D5E"X@IVI*>P2#;A32"?GP_/37XL_?\I?L)J^8^/U M+\7@*$O3,S6WX"%[KH](@F?PV]?[VUTG*M6NMPKPC?NK[2$WL6X9!D0>]7,?OS.>$ZN'VP$?4]\R%$(+DUM[6MERY;/N_IG M6[:-&_DI38#:2K^F_-MG1VO 3AZ<^BJ"/:0*1ZR8PCF,&G9!%Q V1XWM:M4WTR"]-39WK M MQX2*4 H".!L<;2G!\UW34=ZA-K,;N VVBYK(#;=-V6AXB_=Z-E!6 4>BRK MC&)JBXECY8]B)=ZHFAO 1^P2Y/DAA2[&$40^E2[K-("8(!(BGX<.P3H)KJ1@$>"#O0]Y@K#E4@35@(9D"!-Q*&:"/A>>)D5 M3&QLY7H.$(_)3:B:VFI,> T(?\KR7,8W"%NKX>!B<#%"210' 71C[$$41H$X M%:0,QCP@D9.XD8O\%MQ/.9L/VBVQ68#E0M/;@U35SK\$I(GWPX:A*W"]7I<9 MV:SK8)MU >ZQ[)AATY+O \&:W7Y"8&8KO4_ 4YN\]TFSC6A;T>'V^05GI;3V M91+8HT-#WR6)#T,O$)8VDOL0\B-(,/-3PA!& =,K0'J>D,[7/$_IT5W=D6S' MJ-Y:[T$TI91Q2CP8.0X6NQ)#$ M>( T,0GH#UP.7)7J(,N<,""N.!"F'N8044]L3M1-H=C](R(.BB[2N^N_ M_$N=J5K_!%BJ[4J7(S3QSK1E\ IT8+*;W3J,@:6-J8?(K)O3L*#'&]3(TX:% M;[,\6_,OV:LLW;%N R?KDUGU&_Y'4=:9^[(F=]L2G6(<8TY"B*-$F*M86*HX M$KHA(204]KQ::5T%6DM3<-VZ@4T1'?+6+BRSUK\# M,"N>V^V -_6UG#EN%Y1:[$7$>JG%4TKO5&JQ5^3^4HO]KUCJ-_+A[4&,5-?2 M"B(W"EPF3E"^[T#DT@ABC!R8)*&+(B]$U%?*K%>@M335<=H_ TA6C8J5#4&L MIC8L 3>QVC#$[/*>(Z=H3-5RI$/I?3N.G(H\VG#DS"MF*N.:TLVS3##CK-/3 M4993_+PJ_JQ[/3:NWC8\C7+/B9S @P&6+BX6(1CCE, X]FGHA(CXH5:-9TWZ MBU,MLHRHY+3I@:JG2W2Q5],O$R(ZL<[I<'[22_8*'$%]U5Y!C,=<:NLD0P0M MZ2E=ZK/J+D-HCO69Z3!F.F[?R/:S$$C68,OR398_M05BB[SZ4!?,:YY[P#]Y M]>FG4+:"1I;C\NUVS9^KKP(@6;VM6*WJ#-TFJ>0Q#!V*DHA 'C@Q1"DF,*'" MK'(H2[D?8IY0HG.C/R&O2PL-:%;WMFU[6[.P_==:"J:G3:><937-NY"YFUA+ M'[0"!U)%@+VH8"_K=D;;YVMQA2H_$&^79V=/><\P"984_928>O]5]=Q^*.J),LG#H,GPD21R'?AR*+X*(DSC!,4P09V('22GUD.\1 MYAC<$H\27NB%\;T8Z >N>%T>.]N[T.LRP9I[P#CX:IK<#I8SI1^UO,JHG);; MTYL(>_I5&1I+6G*P@+R2^JU0%;X#&T@[D7XLU^+CC42B1^K38F!K;C'#-GBEG M@%73(A?"-;'>4$%J@L/U "BV&IVN#$*+*?1]4@>G19"D/(%^(CX5YD><1XF.,N@CM#2-L/VJ.XP:!C_T0JNF M#FP -K%.,,)*6P6, 6%)#_22F549C E[K!%&G[^PK_AM_K)95U_X*U]Y[6[F M)I1Y3B", Y^Z,BLE@;$?.#(SF"4D\A%A6LV+!F@M33E\%R!G:4:QV.ONUC]X M">Y(QJY21B[D(1Q"!&.'2B[ M','()T'(T]1-/*VR OVDEJ9%9$/!/:M;.UJ[-6,?L(JG#2MP37WH.(O4%,>, M433LM57L(S1W&\41@<^T31Q[0T]',)X]?LK7V?KMTS,OY7"_EL6?ZQ^RE0#. MWQX#ES#D!C%T YQ %"5"50B% 3U$$M_A<92L9U2[B>1UK-;+@$N#F+LVX!JAFL0X)L MUF =Q,!:P=7S5&:NKCHHZFDIU>''30-R#J\^Q(B??LJ>,5('M/W[9\0RV3/>[=@SB3]0QLA9(HD!RYH@0=1!.0SLTWC73/_6R MDM$?FU(&&;:I7&WMUM1EKA-%,$HB*M1.[, $DQ"&#G808SA,(ZV\T@%:R]0V M^8Y7HQ",(6S5M(PEQ"96+@U8>S9;%3.!*T,!#TN*9(C2K/I#0>1CM:'RBJFU M\BH&+,HWF0=:_>!,:J'JD2%7EIX@T$TCV=P]1#!Q&8.AYZ>>SXA/F)(W8YC, MTG3$ECGP4A9L0W6U0P^6JN;'I0A-;G"T#%Z!'4XUCU>@;O!MT\H8@L*:77&6 MR,R6Q)"@I[;#X-.&GHRL>BDJO!)3N'FI%G10B%A"( ML0SKQ X/Q?&%!8%6:,4HQ:5IA2W#H.88'+)L&&TQ#KNB@\,FF%.[.B[#4=_Q MH8J-+1?(*+UYG2&JXI^X191?M-T%ZU.:DVL=\5ZQS^JH[6B5"=Q?W:WQMK#_B\ M[;$&4)N\0]8YV@MIDC4 BWJ?K*%!K%6!E]WEGW)Y!W++! VA0?'.Z=/&R+/K MG'T1/\Y6V3KCE?B=8)7)RPW/%28$+41HA2%)"(?$C'F!/_NGKY%U: MYD]+*\Y6ACGKR&'DW+$]BVJ:\QWG9F+=>J[:_!78"P>ZTFT]3%OYZK+T'0E! M*Z+ER[&)T)^N9OU%W+UW47L;T"I4O;="QC@;O^2XXA]Y\]_;_+3@\;=BM?I< ME+)AVZ/G^TQH=@*I$\OH9,^!L9M@Z#(G\C'W':;7$$23_M+LVRW[X)>M #*% M'G1E^#]!(P7X0\H!6D$TC]^ZTZ3JPIL,_,E]>]9Q-\EM-T'/7KZZ%O6Y<]!- MH#F35VXTC'[_6%DODGWZR>E&VMEW:9I10>%SKMU"=G2@I6FPFF&PXQAL6;X2 M*Z98YX7J85T-Q6&]9!W B;70.'83=)-5!LBHH>SXZ+/UE%46M-M65OTE@\ZR M7X39QGE;U2)_^B)U4OW'UV+]WWPM+#IQ=*=\9ZB]/10?^#W.V&.*.".>Z\.0 M!"%$,>+B@.Q[D""/81Y'8>!2Y1ZTQFPL3??L1 KR?Y5\Q\@%@YXXVM MX* MU582C5:NYI,UHJ1FFX*)M5Z>>(KUVOQ@P=GD2Q%T(_0!%$'J8PQL+ <),H2&2 3IIJW7Q-Q.?2=L&//&WZ%JSJ MO@47%EV::G+G=PX;3MG_3"=Q3^L*BT%*$T_- CW(72[_QWJ2ST ]I4?Y'#FS M7>8;EW>9=+TI93F_77,B0;4.#KV6-YHUY8]915=%M2GYWD_ 4!2$CD,@]TDB MMA)Q:$J<(().[ 8Q2AAQB5:'L4N86=I^T?0^W@LAM4]'NEK'-/'0WU]XW?7] MIFY7IKF17#1_:KO%7+,R\99P(,;5P3C^+4?'JOFZ?^UG\K'IT Y+&'#O029@/D4,IQ%$<0S^. MW)!' 7831S7IOY?*TA3FEE'0< H:5D'-JWK"?S^HP\K.&E03:S$CE+12_4=1 M,$KT[Q]UMC3_4<&Z2?[C#UL(C/\K7XE!R^]XQ>_*YC>!S!IGBU,L!P'B M5T#*!M.BA.)G7$P>V,HGBRF3-R!%O*J]=ETI.U7:+XC)OVC&U MWQ1^-YS""5(.K>,^1?[ 17R]7YZ!#3@'\Q&L$- /:+A_?:E[V&D',)R\N#2E M>X_?P&LES1.Q3)_K*B1[Z_D*U,RKARRHG 11!/KLS/H-(TE@?5 A%X8 MC (/3D>;+="@5Y!N8$'_0P:!!!_XSQO\F7_Y.!GR+J.$HFU]G1E[:"6_ZN@.!0X_;X!#2%>_I+H)CZ(J&#PKC1H "' MQAWY);#,=/6M])'HW5_W23UX+7WRTGRWS7W\'EPB]SZD;S,\E.RZ+&]S]I"M M5TKM9T_?6IJNJ9E2-P>.(!BW!4>>5XW.CB,_C%WF M04)#!!&)?$AB+X:$N"QRN8=\K%5D[3R9I2W1.J8;$LFF#/G;\0GX3_EWS63A M'FC5/!R7 S;QJJX9A#6'H.UA=+C"9\@/ M"GK2/G[X:3WU4)7KQ[_S[.G'FK/K5U[B)[ZM@^:1& <.%:<"A"%R9&A5R"*8 M>"2A*/4=-U Z'_126)I2V#()6B[5E$ _@,/KWPHL$R_]8T0L.AI'Q1]:WN+E MSM(6_]HOZ_YQ9UG1HV)M%_/X@Z8A,*\\WW#9%//33[%J9!X5MD"8((@Y22 .XB3U:,@T2UID=/Q9]4-O>(=K_C^!_6]D'L?U?7/K%+U0AZ^M;1% MN>?NO]1]D4= C/LBS3&8>!5VW(Y_2-8L74">E]?([W@TU&Q^Q_,B=/V./4_H M!X7>9.LWN>/>%(P_LH1&+D0#6\,J[!(*I=S\UZ;6".,^):A2W>3#0;*&:Y]CO1F>>_;UI MX[5KQL1T5O=%M<:K_R=[J;\FGZWLL#,W M71L2[;3GVN#3^D[\^Z8<_UWYG9>O&>6U >=$)"2,$(C<-)2Y%QXD$8IEB6"7 M^#'Q*5=J4=!'8&E+ON6QSH%JV1PS_]2 '/?E7PK/Q"O< !DM7_Z0^!>X\L\. M.YLG?TBHKB-_\#DSM](G7.99_E3=\[*^[]L[>Y,HQFGL$NCXX@_$7 0QHP1Z M:>P386#'*=;J-=!+:6F+NV54!IJ"FE,]7U,_HFH^)RLX3;V/MSSN,9HHW7,4 M#$O>J'XZLWJE1L4]]DZ-OW!IBN5_1!%+,4)FD:P# * M_82$+J6I4F3= (VEJ8+CQ$')Z&7)E7LXQTUZ"R!-K <,\+D@K?($ 0M)E?LQ MWRFE\D2H_H3*TT?US??O_$D.N+^IPJNVR4WB^2ZC3@H=3*3EGCB0^#B$.&"< M8>[Z/L:J-GPOE:4M\"Z'FNV#AM$<-^2M8#3Q^M:#1\N0'Q7_ FN^?^S93/I1 M\;IV_?C#!HDX-T6^+C%=_SU;_]C>4>_*K7TN2IX]Y3=U#T/Z]E#BO%HUX:1B MM3,_C"DDKLS706$$D\CW($Y8@.,@3%*7:_1-OX07I94P?U/UEF% 6X[!>L\R MP.P?0D YG8HVPD63-7)S-C7V<]UT-Q( *<(N!.>@(.1V2K:"@(XD,TR#1G[2 M#-,Q4QK35-.BE_ET(9Z#"5*F8\^71W6A] ?I5I>.I6^,_I;EV?/FN0W)29. MB_.D#Q.68(A8Z$/B1 GTXB!)?40)3F-5 _1@Y*49G2USZF;F(4[CIJ6Q]!,K M\I8OR^'=9Z6]P'H\'&\VB_&L&%TK\?P#9F[?^[)XX>7Z[5[,CZS9)1M.O,@] M0S;+BGR?X4BLP3#Q.$1IF$#L)"'T0A1C)T8D#;4ZTP\16]K:W/):7V#P+:-7 M(!_H=*6/L)HGV!9NTU_YU&Q>@9K1&KE/>^2L]@A3@<222WB0U*Q>816ACQW# M2N^8Z8ZC=)*O&ZF/[M+:_US=;=;56GP!6?YT3:K:GA ;>T1EX2WHT11!Y <> M))BZ$"4AB](DC1)?2Y_H,K T';/E'^(VW:FJ.0?%GG7%6$KC*5%30%,"/;%2 M.DDI:YB7>34-^Z##_Q7XF*TV\ND_MJ)8O,,R1=&2'M,F/ZMN,P7G6-\9CZ,? MQ7TM&W)]^EG2^S*CRK4D#M]:FDKZ]).7-*LXJ+E3#^0^PF+$'741#!,KC)HQ MH(B#5BSW>9&-8KF/AIHMEON\"-U8[IXGS"R,IF- W3!@7[2]J?#^X>TW_(^B MO%GAJJHCIF+/I3Z-'9AR65B"I0PFB'GB[!(G+@G$7UVMKIT:M)>VB'L:+6P[ M-9 W4/,/:@&TXM5,)D;-Q)@([HF5A56DM0T* \PLV1(ZE&DMFA2&]I:NRP M;BTX9-A(;8T!KJ:J+,(XL7JZ",'+:OCVXS)%9=XSU-ZOWFZ_Z(-5= =>,ZS MM<;KNF3277J#JQ^?5\6?U>[@[R%,F!\',$@C"I&7AE ,$D(OX![F)*34T:O# M-4!L:8IEQZOT DAN01PYB?!,(>B;0J31P. MOS0U<6W0FO (,+7%;P[#U+Z0YA@SQ>H^+[.E]7PT^*PK^+Q@QVNVYRE#)^3# M\]-O^4LF:\1K%\/O'6!QR[%VS#UDSS(GY[>O][>=FOB:CLJS>"GZ+"^%:A;W MY7F4+.?F*$%B[MX\.^J\GLXAP4Z[5DW.R-8CO="LT',5M17OI8V\GU9 MO&:,LP]OOU?2S?MM_LJK]>$:(CA@*4]\Z!-'G.,)36!"@PAZS/43A$A(_7B; MVJ.FW#0Y4%ITAPD]$^NXIH-QMF45X!VO)C&?FO.AIM.FP'BVCETUYW*[ +]L MF:]+ZOZE[1V]$V 2Y68(G:T(4DWJ\P:5FD%S$F=J.(QIU?$USG+.MF4/VHP( M'T4,H8!!UW4]8;+Y#DR8.%PRH7T=#_M>2)3*#PV369QCA-+-\V955P7_R-., M9IKJJ@=--:UT.483*Y\M@V!7K,1^D=QA$*S5VSY+9.92VD."GE;)'GS:;.U_ M*?*G!UX^?^1DW:2AK1\)"CSJ(A]&H;R82.)(+'R'P,AWW=@-'.9'_/&5EZ10 M7?IGJ.A\TUU:TWW:+6/@I2CK&_TB!2O!-Q1:YQDPP;F>'CB'+&-A$(\WI26C;@!)"QIV',49E6O R(>Z]:A1PVND=@_'HJO17[/BZ^\ MD'V>/N?Z5TE#@RQME5_OZC. =2%[BL'[3W?@J_A?M\L5^%P4Z[Q8Z]PP#4*I M<,MD"\6I;YKT )SB\DD%*;,+J,&1Y[N$4A'PX")*Z05#NZLM 2!T^G7.ZD8( M/XJ5>+^2.87KMT<>8X>$C@<]''.(@I1"'(01I %!<8AC-T:^CL-\C.#2W.0/ MD@98[;G>Y0ZOWS2MA3&H%4T'BP!.;4<:T*1>%/ M3 S5]\P42NT;:N[Y9$O/UBKV?,2=F,60\BB4U25#2'QYGG.$)=40#4,-@TP6V8=&>EAA$P))J.$]C M5GTP*.:Q$AA^6/^D<<]Y6<>[U]MEG9?;*)5OZ_SZ>:UZUA@99FFG#$W4?&=>#.*(. MY(%#44 ]AF3LG4;FZRF-I2WX;L?G+[N;!LDXV'.^;2VLF_=Z!F(U/7 A;%5MGE_D MWSYF:1\V)3'88&;/G6,%?Z %,P3"Q@-;4) M,@S3%!;'""AFMD7?H/-9$2-B'=@+8\_J+^N'DEV7Y<=-V;0!45S,AV\M;0D+ MUL0_F]HO6Q[5U^T1(N.KU1R,B=?H0XE9G:6B@X?6FCPONM%*/!IJMO5W7H3N MJNMYPLP*O\WKE).J^L8K+M[^<9VSC_R5KXJZTGF;SD#BD'@X\&3)F@@B[E"( MXR2% 0VPAUQ&*(]TC'$EJHM;QE0PG +[?WW_X# M/[_\[X^:-P]J$Z)FPEN'>6(%<9N#EF'PK0MLA^<)$E"T4+)DV*O1G-6^UX+A MV,S7>UF_G^ZG?)VMWZX9$Y];=2/^>E<^%'_FC\RACDN3!$:IRR'R:00)^HVP?HL&*Q!-/49P$3A+1Z MZHY@8-13MV_,V7KJC@C5[:D[]NAEM;AN\HJ5[/,*/YD4XMJ_O;25>UI?ZJ;( MJTP Q)E9%:X.4N/G@LM!FGC=#N$#_I#,3E!YZQ2)B\MN=89\EYI;IR+U%=PZ M\Z1!E]S;7*P>7JV_X37?5M'\*V=/?.O\^RZ;NS+.'O#/#SSG:;86=@)M:_:* M'Q?;V C9UXN3$ 6)Y\+4%W^@-"(P21"#/";4#](XHHE2(KI]UI:F3[[Q%<=5 M?8-?M6* -?X)2"N(1M-6NU,XHHO>=6(F/\(T<@$IV+[,+ZAE YVKBBNPE1 ( M$<%61M 54B:';<4<;@(W]8QJ-.=]MYF=J67O.\VP7D??229AL,^O78KS=?^= M!*F#GL#34##8IS_R,GL5J^.5?RWD&L&K)NS[-J>EW$@^\N:_XC OGBS8(^*^ MZS@.%:=K6;#?&@YB6$Y/1JW1=J[V;'[A\ MXM6CQX(H2D,,/4)EMUKLP3CA+B0$I;$7Q>*$%^@5$SLELK3]X8!'0!LFP2\" M;"8V=,U;H+.HJEWZ7(K5Q(K]$*:6/YO5Q/JEMU9+[ R)F2N)]0MY6D=LX%G] MBYB/[=;S($S6)ICK&Y=UGA[])*(XQ@'T?0?+"A8.C"E/(4V1XP4!8ZFCM.2' MB"QMR6_Y!'M&0<.I^D5,+Z#C-S$V8)K:C--'2.LB9@P"HYN8WD%GNXH9$ZM[ M%S/ZK/EES+W8N];EQAC@.:\ MACG 9I)+F+,P7'0'WSK^:',8DI%'@^1[TN##,4#UVR4:HF>KA:(N^7G;*AJ"<])J MT70<_!B;<:OE8E@F5B/G@LN5 M43((,N]!XH)8\^,19PXY[Q'H-/*\[T$SP^6F>'XN\KI 7ET6H[K>K'\49?9O MSAZ#P'-]Q DDE!"(8F&M8.XA&":O7L!JCI?,LSE2BOF065Y/:J M*6-3 ;QC&/R2Y>U/-;V+0YBKV1N6<)Q8)[0 ?F\ ;!@%>T[M&1 *<%BR%88H MS6H6*(A\; &HO&)Z"?'2]E"Y2[](V^(NO:G][H\X1DY(*(5I&F&($@_#.$CD MQ00CB1,E'DV(7KNF7EI*'_ZLC9GVK$KC.L545B35K*?;#RU/XS@-$P2CB*<0 M^3Z'B8.EVS<*6>S2($5:':TO W;6FYZ648EJR5^+U6M]Y5,S:QUFU5L?"^!- M?O73_1QK+N5?&CYM7@&-0&'M'JB/SLR702/BGMX(C;U@IH0_XZR4M4/:_J/7 M.>L40?Z-8]F*E-WEW[@LA"H[6N7L:Y&7VW_*>FB5Y.=VS9^KQR")X\BE!"9N MF$ 4. %,(A1 /T$.\U(7.=35T2Y6N5N:1I+"U>5W^-6VJ:_,F^M6!M^*".H; MF%:J^JFNF'4AP K\(24%M:B:_BV['X&:[GNWJ9U87[[+K&JKVTG0MZ2B[?(V MJUJ?!-;CK6 :(J:9Z(RG69ZM^9?LE9^TL_[P]AO^1U'>R+#8ZY]9]>BD'A,; M0@BI2QV('#^$!(E=(O1<%I,D14FJ%)QJ2']I6\">?;B2_)_I\_Z'Y%M3G^O. MBIK&GA#KB75R!^8O9C ;Y*<;@64M4UV/^LPYZT;0G&:OFPUC$H/?%G2K"X'? MYG2UD5YK\5,A\3K+-T+=OO"FLL?7C4R:OTL_/;^LBC?.JSK"(^6ET,F/J79U <4NS M-G+-\DYS,;'*W$K4]""H(\<;H4!7*K 3ZPKL)VXG&GAXUXG3"?R??P+GR@>8 M;2(UTP3L(CZK00AVB%1PX16YK:^'+0K/L*/)5%I=E+;Q!;57UA![&) M]<5Q%^]?!\&ZL%W&>10FZ9MQ1.H=&VB<%WJXDT;/.V:*8M^MN7HHOG$I1+;B M7[E,J2R>N4SA?RAD9O]]6;QFC+,/;[]7THW0&C^"#2HT6-,,E,A2+53VZHP\ M)\8^C!WB0>2$,4Q8ZD"7H"A@G*8>UU(P4S"Y-,74D5$6SBBW4H*>UHFUY]&,[@24I5! (^*V MM+_X=5UL92NHC K_1-RK%U'B^[MM(K(>BK2Z^S8WA57V0 M>$Q1%,8$!]"+' 91' 80)[7[*J(ICN(P4DO3TZ*Z-!VQY;NQ[6A;%+3)ZV ; M#OXOG&]P^0;0%1#?'-*J *0X#RHW-Q.@.[FSJP5VRS-X*$#+-=BS/7:JO0!7 MK8I*]O&=K9*2%9QUJR?IX352-4EQL#FK)>G)=U0E2?-ETZ"FD=I_#\4'WBWV M][&NT_*5_UR[WF]%OOY1E]\, \]) R^%!,M8)R]$, E3'Z8AIW$0D9 D5"_6 MR09;2]LF?L]+CE=U:M23D*,^41(NW03[>IMM>;Y<=H-R/?!+6HK"L,#5S<)9-($]CMJR. M;F##?]ZL-R7_+5L)+HJ<;W>2ZYQ]Q^)GWXHWO&KB:.N3*'8]%M. P9@%+D2) M'\$$I0A2EZ0TF/^&0QBY M#MD>4([=LWU,6JAC+'G;E*_]6K%:?BU(6:WN,L9?ZC$:0^[$X M@%-AM^$HB:#+XB"-XBCR7"7C39'>TE;Z8='>EE_PA^08M"QK!A2. :YV.K8( MX\0*X2($+ZN"W(_+% 61SU![O]K(_:(/EDD>>,V\F*J,BOZBF-G<^]Z"ONB# M,J&2R54ATT5MIQF/0G%1J=##$6Z@_OS6M4L[1]A:9O6@<'5! *JFZ0#0(TO73L83;Q^.TR"+9= !S.M)3P. MB=$Z'AAVML4\+EIW12L\;>"+?&@35C_]:Y.MWW[/L_5]R5]PQNIJ6_?BF_F! M*WY3Y'5X4E-]Z[:J-IS]_E+DXN>"CTIZ9ASD>UX0Q3#%*(#(YW79%0H=%J#8 M$7:OGRB57;'*U=(T2UM)+JM9!1O!JPQ*:)F5V6XOC9A-Z3[PT@HJ'ZHEK?1+ M]]F=907/YWO,W<0:;RL2:&0"4J@KT(K55 D$6\' 5K)=WL;=0'W;36B,WGP+6-SX%KU_K@!MOQ=> XIWQL[T)" MROTH"D-(XB"&*,;B;P%+(,))P+W4CTD:JI6U'2>FLW#GJ6K[\.EW:5F6Z^S? M]5U^L1;+44;QR4];0YT.8ZRPPUG#;>)M*_A/Q_E?X)RZ,[JX&\9-8V^QAM], M&\8 CI;TOA(B@\I\>(3Y-+22) =J5^T-TP0\EC6M#.^%'K_-;_!+ML:KQXC2 M-/8QAT&<1A!%+(+83SSHIEXBV'&24"\LKH?.THX?>S:!W->@.$O0AE/=M+;S ML*KYWBV -;6'>IS)R4-2CJ:5[5\.-FJN!N M_8.7TF%2\A\\K^JZ -LTK:]\?9<^X)_WTK@H\NOUNLS(9BV;B3P4]\+.R]>[ M[$LG8@EUL0OC,* 0H9#!..884L)IZD9)RI"6ZK#$U])432T6H%VYZD1;S01: M6[.FIIG>82ZF]M76TW @TF%V;!T#*SU/0C1Q"&Z$ UWI9 A"(]\D:;&6,;>D M-VUQ-:N>M0SEL5ZV/;QAOSIA[=?)='=I0_XZ9V>8VJW\D#D\8<2%OB\.SLB) MQ)DY=0+HQ!Y/XX@1CA*M=G5Z])>FEW?LUP7TS^D%A45N96+45/*$<$^L>JT@ MK=^1S@PO6PWI-*G/VX_.#)J3=G2&PYBIN]8%^>FGO%V5I&HMW)27O=F44K$^ MQ@EQL)FWKWA61; M3XFIP*VFN"R#.+&RVN+7LEO#U]B.#<=7H.79GJ;2 ,B2=E*A.*M&TH#@6 OI MO&J:@?HJ!BG*M[\7Y3]O\_NRH+RJ'B,_CG'H^I"&H;R#H %,$&+0#WD<^5X2 M4[5[_F$R2],ODCGI!GIIV-/-^SR+I)H>N1R?B57'CL$KL$6I9=)Z3;MA+*QE M3)XE,G,&Y)"@IQF-@T\;7$/*7):[M+[W;%SRTL IY&!.?*(?[C));FCIHKX#HEDV-6[1Q:!5N(*T"-O4Y M2/ *[M)M,\T6NAW#5Z!EV2J&&K>15K&5(1J\HAP?9;YK2F6) M#JXJU=_2#["^;6H3[8M&?=$(^>]_>4&*H&6RIQC9%]NQ_^.8& 4.#PP[6^#P MN&C=P&&%IPUOURF5<=YBT)L? 1)XB>0D#1-2>J+_R"M*W<-XDLS'_:\@Y;Y^L!=LP\Z_!O[8K5F1O'6 M?B*\I[[*MPBU_AV_ 6:V+OYU2,\;#6 RDF(@,D8IO=-8K=OPCR;0C!BJ\\* MUH1_UG]^P!5GW?R71X9#Y/B>!V,>.N)PA!",7<^%/O8()0$./$_SSDF;AZ6I MO%H$2"2;];%IERO4UM9^NZIK<6NG-UPR3:HW4)."/_7IJQNUO@UB;_\+:\:W M14:Z]M@5P*GX*F2"<;=2%^,M>2_0. M.(L*&!-GN[Y'G]/W0/RV+E>R'TUUESZ43.P&#_SG^H-@ZI^J*=[](RQMC?Z& M!94,KT#-;AW_=NJ54$_Z'H!NW'EC![6)EZ\28. /R3JH>;?DQ1D'Q\B+,S#L M;%Z<<=&Z7AR%I\U+C/S&US\*IKW>>UY?VF(_*#C2\*I18JP'HO%U;0&=J9TC MI\!,L(1'<+BH#,OQF+,78ND1ZEPIEKY'#>YG?\/E/_F:L_NR8!NZSP^-$HI# MGT"/.1BB( E@3"B%/$PHGPP ,7I?VO#K?'>DP[P<7HR./ M&A@FVR*-&@6FNN\L34WM2WH>5_2\TJXP=8"-@AEB",O4MD$ ("R#U60J1)RO1A]2!V$/" MJ/ Q9QYZS/F3."$*ZT8]RKR'GM(WFC3?Z G5Z;[7NN&$#+G5#"CO0U7M\N$B MD&8*'=_6*$^+$APP:3%6? 0&6P'B?63FC0H?$?8D%'SL>7T__L?6ZFHN"S[E M[*-89H_4CQF/Q'DB]3F3J72R$45 8<@93T*71P0IQ7SV4EC:KKUE$C1< L$F MD'RJ^_+/ SGNS+\8GHD7O38R6O[\0>F-'/KG1YS-HS\H4->E/_R@:0I903EG MU6?!TA?9HNPNO2DYR]:/&"'JN$D(DYA'$"6N6-!QF,#()1YV$Q([5+&>U"@M MG6]WGG)26U:;9M\IIMDJ6[_IIHOU0>L'CK"-$@IYPBA$C+L"VC2"E/L!]PC! M3ACIY>19 ':>3+PNK-_X:[%ZK:.O:F[!9\LX*YI1-M";VHXZ *[FLLXYI8-_:"OC>C/J )JPRO5F^RILW?JEV7<.T[%Y6Q MEJ83#D_W+?--::77ZC_K"B2-!.I.$"5(QYTCMM&<6$%B4" MLWE>=,3M>F2TWM-7))F?"ZU0 T=K1?=C8+1^SPPWVVKM%Z6[-@>>TE^)]YR7OY;%YJ6.KBRKS[GV M7CXPQ-+6IF05U+R"EMDK\+DHUGFALU2',!M?LY;@FMJ.'T!J@FU9 12CU3PT M[FS+6D&X[OI6>=RT&(;E?SY@,>64?__!^?HZ9_N*E9UV1A_>Q#]>B@JO M:I8J,<1J(]6Z?*:0R2L;SNY>>(F;=)6?6?4H/B[$TM2%) X)1'Z00!RF'*;, MB1.7Q;[G,KWB&G.PO31=M16@784R+!;\(1G5S**;:=+57!C+F\JI7K2-@#I!RD;QG6;BZI@ MK*:PK2,WL;YM^6WUJ?(DU/K;-:7E!J^NUS>X+-_$#_^&5QO^ M2% 2XM#S88@#3Y@1C,,X\!V8>#%EG+J<$:7%K45U:0M>,@WHGFN &[;UK LU MP-6L"^LP3JP8:@0[#(/K$02U[0 _:5W>1H;6UJEZNSZP>HIG''(UI6,5R*G=1SN^KH#DMNUW M N0-6N=7@FE[*D@9'TOJ9YS>K*I'6?QCM:/^HD&N9%,AZC8_=R#ZDF%2AZ-] M*U:KS\TB>R2A$\6)4#J,2A<*3SR(4>S"D&&,",$NQZ%R%J4N]:6IHH9_89NM'1PA#O"B F#CB MG$JY#Q-Q1(5.F%#BNSX*J99KK(?.TO1!&V&\QC_!+Z1A\2_;QDLF 1:GP ;, M#W' 4QCZ2%C@280@9F$$TPACAW@X$I:Y7EZ2!6CGR4J:'ERUH[X%P"96LRU2 M@L5=UZI?6B[[:\<:1HCTXF UI..4RCO$8/2*>CYHHO]Q,UTK=/CONT(SR,,$ MDP2B- [%'ZXKRRC'D#-&610X":5:?L#.V,O3J8)*CILP$[UUWD5,;6T;XC"# MV?3[]PD""\Z(:VG9=D>>=:F>$>EX>9Y[Q-1A7V5/M$S'JB+-$X@@-@8ALE.U&,$).2AQ$0NIJ-?S4 M%,/%J$RL$+:!SE,&,P]B8*N-R5D:\S8J&1+SI!7)X,.FJ?"W.:L;9&AEP;6^H3T(G!!KOMVI)G3W(\$ M.,UP/W[ -.&(KG!596E&:\>4S"JXIG3SO%E)<[]N."^K793\!\^K[)4W'L&V M^WQ3P4RL\[OT ?]\]%WBABF7$<0^D:7)Q=9+/0:#. D(N2A, IK"(/3B M-(HI]QSVN"[6>*6F\B_D1TO+[[B:3HDT*H(>J BIWYM&F$(AK/%/KAGH?>F4 M(4Q2YO@.9!X*(/*9#PD7IV04X"2D<>SYJ=8!>_NN)8 M;;67P##H(^LPD]/I>RO(C3C7=KZ;1]JW;B[*<0\Q&'$(ABF$84(B[]A M).Q\%X4>"3RW=0D<0L:#(V[:O&+@1/W@J M2LWZYVJSH:; K&,\L?(ZY+<+\A\USV"2BUPME&R%A2C1G#&D] 0K9=- M4COQ>KWB[>4D=5G"B(MAPEQ/>IA=B EB,'&YPWU'MF!0BA8]&7EI^J;A32?5 MKPO3R#W1)<)/K @:MDP:61X H)/': C$7#F*PQ^"9K[A&5F'_8X?!+4S,-=^"/+7^:Q5./L%.S3DPLX32UDV3+9B=,=*(H415$K&66#9":.;UL7.C3 M'#.%=\Q4Q8=-);L[53?%,\F:S*MOG!9/>?9OSFZ9()NEF3RI-,Z5:RKT5,G9 MKT7!_LQ6J^N<;0L*B#4EGA$&G[QX?0P1#5P4)I"C.($H2N6M)V>0>D[L!&[H MT2#2N?6S*OF)H3[> M'Z8F=T'@C."#9Z^2MKQF;.-S'N-8-E%F'N0NCF5*L]@=,./08PX+4M^3)0ZU M RS.DEJ:!=I?;2<)J;/$_S,9;HO2B") MHRRAF+H()R2)]2JB&'"ALU#FJ99BE-MD@K_+>.@Z20K], X@\@B!F#HQC-+$ MCQS*>1@IU82<"?W%YI698*^FWR=&=&+%K]!\XPKL9 !;(6P'C1M#.$\_CK,< M+*D[QQ!$FKTZ!HN-=J"9.VX< MLG_::./H]S8ZOM\4W_F*TS5GOW%\Z$8W[OS>/^;25N)(XW+Y:YR_@:TXH)7G MDG[P X /K^@IL9YXQ1O"/$NW^'$ +76-'R#TCMWCQ\4?[B*O\+YI&Z#\2:B MYX^TD,==>7J>M3\*7#[)A=#A:57-[12'F7J$ MP3 3!&*1Q#"+.%5K7C(2,D:Y6HDG>=&D"K&0[:"5/\J&U$L(O@=IFO@ MD#\A^GZT2Z\(&^183'M#'C*PYAD)NRR M-]QQ[,WQ6E&=F^FHN:VV#*Y_D%N^[1PR9HB;>6A& MQW%JEW +8?7##LL7@.ETY)KK@2+2UCX<*Y1&RFRXZ M4GYM1*6LBZ-4/#11DP\HPU2GN<&8ZY-J'$60T2#6^6]QR,)49].T!K"94K(A M[V#X^M!.S_IR)5^N --\EH4V-2S5D]4DF&FIT8'U;-.NMY;4EO--2:<*^);] M\926"V@CZ2XKTEY5F LHAYK,:0Q'XTH-4:P_,UZU^FPB."*1<1)&*<0R9#KJ M.H T0KIE7Z!,JB"DG!@YV_J(S,YTJG@$+9.603"]"-+5=9(N/O0W4 M \!8)D\7";\63H^01P9-W[,NY3^:L+FO;/&2J[]?5LHJ:JH\Y'D@LA SR+-8 MATFG"60Q9S#C^H@K&$*!80O)(5(VWVD_4=&;^-$];FWJ9?0 :^!6&PFLJ15 M)TI.Y45ZX+*I-C(.;+Z*CSC"9UF59!B3_B(E/>][K%DR+,5^"1.#YUU[^67K M;7NN]ZPLRKOGE63B9O%_;%6ERGU3)Z?P@2((D0##+1 9IDB89 M0RPEJ55;+5/"K9+SQ J<[ MAYN;ZAD(YJUS14<(E.[&=L#.FP;6R4T^@^OIF/Y.\A:2K=WJ+5] MU]'_KX[.:DSUM?JP6TM*A\TWWFL2YEF@@%:Z.V$0HRB$)$XSB$.6\)"D/$16 M-]ZZ9NKC^)": M*=KS89I8QQYF*V_K)[4M>+\R?;>V[JN*[92^?!J6$1.8.XAX3V$^+6A7$G// MTPZ^N]\?EQE[;.LEE8U/(\YB07C&H8RDLKCR(((4,66 "91F(5>Z@ACIU=,D MYJ93:R8W=<(,@T][(#1PMYT-S-3FU0$F+EZT;G L?&9G@^3)0V;\!;)SA?6* MW^OXZG[3GYNKE_,]IU;_DVX&XQ]2N\>DN%16!/LAKU_TF#?YQ^+Q1?WV[B=3 MZCD MW^+_JQ$#LEJ.9C+ M=6!BP>NJ^6_6L3A.@\]MBVF$ *T4^FBYD4.ON4-)S,-SW, ?L-A]X#ZQ@K.& M?(+XG;,P=(KF<:/H+;;G+$!V(WW.&\C]IOBPZ'+5)F2G*\C;08?EF$8LB., M(D9U4C[)("-)##D361!*)A!);>^.+7F8FR[<[7Y]J:;I5:\]9=;=L4=E=7R3 M&5NKOW4"NG:M+U]T=N=&-/M+9ML9,[]VGG >/%Q$=]6+W_R^$F7GWQN1Z@Y, MVR87D[;4/@/D$6^T;3GP?L?M"%'7K;?K4)/T-=FN27U.1IPD,,HP5@=F%$*& M>:KTJ)57"ZY4P9=E M6>H*(9\?E[_^5XH?\G=6+/0OW\M\N=*'QD=6ED6N3HCZQ'B9JZ57]TS#:9&3^YJ9,OB]6DCU6[5M_* ' NT9I8H=4):GNB@5HV\$X+\MM%71I)2P@J$2_ M[]5<-I]FE:3@4%1U#-3"CMM-;*)I&+,OY8C<^6]F.3ZTG1TP)R#CMCU<"E$5 M5V./.A?P:O&!/1=K]MB$902AQ&%&4DB2/% GR91!AE(*PP!'F,B M:G-3W5MFJV16J%9\PZ^=ONZ'V$S[C@;,A+[ M4.N8O>12+JKU@C7?9QPE2-1;OPC-L6-#E ;.!6>B<74)\+6/W3I5.?I J;VD[ND/BJYV0!C64- MIV[9^^LV';SCL593-[?[]9E./.-FV-RME_S?5V7Y(L7'JM+3K5P5RR:DX\-2 M';Y69743^GU1K,N'%"5QQ (&0Z1+$0C)(.5)]TQG]U'0DU57"F 5;Y97 C5,AKY_:^%] M&&HC'C3W!1S+85\/ZM"YT[/?5 M0ERKN3(-P.H;8VZ;JN;)/-JJ%YV!H].(P$R]]BHV0<6G3@BX+YZD[NOT]?KV M:J?J466PB^*U$"]*1?4":16798*24WQ6[\#>XK1,Q-N-US)ZWK7 45EN:JSQ M0I9?BH6\6LNG\B'.0B3S,(1(1@AB%F8PBW(,,RI3K/XC.;)JO'2:U-PT@N84 M[+$*_M3,@HI;2T.[!V&SC7DXN;F]0HHCG6C9HHB8B^BF4ZHB' JDMRHVT@O ME;FIB)9/4#-:78I8> A/@FG@?!T#HHFU01. 90IY3CB 26Q5:;[U S/;7.O[LQA)8R..=FVG6%-COP%6$C+:IV33[JA MEV]&4SFU#^/VZD,3PP+?5W/9M#(&EZN5>E#6;>,JB%#,,,6%JJ\ 2 M0QJ3 8(!RQ%@HLD,=DJMD/.39EK\T^M_;NUKF5BIK-W\.G7JFY23ZSWOE]? MW7_Z".[N+^\_W9VOP(YE[#'LFH=K#=/\8ZM<=H;RLOR/66\7:,W9FDQ&^9J;/V*A-O(PUNZ#B]P)LN)P@OF2XG61]'"EEN/!,LC5$J20P#H>O9BEA"QL,,AGFF M+VSB*$ZL5(TQY?GIFQW&FTI9%>M@R[N)'^3,^3!339.@/+%^&@M@AT(^EF"- M5LG'E*[G4CZ6)/O%1;R<=,23XEKE,PV/Y(WJ*_.@78#??J?L!MT]WD9'QC MO[ZJ;7U5L,=2;?)W+\_/CVK5/F1J&I$N@QPF/((X3U+(@DC"%*E-EX2L7@ -XM<]$%M^+\#O MJV4Y8A2W*4 C[<^#Y+SNTJ;"'^[5QN\Y5F/?J2>U]F6/M<>S7*\*7514?U#Y$79_L?-D?9?9 MWKM_E/7?FS323W_QG_IZ_IM25)_R7/+U0Y*@/,\Y@R3-$*SZI1&,$ P(RD6, M4,A19)/HY9=]*QWE(:'L6I<8:*,>WHE& %UC!7"]1O7^7?T@MT+;JS&/7P]S M_3C/2?>@>)OBHCL2Z5NE5EA0/U([RD5^<_% M@BVX]L8?7RB)/,UHA$(8H22#F*%4U\Q)(:5J)PS#7++$JO2!/0NS-;G+NJO$ MAO6=BRB[[,Y%A.48=-2*'[S+>9/K' :1!AR&A*(0YU2WC)"60)%RS% M64I(8%4Q\9#"W-19PR#0'%H6-CP"STPKG07)Q$IG%XT)_ 4G11^KON#1^'Y+ M")X2[ZA*X,D'G>[P;N7R6BZM;_%V7YO;LM2W6;>?;L#UIQNKJ[P]*(PN\UQ1 M\'"=UP P_HU>E\RN=WI[8_F\U>L2XN!>K_,1MZVR3F[4.0/+A3J[?%P^L6+Q M@-(PPD&4P2"B$N(\"F$F10+C'.4TE23*$ZOV?)U4YK8VFW39#9?@SYI/RZB^ M;D3-]M"S<9IX]=I#9+V7]D(PTG[:32 MOP)*70+L54SJ?,"AZLF=5/.[7G[039'T:7>Y^,)^E6I1M_%9C,0T"V0&XS!@ M$+-(0$;2"!*4XDCB)*'8*-?:B-K<%F_#+Z@8!C7'H&79HL['(,H#2WIL["8_ MU/; YE(G91 _BWHI8^+HJ6Z*V]?0KH"**2R]A50&!_%74,54GKW"*L8O.7D- M?E<64Y-#]5&6?%4\:PK;IMCFCH2!D>:F1O71^O?+R]M-C]L=IJV<#4,(&OD? M1@3/@TOB%&XC=Q&WP\;5=3$TO$]OAJ&H!PX.T[?E?YLBFD MB"*"1,1RF 920DQQ#EFT &P?V5J[51+S=ZJU&SSMFPFAN M%^M57;6O*/]]K\9IKHZC3)U+XXC!1+ (XE!2F#&D_J \SS$FD61&Q?4,:,U- M*>RQ"C2O0#/K>#/?![*9S3(2=!/K!F?4[+,HAO$8*^6AAY+?_(1AD8^2"0Q> M&4EMO'][+Q?\YQ-;_;NZQ$XHPDD:YI#G+(882:;.3(Q#2F6 4LE3RJSB7H<( M_C]0(!M^G1H>#B+NJ$C.P-&_-C&&\'R%<@*7J;3*(;F_5[6<$'Y0OYQZST[) ME*NU'KI:NK=EY^7JR^%4C2E_"QE^1"B@.((89@2RB".=*$]&5#( M.0IPF!#,L\PX9*F;QMP6?UOY7_=P^+&258U6B_B:$T#VK_>1X)EXL;<, L4A M:%@$FL?SX;$(.CH?)D^A1NT7Z68!+@>_2'811OT8],85G7C57S11/^][,40# MCSJHNWK\SW+'HW;6[?/STTO*-T*7DM=IB5?KIZ8 G>G6;-Y).$&C@%M MX8C$]!;-:1# GQ6[(T4$'DKO%/>W&<1;=-\AV[LQ?$>?.2;RZW8[^[%D%"BBP)K3+YCTC,;3EN.#PC,J\#2#-'Y7GP3+Q& M+9&QS^L_*?Q8B?W'!/QF]I\4\"BU__23CHG'Y;K0%7-O\DWGD\T/6T7;MC[" M-*(D"F%(4@8Q"F/("**0IAD3"*4!"HQ\#2[$YZ8.MAU]+/.2;0 W4PY3P3BQ MVFC9UB%;6S3!3N.="6J$N& U5KJS#6F_6= .H!PE1[N,,5:41F7?HB@44H8I M9$(F$&YM"M1W$EF;GJHXUYPR"JV =5, YT/U?2W(+8H MC1"%,7":&"< P]]IPTS0X;"+,TXD^E#S6?&]7$C=/O55KMX^OLC[I=(P_WEA MCT5>\(K.37[/_GHO%S(OUN7ET]K4%^ R]MPT0B,#:(4 0NVJZR4XE$/ONTH2 MT(IR 2Z?="=-<]>"TTP,NR&FGH2)=-0(N876XGR@S*>%)VOB^="FU)6WLW3(\Q-;]6<@HI57;[\OGBJULW7Z]NK M':>?1?.E'O2&M= XP$U]DV*(V;B>TF%HW.K/G![67S&:0='V*M,,/^T2Z;%\ M>5ROWAH?0"P2'& 1PH#I?M,A8Y!$C,,X)[G@:1QGTKPFS=[0=3YS2-+L ?E$__?,?[6_4'QDKY3__\5]02P,$% @ U8%G5QH>\4'N M@@ CO<% !4 !E;&%N+3(P,C,P.3,P7W!R92YX;6SLO5ES6TF2+OC>OR*G MYG6B,O:EK+NO:%+I 0 6 DEB_?CRPD" )@ECBX(34 MMZU:R04\Q\/]"P]W#U_^]7]\OQS]\A6FL^%D_&]_8G^F?_H%QG&2AN.+?_O3 M7S^])O9/_^/?_^5?_O7_(N1_/?_P]I>7DWAU">/Y+R^FX.>0?ODVG'_^9?X9 M?OG;9/KWX5?_R_N1G^?)])*0?U_\V8O)E^OI\.+S_!=.N5A_;/W;Z5^\%Y13 M9XGF/A')92*.&T^.AN.__Z7\$_P,?L'EC6>+;__M3Y_G\R]_^?77;]^^_?E[F([^/)E>_,HI M%;^N/_VGU<>_/_C\-['X-'/._;KX[67TH9 MY6W'4 +?YS!.L%S?^AVC2;SSH5'A[F2Z_LN1#S!:_'208#A8//E9F,VG/LX' MD&U.B4FBC (B0Z+$9HL(%#QPK63V4MY=>"%ZAE0OA#&#^.>+R==?\<&_%F:4 M+Q9<67#DP>N6G#F.[O7N^X2?'6B7&.72(,7&$ID@$!\"TLX=2!-98$:<1/;F MV^Y2O2G19]/XRV2:8(KJ8_TZ/XT/I'L7N*M/_/K%3_%!)'X>CM+ZK_-T"\<\/9Q< H_&X'$>Y@. M)^G5.+W$@W@@ _@0=216YH@+H(IXZ0Q)-HE 60*A=15 W'GM7G 0[%XV M H9/4S^>#0OC5X#.)HELN2!:*51TPN-JG*/$N>B2H=D HW5.AWMOW@L2LGU( MG,31GE'Q:CP?SJ]?#T?PQ]5E@.F ;4)C.B?E00K-E535&$+QG]$_L.+R=5X/KU^,4DP<%EX M&ZDD1J$)+)T+Q$7.B68:'3M(S/+3#(<]B-@+)Z9UG-3C2_OTG(OF$> M+B,5*TUH@E9,1DTD%XC_R!EQ%#DE/ U@#,(Z_?"RJV=:C4X&T3('F6 M$HI@MOK/V^$8V$ Q)97*DE@C!)$JXR*89R08'Y.+ /9$T_/15^\%#M(%?OIM^FGP;#VA*8+B1!$TI7(). 1>C+-$232B>63:BA@WZX,7[A:[H M#X**(QG:$B861^.[Z?OIY.MP'&$@LI%4:T."3K@.EM&T3D$0;K0&2ZW(,=8# MQKVW[X>.AB.;U5C;$D3>3V9S/_K_AE\6IA.S+$0&B7@)R!KO<14>5^&4"312 MRFPZ+=+]^+OW@T?# <]*;.T9'$7K/9N"7UK2H+0 A#*2*)$5TA/K&",J:.NT M05^,G@:'S;?M!X"&0YQ'LZYGD9?[T='[SY/Q.@(CK8[)"$NX=)Y(X62)OR$# MM+:4<_PU\)/$?O^-^XF^X5#F22SL6?P?(5Y-$;J,AT_#^0@&07!'(6?B,P0B MC;;$A8BND4I1&\TAN=-N:>^_<3_Q-QS#/(F%/8O_T]27')2/UY=A,AI0!B(8 M-&. 1H.^L4'".<_$,(XNLJ/.<7.2[.^\;C_!-QRV/)YYC6SZ5]_C9S^^@$6\ M-7L1O%.I$,R(I&BK!/"9J.S1]Z4YTW2:W[CMK?MAH.&0Y,FL;,(=>'$U+>Q: MWL 52*,,KF:#'(6@4:)'(\IE3 1&;++X+:3H/>=62W82)':]?3]H-!^"K,#: M)B#R9HQ/0W8,O\)+/_>K90V0TH!^#"/!1CSKDHPD9!])+'&19!*-ZK0$F5UO MWP\BS0@">HQH,NES=(<(E'H6.2D=R,L8&[B%Y M6P$9=UZZ7]I4\S'(XQG9! X^7OK1Z/G5;#B&V6R@(I,BR*+?//K"4B3BG(E$ MXQHLL\YZ!15P<.>E^^&@^6CC\8QL @>O+F%Z@4?>;]/)M_GG%Y/++WY\/5 ^ M:4&5)@H\PMF:0%Q&!1=S5B 2:#27*^!AZ\OWPT7S8<;3&=L$/CY^AM%H3;V0 M5DDJ-6',..1(,,0R'4D2U&:G0 /U-=3$QCOW0T/#,<<3V=@$")#PRY+&,8E_ M__@9^39[=S4O51S%LQZD+&*RE"Y++B2WG'B(C+"D*7I2$E>3*H!B%PW[@:3A MZ&1E-O<,FF>7,$XE;_3UR%\,3 )G;: D<#2(T'>2Q(4$A )2G7!-"D[S/NZ\ M;C\H-!RI/)YYC:1?OQ[.HA_];_#3U_B3V4!3FF76EL1@T#XV&9<@.:H\+0,> MA5X8<9J/\>RHS@8XT1SQ+5F4Q 8= MB':.!2T\55 EF'GWM?LAHOTHY@G,[#NG81E.N]5TZ_(C;D32J413O$&KQW). MK,UH*GLE!;<)G>O3\B_-^F&@X;%F%I=5@\:^_/N#C6_S!L679"/'Q#!)^ M,9N,AJE4WR_2O8I:G$WRNR^PS#R?_77LK](0?WUW1?M6N[\2Z M\*L9N?#^RZ!D\5_"S9MO,(EN*YXEF1)E\1^IF27.Q%32^<$PIX4"MV-79C\+ M"[RLWK/QQ=%??KV6P&^+_TR7\?&!Y82J;<%U).I,"OK(NX@:3/SE.#-ONNG*MC M5G\$F?U4J==$SEJ;G4M61RL[5-=AI5 M#-D+@B8^>H*6.>*ETB0;ABMB0C"SRXTZ!G6/T=)/X7N7T*K"]1YMJ,UUO,N_ M32:IK.8C3+\.(\P^3D9IH(T7$J0@E/I<>LL$$J1@Q%,F#%XI&?I%!&7 M9(KUJIA0SE$62$3G%+6W+5>HF9.8O:%&<8ALURW",;#:C[)^VGITBJ\.1-( MT)Y=EN2M?RY$\RZ_02&-+X9A!,47'[QPVE1RB\^ M^^D%S 92KL_(3H33 M .Z*#?EM.!K=+N3M9#8;!(N^;)"94 V22!4B[AYKB4K!*K N";TK\?\8B&VG MI)].)IVBJ0++FX@>++)4<6>LCW!.'4SJ:S<>KFLG$V$M[AG-.?$25 D1JJ=9-ZQ6/]HZVPY_489N@BIMR+[9K8!+G&UCY_# M&/)P/A#")+#<$AX%$)F5)#YP0;*,*6KE/9.US]M'2.DW%M$=_$[C>0O&&OJS M-QMI(&@(5OM$DD1S4YK2$HV)3" &'05%XT'5CKW?(:#?.$(7,#F>OPWHE5=^ M.D:U.'L/TT6^^ U'DG-(/)6$:\W0.$"WQ#J(I1Y)Z A@** M)YL9R5%Q)[@20=:^#SR0Q'[/X1:0645X/V@11JEVG\)G_,SP*]PZV=U69#SY MTG.49QRV\DJU&C<$E,2;\LIGX[2%D!NT"T]C,!DM L[1ZP#0Q"6T1H,%!*)S M@MG:;MZ!)-:-G06OLL@,"!H^OER=X'I5Y$10X85(3%"6>X^==79,=XF.W3&U M0_C>P"G\;OX9IH]L8%S8N_S)?W]?LMQ0;O/Y=!BNYCZ,X-/D_4(.-PQTU%,( MUA&>!!H?4@5D(-/%19.0>9#"ULYGK41ZOZ?V.8':AZP;A_@+/_O\>C3Y]A^0 M+N W/QR7'S[+^/(/$$=^-KN9TH)R*>Q9<**TJ1#.)UO679J3A$1<%)SH&&C2 M/C@K:Q>7U%]%OQJZ%S >L"'.@(R&]\;KR10M_/&RJ#I>+P8BEFZ0R]66[T;+ MM:?_NIK-B_[:0V;H<8"2U#$B&"\CCI0@SI&MYL+R$/QY!65_;OT?V:'<8'3K732I=(.^=E0I0C 6U0HJC3-&J5 MHZMMZW>UEGX3@UK>0F=%21-9ER=*8R!H=M:X3+25J!Z8#67!0#1E+CL/DIWM MN-F3Y'[SDEI&?QW<>QG_OR*?CX&4JA9JU ]=VG=A6)WD%[_5#SZ^$8 M7S;TH_>3Y8#XVVR'*'V9 T^XLPJ57BRC=G09M\0S6"-XW#GY],3X\J-TG5QE MO"AEO5EEIIP[-+I)3F5(+=- ;')H<7/%DY,R^5#[$NXN!L@X4%%\?'L M;L#!65*_ZL1VJXLU:&60:O 15N6H97QZP"^3%)!"]02[K83T"YU3)+L5)*>P MN0&LE/A:.<3Q/Z_^<37\ZD?E,O'9_(6?3J^'XXO_]*,K&- HD$O>DBAL:26C M+*Y'E1)Z$;D ;;S;U3;U*!MH'\):P-)) +AO\U271@,0>Q;CY J7\0$BX)+0 M34 [;CW)QB7M56E%CQL.UQ+047 Q!F(SVG) C95LUVBQH[32#GKZ#1W6!U0U MWC> HX5/>KN0V<9*I.)*)U"$9H]GO0!4XRQQW"#:XE$?I$^=1-ZV4M.OBU8? M0Y7XW@""WHR_(M63Z34N81 E4NE=(M24H$@6AG@PDC#F _[/:)WJE\'=OK_? M&%-]E!S-VP9P\7X*7_QP7>^,!_ "\G=X-$@^,VX9:L=H+!ZZVA/'H,QQM\PF MYBU-M:.8>Y#5;VE:7 4F2-3)%8I($"UDK@>QJ$V MC X'3&>%<1T8.$=SMX&P\Y+X4FU^CR/,6>6E#(3[,L^-E[BIX8($X!J,04.? M=8.2A[2T8!%7=-=/9'8#^F3=-&K@C4&OSQFBI2[&5_3$6@$D96^S<1 #KUTA MLGYW"W[WJ9)\I!?706QMHI[V?L-#-,!NFI+?K,K*1"%P12+E:)$YX4J]@2+9 MAB248(;1VAIE'[I:T"Z5@51=' WHG TK[)9;@PCEU&90QLV6"F(\;5'_ID68 M'1T #M'7OAG=2D@+#G=E$)W.\"94T_MI:3TVORYI,O/24>H?5\,OJT29@?-H MX)6D ,/*!8U?Y"<8@1:;E";X8(V+U3VJQ^EIP2&OC*)J[&] !:V:^2JI(4HI<^R;B@+[)'2N9BG;P08QLP%5Z._1A.!K.A["8 MC)#ILP+J^?4-:Z3S7!C*B,>#E,CLT(]DVI.V4- .FD^3\R&WH"4QO #K;II"M&79]]I8!+&4,?!1E)JCP MG/C2W"!66=%;>6TA8Q^#?&.('0JNYOP]A=!BX<,&CC@3CNJB*&%,<'A M0A+-)%,&5BH7;?6&LX^0TJ^/WQ%V:K"]!8WS< 44S<$H629@LT13$:U$JRPG M@4/.4F7KJA]B1V*FLROVKO3-: W&0;S 2B@F4I#$G>"2/"H MN5&5$QQA;AQBC'.9[<5J'JUJB_ MK0R1Z,P<5^!59)WTPME*33,^6F4X5>)_ TC:6,3 15RW0Z./LE &9*HR!RJ4 MA$IO?8BNI+]T9RPU@Y6SF$8',;L!,_O%Y/)RN.AM,5O4>I=Y.A>UR1H(W$I43CD^7,5Q^>O(.<9GS[[G!42Q@-Z)\=',*=H#F(2$!+ MP#.9:M2DR1#KK [X?[E^IOV)=[;G\/Z[0U4E430 JK(_)N/%>I:5DEE1GAEP MDKW199*J*^WH!1$VXVY1C =?.V)]GX:^*^7KR':+(CJ:T0T Y5E*B[P'/WKO MA^@NN);5LXNVD])WKD@GL*G! M]@;0\P'FOO0 6T]'>1;CU>75J'1!*=W!XG ^,!IH:?5/M."BC J,N!]2) *4 MRLDIQ47MR/735/7=.Z@33%461@/PVEC!/FVX!LHHJY5-!$),1%+)21#H>9K2 ME5%1A8=_;3/\0!+[-6<5_F15LN M) .=:B=L/Z2B7X.\(RR=R.P&X@1/>2H#[BF/T7I4PN6.,@5#7*"> (-LHU%" MF Y3);?2U&\M[+DC3Z>+Y4?MI+?L2?D9YL.(AO6=Q=1JJW?W%6?IL;=C5>=L MN,*J]+B$8AG%"$J?* FZX#^7_5#H?N&>QL>[G*,TK.K^>?)=/A/ M2 /JHP213:G H3)&=H0:3A)$$QER#Q;S M9C:[*@M1H(-(F; D9;$=<"%2:I(CQ7,^00S=(VI)2M]QAW.CZ0@!M(FDS3%O MT5OI9%#$9!^(5,*1D+,C3'E>:GBX8;4[ ^RBI^^XP[DQ=:PH*@+KO#/WEK9D MMR/V[K_C'!/U=JZKOI&UPP=@R:#Q#YGHB/](+]$;3)(3Q9RTP8I@J[=OV(NP MTZ,,JY=\*@4Y RNX="8#4E/F4T:;B5,LD22SCC)*1U7M^YJ[%#1C3%7"PL- MP]'\;B(FM:)^R9$2<9N,%[?AWX>S 4TT&DHC 5@TG<.#W";O"4^2:JLB,[1V M4^R=!#6"I2,D_1AH3F9[ QBZMX:7DTL_' \\U2IY;0G++)0AO);@P6T)) /: M)J!"UD[LW4I((Y@Y7="3VEQO #H;AM[O4"8M#]" 24P6VFU)YI),$*<5FGA1 M>^:,U<+7/I8?$-$O9"H(]G%S^@@N-P"31VZY5XO)65HH+3>H9+@8]"^) R.( MB=DK \;C\7Z>%(,#X-.9PU\?/O6XWP"4[E]NKU>A-(/@**&T9-LX'5 3,\!O MHP&GC&"\Z^R" \#3F6=?'SP5^-T :O:XF5XM3":>.:.2A$7B#82%9@62K)2& M@<HC,PE(-YSU,$Z M1Q)HU$0;)XPRVG)3NUG_@23VW-ZT&Z \#L?J4FL+E%OGVJY-2V8B#Y(2!:7H MN?10\Q2_I0""YQ1M,KP[+.Z@K.?&J.>&8"T9M86\G;-B5ZNCD?E8,L*HD:5N MS!0&:DU "#Q-+)/"5T\Y/HC"GAL?GAN)M676 ")OPCIO<65O\,O90%NEG0>! M))O2*%_B"J0OR\@2;5UE$G06*[VAHI&[YHH!TN,8W !$<"=-P<_@)2S_^V;\ M\ +BPV0T>CV9?O/3- JC&X,)J]T,'7]D /)+&12.J1 MB'C04[P[\32 OITWZ$BR0UW+B5(Q$TF])=8!+[UNI0P^:<$:XS<&VEM[1V MYM61B@JWY9X##QWU$ET3A*UI5.?P,W@;23>V*P\&A1! MU[;A[Q#0KXE^3OP.6T!E#'XW@GM.6)Y3M@W8:PM&+C-G M7UY-T1QXOU2O"RMA\>]SOTBKNRQC_!82'V07$B[3$X;\1?^*SX1P^PO3K M,,*2-Q\@3B[&BZ2D>\:G*2T>MI^UVOJMR;N MG!N@*70TL%MV*H07D_%7?!.N[5W^*RYR-HA ==")$5R2(=)12= 88T2XQ+E2 M--I8VQPYC,*]D&Q^!B1W*+D&<+DS#(&@!:)+ ED%("O!$4I%$%6,P2AAA M:]_?G1P!C(B8'PSS+ -") MACL\-.1^!D2=*(&J.#IO^=0ZZ6+6;075EM>>--R0Q$\,*Y M3$P0M$SX"20P#D13;ED*.:I<^YC814_EJJF<56)6<@+*TG+SK8EU1I,@90J6 M9A-2[7;2C59-G2;Y)XJE#F%S W93::'^9HQLN"I+6%1P)&W!E*:@A5@BC>7$ M:B4(1VV=?&8QZ]H-?!Y2T0A8CI#I@][B)S&X.8C\X2]AE><*C"KMG"3&V7(G MHU@IAU?$"<#E1*W UTX/>8R6?N%RJHQW0N9(AC< G _P=3+ZBJ;^"WSW!ZS'*K'#@_/".H,/%U+>V=2T"&L;P W=ZXARQWB&,]K MN+.D3Y-#N>D"*S?RCE@FD)LB O' ,M'HH$2--F!RM1W]+M;1[RE[9A3W#H0& M-L-+P#?'X4+$^/4(%K(>IV>7)7EJ:= .3*34,TF)];DXX%00W-J4@(P^9'") M59\*NP]=/1>-]HZ>!Z&.RJ)L )Z_32;IVW T>G/YQ0^G"^NHG#AXJ#@MDR(: M7"8R\-+C#RAAG#/E*7A?O:7'=DIZ+AIM#8(5Q-5$K\]'LO&$LRGB]B%9!'3E M*1KE3G-<5L"?,^N5U]5[ AZ?--E=A6AKL*L@KKZ##/K.(+=>E>%B?+ M6H\ZD]2#8#H2_#<1R2V0 *944-I@JEVP%O]Q-9P"+A1WUORZ]*E:=.W^LLA3&Z>/DSS_AA(8 M),6<%EX3%;W"Y05-@L8U.L:21?3EY#5H# YGUS:L2 ?+/3Y MU0PW[FP&RSKWPO'5;](@.\GP$8Q8 (E6#9"D9R&6-N(/(2^)F\7 M:\.S<\&=BLUN8/D&)3F^&(81+$)BLP&C)<:: D%C&K>;BQ%WFJ,DLQ3QA,F> MJ=HU$D\2U:1A>#8 GB2B]C3BZ\ET,\*U\,JV\'+ A$!?RULB5 (B@TW$<]QJ MWGC&A>$VF-JI&0>2V&] O2=8=B&^)E3C_OPVJYFL4JO*+2*&5Q%1+5M<2O?):)) 729)M4K)X.NYV2)AW9.@+KWP+ P=2H+G+P9&TJ&J-997:9Z( &9F8C3'5KC@_D,0F MW==S*+S:XFM [^W/S8$%X!)Y00S-N/V 2>0B0UN#J22T 1JJ#]C;G[I^T[[. MC,F.A-9 2.55SA#G[_*K[_&S'U_ !]3%[\9EL>7_R^7C5S\J6_ #(!^'$37U MXK9GG.[^8..3 R>UQ?_+Q%IGB%0BE%X2G'B/6Y'3Y*.IW:VY@V7T:P!4#LKT M+>8&%.])BUTV17V8V[G*C=]DZY+5 T@F G.2*.=16CDE$BB*S/(@K73(,UO[ M_OJ\*^S7**F\/QH&1P.'Q&EZ(B?T/9751&?J<+%,$R=13R GC)-)R5A]X'3W MBK\SRZ8E8!\DNF;&ZYRV9.O0>O-<$)/0=)/6X:GF<9,F+K*PW!A3/7F]>[1V MEM#>%%H/$5V['7^?^]EP-LGO-Q[FQ^GCU>6EGUY/\L?AQ7B8A]&/Y\]BG%R- MRY7N^\EH&(M3=F=U^[7^/>E]%7H UUMOI6; [Z87?KQJ,G#;EWC9@&"3RG=Y MY?_YT6W+XAMW,QM@3):)L@"42.U0=7KMB**,1F4E35 [JE2%\%.U[T*<[_*M MK 9)N<2E*5DOS)1!6XZX%-'[=J 4S\!9J%U?\8"(?B]#SX^H^XKU-*E4\]ZJ M*LHW1;M=KI\SR7_ MQOV;:B**?[N:AR7S#Q&01[UG@J*\?3U55*(MR][L7!D M9@C;5]/I9/IB@DB(A;I;E%*>&+5ECIXL'6XEC23HX$D*0?M$,_Y$5M[MA]!W M>OCVVV.\Q[>NWO]FO/F9(4H,)3G[A.)XCL_Z^T &$URQJ 4K+5:E /3\F"R@O@_&TX__SB:C:?7,+T!DP*C,Y)1**8-646ERZEKY9DH11SAEF= MZN?=[$5:A5;OI%-)2^*M+HFB.I4>P)D(I[(0I6K=U+^6WX^V?K52 M%QC:TJ^[OI3:5#J+\H[98@[>[.5PD; \O\(GHT>XN !^-IT6]7NT+7?0\RNH MK^/74TG'K2NU7DPN QJ/ZSYZI6AF@[;;ZNT0'% ')%B#QY;GBE@9$:8Q6B]',Z^3&[$-(NCR:Q(Z79G.2:B!\M(2D;A M]O7%GH@"S0O+D#,9?U>;+\=1VJ\V[!!M]Y7B&039J(J\VZ9K$0Z]BO/%[,:U M6OGXI73/'*U:>!VE* ]_2PUU>>+:JAF&&^]=A)Q')45M2U() 'AN;";.FC(A M*CGB>#;$")&2-B7]J'9EZ-[$G6X<;KSH5BC/UD?7S0MO-]KM/A,J4B/1 2MU MF41&KXEE)7509"L%,RZ(^F-W;R.R"[P]-"//),\V]>:Z?^&1UR2;?UXC MN/<8-954V$VWQEMAWH H0\>?0O;D",>Z](3:\ 1J1"Q3C$@4>#7SCH6JP_KV$5/OVJF%B8>MKRK)($V M%<=JENX1.F-S"N]IZF(;#94TQ?+1F[=,/F69B4B.EQE/B=B8,[$N>L,=S4K5 MSG^X2T']8.T!2W%4>GZ8F'[Z^D)RO$V+X>::_K9!]5$^Q];G5- 23]-736L\;-5= MPG3_ >GB3MG,%F@%M ]5-)ED7W)/?3#]7=F234Y76MF??8M;HX*VSGN20\1RGTI, @2)ZEVW'(,:8'.L1>& M1+"12)'00DYE+I3++!K&> ZUO:Z#"*PU*F_;22@Y9!:B)'8QH97G1((MV32X MH2::E=# MJ^=OPPB7V:"\2(RE>T$4GEAE2H(&4&NY]L!J9V_O(*?"2*7[C[Z%+4AIE?2, M..DSD6A#$QOPS&5&9LFX0(N^=I>"7?3T?354!Q-;IB'5D4";BN/%Y/)RN)SG MX\>I)&>B)P?C8TOQ=CVN@F+9F]I*BF;C?<_NO6\+S,"%TFLJ$2X9NKA49.(< M$T2' -D!C]S6[IUY$(&G*J.W<.%'O_MY >3]MVWDIUD=1/(2/7N.GH#1Z 0X MW!TT2NN2B!2JW\WO15B_ZJD[)-U76/6EU*;F>N6GXU*Z M/%Q-FC;K?O/:+& M-??K-]R.T MG-S5Z=YS-\YTH0MZ^/A<3$](@SXQQ:/0"1R]= P%CL@2&*P]GK"D_'JF= M]8SO'ZF=RK1-F^&8'A:??!@=&8@]_FT]]>O8MM8^NG:HB)!Q+!*GI")2!$N\ M\Y3DHAR#%\'+VF[!.;MV?(R?(5V-X%VNTMQ! <_9:V%K&U!GZO*Q]=F+FNQQ>COT83@:SJ\7$MBH M]Q,NLA05$FU*N (<"=(DXCB7RH//PM;.5#J"S+[+-NLCZT%'S(YEUX"K\W(X M\Q<7TS(&9&%^;ZJ$C=XFGB4+J'QCA%0*4!VQ98X7H]2#"EG@$FOGN.Y#6+]. MS3D@6%\^#8!N@W&O\)R9COUHS;39\^O?8'(Q]5\^#^.STLO[WE*=2SF&X$CT M:(V@#U8:,2H@/*5DHW+.QMIW=">0V^^TK', ]%RR;-.F.Z3%T/&&WQ%O.7/[ MI Y-R /;VFAGDG24DV0L8HKF2'SBH8QY#H@GHTUU9_J\391N_:KU>S<%]?QZ MX[N-$@8EI4^E!Z-V>$ HG0FZ;I1('P-NLLBDKFU?'T/G#]5 Z1"D/>X<=R3$ M!D[YVS5^@#BY& __">E-0CD,\Q"6;%VN&DG;,*A+QY79[.H2TKW3PD;JT(Z1 MA(/$12?G26 N$N"920F@O:B=(E!Y"?V:J[W ^_RB;[4Z_?#V6B<8#,>^JY.N7TR>L2:4"4F1&N=U-J(V+PXDL>_84Q>HVJ5$:TNM,?-@ M8WGX#4R_PO/K3_B<=[FL<>,2 +U#=!,IB3GC.4#Q"'!0CH52ID>C3"'7=OZ/ M(+/OJ%2/X*PFO3;=_8W&<2=I[N:F$E-J1>Q*)U2)<\HHBD! MX@I\.8Z<[J?HRJOMO%G(R*Q]5'%4&TJ3BV]9@Z7I'L>%I'_; Z533' M=R"R/CCMP!-J/2.R= -RVC"BG!%2V,P0*]6U46]=L=[E/(-YR324&*=]$3QK(4R/GI?.R:[!UE]*ZWS(.R^9JLMKT95V[KCS@GZ M[-XC:K:UZE!S[6QBY 03'B0C(K/20EJ4/B 2'6R:>?3H:B-Z*F_$LS2WVH#R M[^#+.]*[\0>(:/$CT!?E)QM-;$/.E,94X!R)Y*E<$U"T$+@UPED YCMK>G4( MH0TWPSH$1X\VP^I,:&VJI'5_GN,UTKTG5&R8U:$^.JP!4N*&@3>9:(LN>1E? M3WR,C##MT4^GGGE9.SQTUK99MW[%#>LWTO,"#5P)XJ+@Y>(^D,"9)3J%R%+B M-M/N8D0/R/F1VF8=@IK'/;W3)-*FTMEH5'5**/K^0^JVT.HT%/UXTR2K%+KO M$MUVY1T>)#(0SQ,E%*UK-* EGB^U<\ Z;*1UB^,7D\LODW%Q)TKP<_7"5]^_ MP'@&SV$,>7@_!LJM,IGB^B,7)93A% DE,5B#$-(Z8S6O73A] KE]!ZSK(.IQ M/=2M_-K44_>ZRAROJ[8_J'[?FPYUUJ-=3Z+4 9++!$J/6 G!$,C4\HS'SRJ7J'F M;BK/7+*IHPXF<2!H,B/>O,[$>4^)X0A$IK+GLO;5W/E*-B.4QQ^VW]IE_7QDPW3&Y!&3W4U\]A'#]?^NG?%TH[6>.] MMR5)7,(%X82" H]W&30"NB@"\I.FEJ#5A=VTO%":!)4Z]6LMJ#G(9F, MFR3&A-<)XF@ 7A_]"&;K8 S, M5XHW UA\F25"4_1T15S,X+&$295$#, YKUYF\2UY-;5/O;V(JRQLZ\FNNH+ID>TS:;S MP>_^OR;3FS8\2S4N3$X*^$8%Z# MWF_2^A/H>)2 ?HZN&A*=U&9OWP[]32!_I?9\1WO_?@_D1>24Z32DSK6^"_C29AHVG;:@4)M!5<&T)M*E.6(B66 M6D, %&BCS^^'V.B(^&?SL">SX55>.G=]"-,OP[C,F9N(1N>:"3, M1%M*422QSB=BN0E*,9VMWFO.[1-'PK9W[X4.^8.8#"$XZRQVQ,0N?Y@40SD$0R_,HF(Y!/N*^BU,:QSM-I-NAI+!)[I,R? M@M*Q JC8H?'D"3VS#Q!A^+7LLS]@OFHD,Y J:$:S)XDQBCJ59N)T\L2A]T:- M3ME43T;>14]CH=H*(_CYHH5V*3)9K/]FD,3IJ<=' MO*Q>MI.^O Q$+:8I MO1EO>\$-_S],1J/7D^DW/TV#'$IO&P&$ZF)A>+0P7 R,!*&2 )%L\OHI^!WU MYA\CB_D0F-R-"'8IB#;,L@XJ1P-L2\P'4[2Q[F?SBM<1NQDVG(/;[08'\?152JC[99F MQ/\&/WV6TK*I_H &4(ZJ@'ZW0&/%LD0L\H!P+Y+SD?&8][S(J$=4/Y;=^7#9 MJQ#[OEC9N6Y<9IF(LSR!_.SSP@S^,I\-T(HVDJ5,J'&"2 .4>";1L-8R9Z.E M]Y*>#M/'7M_/;7U+@*PBF,.AYY;0&Y=)7Y ^G0&!R$887HR7VRQ>?YKZ\6RT M$/7 R\2<+C=6WH72 3&B(^\-B<7-MP@SK(I43[<57X]1Q).;N M),7)>I+BZ5&7)QY<+\)RR K.'$VQB0&S( CCTA$IDBA])45148F"D2[0VGUF MSE0,OFL YT#8%%/DDD"*:!*41GF^U/=X[IF)5&JF:U<3[*+GQPBI'(*50\:A M'B2--I(J[B80,(4DE]I4*M$SE\8(@GQ!QH!.!JP.)N[5(J^KC)ON.N96D^I3 M>3>'L+@-B&S)(O TAJ0\(Q$90"1G>$!3=$2XL"P(0ZU@>]U._21Y-P?)=*^\ MFT,8W'>0X3W,_P/\:/YYE1B"&\)9;S.QG*)WD+E%VD,@G ?%98(003QEV&Q[ M<.]"/U5.DTI,ZUO@K_WT\MEX>.E'Z[I?:X(RP2V3U*67GJ!=[@C2GIRFJ#6Y MW$OB]Y_<7Y)N!R(_B6U]R_R%G\]'L"*<22J5$K*&,:#2JN&/: M1!'WDO?F4WN\(#E-,I,:;.I;ON\G5Z/Y]'I%>2$O2&_+):,JN7U G(V4B. U M.O;,9I?V4^&;C^WQJJ&>A(]G5-\B_OAM.%Y#4\<D M0D7DM38$G#(Q*CQL.-OO('[\)?ULZXYLL%K,[#6!M/#F(XH RER?WV!R,?5? M/@^C'RV=4>JCM%!Z9#A=\F S\5X9XA1^SZ)DVM:HFGJ4@'Y313L)Y-1A=L_1 MG(]P<7\)J]VDN$_X-DU4=J79%R!'!$C"-,LAX$;P,@1C1O(^Z/H&PHY62"!)ERJ4Z-0FBMK=H5Y9M!_//% MY.NOJRN*]]]7V5AUF&,^'_ MTB?_?1#08V,*W;^ ;B"14@7PBJD$/7 P4HI2,^O9KAS9C,D M) S'RUT\3HN)<1N+NLTNH=Y)QPRQWC)T'8J=H'PF3'F)/H341M>>,W@8A?4& M[*S?NRG;Y]<;WRW//.>UEME9 K;DVQB&'/'>$9>--"I(FU7MVNA#:>Q787>( ML,<'[70@O 9LBBVK6CCT03.NN+'+B+$$C8=?2I9H%1C33I0>LQWMRGND] NU M;N4_J2^,1C%5OIS"NJ]ZD)0I&8 D&77IDL&(I\D1 >C:\>2"B[4UW)-$M:'2 M3A+]'G Z7@Y]7^S\<36?#O_G%1I";]^^6*<,4".$09\P\M*?GY:N?2 \B8(* MZ8R4+N>G+,+''MX>'DZ0W:0B(]O4,+?>6IG-4):/>R2AMY:\)LY:3H)%*T P MP'75[D^TBYY^+WCZ/K^.$TL#$'OOKQ>^U:?):M^M%P>SWZ:3V6Q 78[2)$Z$ MYIE(11=]*#W)^%7PVGLT.RO#["F:FE-91TK_?B.UFJ+H^QA[N7KGDXN**JN0 M #">XL:D^7 M9)60XW!\@4N_\XE!!*/ H3&)/G B4G!:9H188AQU*A@EI=HO!?ET6OJ]?.@& M=F>64 /'Y0$K9@.5/+)5I5( JU!?9T5"YI$(XYETS 7F]VI>?UK([U'Z^NUF MW-DQVIF(CH??9.Y'+5Q!W+I$?_VX\7>W/WX^]?\B0!:!SBRMCQQM;^!(KQ32 MD%"*1+@VP4@#@?*]]N 3694W+_S!KA4.DNGD5 :W@(IUI:=SU#@OB\6S6'@D M#K=.F0D-,1H;P>_5L6$?7/1=.'NDL.Z+^PC.]3[^[/OP\NIR1;AQ,J*#HTF( MQ?;,.I" &"?@F-"::O.@VNK(R6<;+^U9Z,>(;%*#?PVYCO>OOL XH6G() J+ MS+ E&YB&TLC-.Z:M$(KGCJRR8ZZ@VPGA'W-6U!1&HYBZ>WTF1 300A. R-&3 M+A4+#-UI!EXK2T'*),Z KA_@"OH@T1]\!7V('/H.O&Z[.179.H__7R9\($^B MI\1Q(8GE$813R26Z7_?/'_ *^B#9/74%?0@CVP'"XJOH)\N:V[?SM*Z9];S4 M0J/=IH,NU=#>EGD_FG 6@W"91Y7VZ\CY]+N:N[BI#Y,J;.X1-0F&@[=PX4>O MQO/A_'JA5V64,3IGB8?2PT8+1[R1B>1HJ;;4YZAVE0RMZ\7PT<2Z@_9^)R,4+OR"YZ& MQ^;;^CEI3A;7I +OVCE+-M*Q+)>^U-;C?Y )L8R=TY02JKWT"B"'L%_G^V:, MBM-$]&3ZV@'\:M,[N;WBLRXE"QS-[5":-0"5Q.NLR@1"X5BT@?+:G5E/3E_K M[#*T;]_W.+$T!+&[E[W;,@UNNT=G6_:*2"0IBKSC$55O:=&$.M@&@\::2^>Y MEM])9G-.T9$8V>MVOI[ ^C[F*J3$"$^]]AJ(2F5D(<>56C3RB8.,QH*A8-E^ MV=YG2EKJ)U?N&!#V(:$&E.3*3TVOA^/A'-X.OY9A-G,_OACB4;*XRYW]#887 MG^>0GGW%-5[ 7V>0KT9OAQD&V0490">BDRZC@6,F07E/&)XY&F+@Z.U6UI:G MT-MPFMTI:O-L(FP KL>4DCN6K>4I$:5*7BN5&BUC<&6*-07F;$K^S'W^CZ[_ M[R?C[A1P=BVP!C!Y6%*A2-QS'XD&Y8ATRA(7&,/CP>D< V4\JK,8F"?D?78V M2_S,EF4%$34 OR?S^G44SHB02RT(*ZTT)'&44UP9ES$*RW7UU+XJ=1;ZAX-9 M55'\^%U-GEVNAV6OQB3FR71ICZQ-%ORKM2LWA!G^[NH2TIGRBD^D[LS)Q35Y MV4^&L48'*5(F2DE,FL ='4<'*S&12G&K;53N%1C.,+=- D2DD15$XDM#$ M<4J3)(--M)2\B]IMT'[J#.-#$'9RAO$APFO 2G@LLR4G'@Q7 HT=YTJPF!$K MG"?X4ZLB1(\#&2 M['0JOV""=]78Z@?+,#M(] =GF!TBA[ZCY%LO-UV2&M]$0*(I+D.I':%:$!-U M"6"9P-*3MF%;E\$=R>[)6^(#&-D.$!Y-?6(H86IY),F6L<+2H#]5YN58:82F MPFL.ZD!<_*@99A5@4H7-#9Q+.P+ASZ]_]_\UF;X8>>3E(K,7 GKT*N""%!!9 M;LQ#M)3@ ;Q?VA[^\21;5AE+.'EWZ@$8A2I8V0E8&@=J?$4E3XE 5JZ'YS^K8_OUGC 6C=9X*DDRWA/)J2HSL03Q+@3+8@0O M:A<1[458OT?G.:#6G9P: -\B /Z =:NQ6TF7=E0)=T]I"%JF(E@>*,D.V\ J2HICFWQ/$TA#$-BXO;F_OWB1D_3 /_ M#ZQQW'N12(RZ[#-*B0?DB?Z=UE+2KSJY5%])<(]+:#CSNA6\'RKH:ATG MC\?Y;Y-)^C8-A?5:X/:!&(D,,1-O MF2D#&FQ@.9C86>[3>?)=WZ 8+^%F(/IS7P0+'S\#O@W?FM+B;7[T7 M4N92CZ&)EDII[4%DRBLS\DQ+:R,(T@&>'UY1M >5!JRE.RM<1.KQD(S^)BG0 M2PO12DJB-4"D,:XD!2J"_ :>.$NJ.O*?(*E?Q#8)HX<3MZO)M&V(KFZ44 GH MP"(C04FTT,J\#I\=.JUHFQDM7!"R=H_2)XGJ?9AV/0CL#Z\CY-$:P/X#1NGU M9/K1C^#==/D;W)WY^77YR1^3^?9-N[J"M-$GW*OH*@2'KK)BG'A>VN)I)G7F MBH.K'1ZN1GRS@#T&5+L@>S8)-P#M[H^KA3J)4L;,M"602TZWI1SYPP+1ELJ< M-:4FU(Z^G6=E_=Z2_ C&1H,(:V#?';3 C=P89KP&$4L;%(Z2,"7R[G"MC#F: MK>#,LMJI;$>2^K.;X8>C;M>9TQ$$>D_A':+0PA!%\>'E^Y&?Y\GT\H6??H5W M5^ND/Y]3]$ CT52CI2D3D"#PU!2@M)=21&#[=6!^^ET-63!=R7O2'?/[QM+' MS_[;& "W[\"I)[4S).U%$*1NC-DQXM]_\U:V/[_=X M/SMB3F=QSQ-J2L>YH&4SL9K4&D3>:CM"D!ZUJ2"9E;;'3%$2=!F##8;*J"(3 MLBOL]6F*U9/L$U Y@LT-> #_Z:>+R^8W8WPFS.;+MMOOI\-+/[U^#F/(PSC$ M+U=*V(GD8^:HR8U&AHDHB;4J$J-4#%$Y):&VX7\8A6V![!A,3,XFH-YUU559 M$W)V?EW,AL6.U(Y3(;,AW((@DE)%/"V#77)VZ,NXZ/8#V)-:ZN&[^TV0:O]T M/%%:?8^)A"]7T_C9S^#9Q106/+Z_I-5NY6B0@X^&@*2YM$2*N(42(U'A::$I M-ZJ*D;8W07VJM%-E/NE: 'V[@ZO$FMN^(8#\"4H9$K6@1/I(B5<\$5L&HD5G M ???7I[@_2?W.'2R&\E-:K&Q 3/JH$+[I+4.RA)6 AW2.[0&$I1OJ0R&)YI= M[<:VM1MI=)9UV?(IV+6LVX;QUAI9KH+BOE3GJS+MT1E'2LR'9"FXI""SIK63 MC7_>_AN'0.7$_AN'R*T!6.Y7MR]I]"PQ(!Y8691G)%C)"%4"(+)LO-AK$G0O M_16::>5Q$#2.ZJ]PB)P: -\CXTN>7W_"!RQVKHMH!:./3YPLO:I5]@1Y: DX M'85/R4I9._GP2:+Z[1O^(QSC=>7:+E#+C2-!,$##: M&.LU#;)VWM>31/6K'2N#8#^('2F1OEW=UU>EFN3WX0AF\\D8UBW\RS6=QY]] MF%S[40EZWMS7!> ZH0?(I2KU2*CP)?J"FDG@WJ!O=[\WVR..\&'O;1)/QTI\ M"R"HVE'I6R6BJITT_1@M>T'+ M_'<^4ZM(L5$TKK,:9%):V$R"$;@2$)98L(:(F(/RF2?A:T]R>YR:GLNBJDA[ M#P@=P?J^#\M%0>8'B##\6G;56BN7312H#20NA\@E3IR)A3TQ1L:09V&_-+/M MSV\/#\>(;E*7CPWHD^YU]]N;VO2HM4-^%#.UN-<"6>UR"<1S$8(7:,W2^F&0 MLRUO+X3;_\YG<*M8:V ;_H:JZ.UD-GLW7JYWP8EW>1D-8P/N07)K(T'.HY)R MP(F-21&F%$T1_3W#:D>S=U/TLR>O'PFD^QU@ZDFU;ZOA#O=V,^^/JW(0OLNO M+K^,)M< LXW)C .O?=0A>L)3$B4+")U,SB)QU%A%6:8IV[W,C$H$_>SU2:S49L MB :Y:#4Z*H"GCU4NP=-7Q'$J.(=*(^>K'&A]GBKC=?_ M[-====!WK+SZ/MS7]\>O)].WPPCC&;Q&3W+ N''>:DDBY^@^,E$ZUQB/K# V MEM69N-^130\D)OK M%J8?OT <^M&+SWYZ :7?XI?)&#\[R8?_\2D-8/NAM$:+V 9X7*F)[)W7X_;\ M@&N=0WH6Y\.ORPK>=;_-+-"E4A'W@B[M3Z),))31KIK[H"R$D%GM_K%[$W>J M.7 [5.B15[Z8H(NYNC4RBC,/C@B>(I%)!!*<]$2$G!* =%G5#I8=0%Z_EQG= MH.F^,="5M'JOU'VD?CXQQ;FUN8P++6WFT.KQ @\E%;*(WL84Z%X>4Y?]+#J# M5&?"WJ[7D^(0-C?@ A_8\D!E8RDX3QB:VD2Z6+*,D'\\&B.XE*<8:Q] MER? 3<9TH6Q:[Q*Z"X]V3 C<"$S+1&:Y,?M:_$03(_JJ_$ M(0+H.SSWH"&"U)%+A=1&*AR17'$2*"I1!4HQZ[DU]T?M_D1])0Z2W,Z^$H>P ML0%3Z,TXX6&Z?Q&Y9WB8 A[CP@:+IWITQ"8N"5/ $V4Y457["NM $EN9T=S- MB78.N;4/RZV%Y31+)C5+1.>RQ,PLL5%3PKDR:'D:8T+M0JXCR.P[Y;9#V!P& MT9-EV 1,]^E'$,%;+F,BH72UDDYJ8I&OA#-AN9+XZU@?F,WWC>@<'D?UCCA$ M5@T \*GY-CJG7(:"H*7+T_*2T):"IES&=-@DDE&U+_AKC*WJ+ /P7,=S3;FT M#;/5SI36"Q=P9WJ?2MIADK@SE2(I&,\C[ML0.AW8\..-GCH( @>/GCI$'JT! M[*3!1,$DFXP&$CP#]/*C**G?94J]1M_+*MS"H4L@_LRCIPX"56>CIPZ1< /0 M/M.(%A,\Q,@IH=$K4JJAB2N&.P=F/'7:. MG0R2@DU,&TX\TX%(4YJ[,J:)$3$FE1(5O--!F/]G?-3QJ*LT/NH0"/0=BU], MH?F(GO#:"95(8.2).HLD-E(1@D4E)T)0I.&EK-R#= M1D=#&9Y5I+T33D>PO@'XK O\7DPNPW"\E$W\Q]5PV31C<_L-0%D1=>G1Q%0) MM5I&@E26.*L=KIKE?'^0P>F-SO:FKM^\F,ZAUI&8&@#@;7G!N_QV,KY87"XL MKQ0^39[#;;!A8(W@,7 @.93Q@;'$$0)7Q!DC@I5>15']*GM?XOJ]Q.X'<1YC/1PO'JE3KWRSY_73R%3<:&KD#95QDUBBBA"AMN'")UJ=$N _& M!: Y5[^>.8S"?F]KSGOBUA77\6"?WTOQ6Q[ M!&X(LQ1WOV$^V4Y=X(2G5$/-3M5YHE1:.[A7 MRQD$FVE$&X,H*2WJ^\AP#09]+\DS1^9((6M;B-OH: A.IPIZ#Q =Q/6CD?,% MIL-)^CCWTWF=%EZW1?5W%C6(R7JMG"BSYM%],J), +:1"-QB3J3(;?61&(_1 MTI!/6QE'5;A_.);<$DMCN"@*]E.WR@@@9%WR17@HERC*!^+0-2JIF-XFPS/= M;[SV.931>3S3 MO^;Z]B[SQ@[BB!'GI2,BH&@E6C_$ ;=$"P&H/9))KO;6VD'.Z0DGJT>7OE6S MSY!^FTS2;&"UX8XI29B+%!>I./&&&J)IHM+@,IFL'6O83DG?5]YU-D MKC=@!M^LXF^3Z=]O,J8'UB00G)DB8E5Z QEB&3+&4ZIY$(()53N[Q\\-]^1X-H.O2CQ?2HJR]?1J5[F?..Z5CFFS$:T1BCLESDXUV2E\9)9'Y(9"9R88OA8H%;9Y(NW>7LZ?=K]^0=&"RGOF%Q\<#[8R0>?J'C0GQ8 TRVC,0)XE&2A(C M+=T5Z3D%Y3H??IE/_!^O[A8> ::TJ)(L$4\4H\P"^F H"CI?4'IG$ M<_PH!"8H=I$6'TBT145EV)01[^;(H'Z\KETC-RZCGWS")#X2>CF)&4"!:[S7L[(O)G'ZTL]'-$-BG!O\8LQ/6% H 2.LA 6< O.5 (>6:Y9'DD@D<'"(*8%HTQX*TAI M/)U"7SL6Z)EPV/1?AY+-V;C['J=N4AYYGZ8C'S_%Z6)W5U+9J$'YHI!83LY2 M&ADFX$SJ(#F)%)M4NBO#/EKJVK*#(NI\GK>&GMQW,7+Z>CZ^N8RQ(679-R M,?*[\6M[X^]NEE.TTYO1S=T\AJ47\?%N/IO;<6ZN]& '.JLDSMV,H[7@10@B M@>V6(\P54=H)33P[$W/#4EYW2/#@&&Y([.V=B4_3^,V.PM*M64WR +-SD8?P MU&'^)UP6\.? RMG"[ 2GF"E"D1&$Y#:E&JX-BI%/V>*,@MK-,>N=L7X>176' M$@^.X1<04YL#A[.IDMN7P$=N\\\]\L'V+54@,ZP3E85RQ!;K;V<.FI@,D]8A MX7+.D%2@AA3XA1Z,.*D2\>4G(.RFI'=#4ECUW3C7"6:S8QEJ5II31G $ET7E MMH)1@)>;$HI)6$&CL3B5#I[N(*-R;\?^NDOX_UDV0U6$ M.185$E)8Q(.DR E.451,&@LZSY%.(TE/@,LN.NKCI9=P)X4YW2!:UC-/+"98 M!X.2%0*N29PK" -!1(F4E)3&\]*ZFBEVTJV@++.;+=A$L_1K?QMA+' MH\GTPV0>9P_9$)I)'0V*WJ3QC@&'S=#4?W?3S:)J/L6-P!4 M^K&Y :6R1/E;ZT:HQ"8I7;J-S385 M=9%2VF;IR>7F<+(Z.8EKQU@>*A^21YPGP#IA F'E-.>"J3@P4EJP5OK*]B!4 MSF!T V#Y$CVXAB&?HG76=8I1"T\0A?TCGIA'VF&+!!:)8H<%CZ6;%FX1T1), MSI'KUM73A\G5(\!P#[]Z/['C-4=6>["?X?7+S/;?]?<:=M>6MC<- .;(.%"J/>5RW M]Q0ESW3@\#_*EV]W>H"@RFD^I;5(.>8W@*3G9MOR*C8FN$ HPC@W%3&ZW"Z*+ MN^N[V9Q0V)A>;2QJ(S#\ 8K: O-T(LB"10]:6BG).(V2'GUM/OFK+45>A@52 M3XXW#*5OT]$-,; OL]J72%9CZCQH:Y)GJZB C-0!R908-2I2:;M5CI_PT9:L MGH&!U(O?M7&T""2,YJ/_MY#-A@?@"4U.I6S\BP"&HH-;GS.-L"4NSV>$GTDG MX!SZ2MT4^/)(*<;1VM"XX%31)V\<@/4LV=5.-"'*!*40"1BZH-'9_H6ZV^Q *HP G:\/A0F"\G3&Z?A<50:9(N$-!&9.[ZR?D-*@] MSW*]!]662==-61SZ3-T4\@&413&>-I&5\+N=CG+\*1=QK/I[@$44F$3*4W#= M'/9(&[@;@Q=&4##&HRM=U+E)0TO&1__@7"\.-Q":>TK_ZO (Z8,Q./> "@10 M;A3L@.5Y?,D(YHQ-Q4\?RF.B3DI(F35MOD6C='F0$$;1)QZB=TAI MR=4I_4YT'K^;@\UK.YW>YV&+MY.[\?R**6X("?F!/?,G8> /QPX1[(CB1#GE M2L^Y.$1/2X\ 9PK\((AZ<+\))"T_N]2G<3%S/?=(#T+F?G82$9+?[Y5@R%$M MD;!&$<]E<,5G4NTAI:78?RG\].=Y.\,+<@;SY2J#^8HZ+:+'#%&> N)P$)"& MW>31A\0*K2AW0U07K;_?4GB_#%;.YFX#,U&>TO[Z;II9>&6X\$"-0W"+YX&& M$3"N$T64:*&)H1Y /B! 5F2TY%^7Q\DYO&[@*GJZA0^3L5_M@@.Y3L(UFI($ MER'FQ&6-P ( ^QV^KL>$?T_.-\*@P3I$BPF,>,[$8=B,M\M'8&,!_-+:T M [^7F+J]8X8 4!F^-P"@]T]*@A_R.9;-QE]-IM/)GSF#WGZ#OYG?7^$\>MPI M@T)8# +&) ]SY;DBU J&HPR\N-U] GV=8&9^)I@-)IT&D/><7Z_L;#3[ K38 M\''\-.9/KH+V0::@D XN[\N*/*Q+($*-]\&$J(L/:>M*6[>P)/Z9(#>(6)J# MVU,C\I>4HI^/OLE#^[7_.I\A'^PT-^/^'GNVH=M: MIQ ;#M,W; ,ZKZW4,A"D?)X=8Z1!1KF :&+816E9)$-$'5ZF 5UP(FGN\TL^ MA5-,'4>&TH!2).!Q!AL$@F#':N33*1TL&1,VM?7[3YW$F"/5[[>@J7F\/)DQQ5L$(L-8PA M0J1'G"6-#,[] [RF)$;CL"B=BOG3U+Z>)..NM:^G,+R)I+M]%2TZ.L]L)*!J MP;L!%X<@%P5'5DFC!',Q"G',&BE3(_3R]:TG";%SC= I'*T-C,T$C&(Q)S@H6.#[OXU0B]?LWHV.,KQM($;9V<[3ZNPJ[6P#-=L=6EGAN>::1Y!PC[A0#IDB+ M$HV2:V:]"Z5#D]M4M 66%!.EWXX^3D:X_8!2C\V-X"3'6T]*=;:>)*0X+GHRF*);-!@E0OGO8?[ M.;P\GJY+CD- 'MAZ3"@'6PTY$1AB+-DS?>.I.* M]V7_*1KCGB3;+HUQ3V%T V#9[MFJA)&:)8.TI. B:J.1-1HCK$@RD5$>2/G+ MI_W&N"?)]6ACW%.8W !*#O?DU-A1;P-!3(4(]I;AR FK<\LS(@/1.+K2U4+] M&Z*^;$?=/N@IQ_P&D+15-P[;YT(XC+QV#G%% K*Y/3EW& QWQH7GI1/\V^^W MT,> Z<7AQA"R-OLC3\'A@$BD)'>O!WCGX@3OG8^"):KE?UR_A9.D>KS?PBDL MKAW?[]H-P$A!#";@'F)C@3',PGER!HEDL/)*1LO_VOT63A+J.?T63N%P ZIE M7_8;U=Y+!G=RE![N4*;\,L @O4Q$18JMX87URT_3;Z%<;L)Y_&X.-F!_Q56U M?Z3"62,I8CS7X3*FD)/P6^5HA&.11$C#)IL^TM+28_29@CX(GC.YW@!Z]I]QI)XCSSC+ THMW M5_EY@]@\OPG[Q3,^1O GL W"@"U*AR#8H(HG4]%2W'<(E7,RIYO#RH$B$.LD MIBH FT248!KFU0@;\ M%<2)R=>Z ^PXJ.&U.I:C?/>_%&SB44TP]N-\ DIXVT'E4J*\B7.GCZ[>C M'S$\5;Q7H$^%#LP@(7,C?2$<!6GOSR,E9B=+,3NL6*-4\G?YBI9O3T??%5YY\^6(<_A'#=590N8QY-!_% MV8XZ/^T##U)B)*("A'IND&98 6 9LTXKQG%IPZ,'N?WOSQV?_M6.QN\GL]FK M^Q4%GT&R6?BSKZ-OK^[?@9!OEZ;GXG#GC\!?OKK?M=CGT>R/9>Q9Y_*!I FB M,F3+PN5:<9;'!^/$B"6"Z/)ACI?:7>V([.V50EA* MA434YNY6"C-D LVO;=$23%-RH7SA['YZ&L1N QCJ /6S!-H4.%]/Q@LM\"0K MV\K K4D!>9%S*&D>"12]0DFZ)&@0(KGR3M-^>MH#YWE2WPNGGB)H $YO)],X MNA[_\L-_M>/KAPVMAP@1:9D.$CD&OB#7C"-CN$ !4ZFL89P7[Q)PD*!6 -57 M[I.AA- HIZ%./^TWU:[X#RWK94>,<86>;; 'Z(XRB7+BBH.RKUT1_+=E-1^ M7QT(0P78W@!X5A;#FSB#\[ 42M;6D3&MJ&7(!TH1=TDC9ZU'%GLF8\#,%*^9 MV$U)*^!IVMPJ(,0FH;@ZI51[HQP<4&V$@7T(BZST<*1,DEB(8 TIG62_CY:Z M]V$).1^%SAE,;P \'R;CL-I##.OZ .U P6N#O%<.<1S 62<<(^L]"4E(JVQI MW.P@HS7(G"/?25EF-X"7-P_T7\Q6/'K4RNLBV:2Y4!&CG','U@'LRSJC4>2: MB"BXL;R\4K+HWXB!X*BV,BOB:3>=7G[-/L=#,F&@L0R((='($8U!FI4ST MHK6_R1TAXN:M#D'!#8LM4]H+(SO%AHZ(?N?'*X/@'!%.2O*S"8OE5.VZ MJO(WWGKC$)9)(.Z)0H;!;[TQR47/ V?E!ZJ>0VGMW->F[ZX7!$$#4-^QC?48 MY21B](PA8"%!7'J+C*7@;P3@GC(4LS!0*&";F%9BX\,A87>LH*=8&L#7ASA_ M-_X>9_/,M-6N5I<"_&,GG Q(!H)S;\B(C%84P0Z55T+X*(K'#/92TT3HH*^X M-V,'97C? (H.GL#W#TE\ 2&$>%)14RY+G^_[J.E MX>OU3+GOA58/(=1N2+%O$W!4I]'.XINX_.^[\2?XEY-PI7)/9!D%TBJD/)O7 M@U-O0-,KABTVT@JYT7!@3V>*4[_<\$MB/SP-+X5YX!"N%Y))"(DGP/\$HK#IQVE*Z;2AQ-8#%C_.OV7^&#.Q#29QL_1W]C9;)1&2[/E(@%)E_;'%;$Y+R02I**$ MH\@C,#IX ^9*8CQ@:9PJC=;"6V@X=E,&SS5%WNH5O_SU<\PL]_/<-.G*$FFM M@^,;:=1@:7O8%E4)$2+ B;,V!N9Z7>[;WVS8BQGP6N_)^]J0>MJ@9!<+/WZ+ MN>[I:3'&E>>4TN@PLC$Q,%AR7R;-&=()1\UL$)9V&UYRQL=KUS0/"[*AI=' ME;VIB/-6+[R_N[V[R6D'^]3[Z[MI%M#29/X0YQ]35MY&:J=UH(@2GYNG8XNL MS>^2L.N0L"/&EVX@4I+^VI75@U_6U83= -"?FMH[#9/+R:LG9DD,;^YR0?"' M^&-.Z&^3\?SK#+9^%7V*+F&%I$H!<4EAUSD%/CDI@PPY)[YT76<9RFL7<@\. M[@H"_HGJO>,\LR N>#Z;C'?*HW0M^"G?'*I._.Q]-U!#;HEC3!*"W,)PE=HB MXX5%4<4("E98D87E2B19HHAX;5T#'/KS4LD0?W'U9"? MA*&3:LA/$&A3X-Q1A!AU &Z VT#RW-X)$=&,X$8T<+Y2#TCP_50^;EJR$^1 M^BDUY*>(H $X[2D]Q90H%C1%P"(.I\V(7%VO$#;)&2XM=J%T7*)'Q6^=JO&3 M)-VMXO<4MC< GL.U[\%9;;G6R"N3G^),1#J [J:$*J9B8$R7;E;:OP%!G>+Q M/E J)X0&$+6G+%53$R7P*(_"ALO?2X<, 8LW6B*,2=H[6[K'^W]X#7D?%&PH6*H6CY VH=!NUC^7G6PQ6\?=7J%8O'08K#((&H+Z_UBA2*N&+ MV3!)N:\(EOI0_%IS%J$6( M02+A&,[GDB+GKVYP@ JQ/L&4-0Q*TA8BI4U"DF? M+.*,@W4:6$!)2^N,98JFX6KO>A>*_A4Z,PQFIYTGY*:@N][*QR?)13F1+%C- M::X%5_D73IU&CC.+K.+!<&H)=J5'NQPEJF$[[4PD[ 5;";'4K@8X5%RS=0L\ M[/@A0Y>#\RZ(\CF!!A@)9Q5I _:NX,QQ0Y1D<<.*VU,8T(^.AE\9^H'NI65T M-AR_QZF;#)AP:D?3W^W-7?SBO\9P=Q,GZ>&/WHW39'J[C&7U2"\][0LEDDE[ M[*E0ZNC#]QY3Y68/N7)>26&4D4B1/&^%"8^,, 3E,#%7X,Q*5SJ%\1 ]O=_> MUVM?S&9QD3#X?F3=Z&:1*OA;M/ECX>/X<_1WTYRU#?_@PV0\7?]V,3YU9:H$ MZW7(S5$BS?4WCB ;74322B-I"AHG,A1C^A)?]WHNAK>M-_TJPFW 2'QELU:) M7[[&^&!J+T)/QB>ED^=(F#S3-X CZ*B(R$65F."$>%G:H]E'2R.8>UEH3 :0 M4Z-X6P]T2-Q'0S3R.&?.:*H1&,(64?#JHE5"6%=Z;-I^:NIBKHRT.T#H#-8W M *)/T_C-CL(O/[Z!.1OSD5R:N,LBP.4Y78>;J'!:1HZ$T +O%/D"W^QU;T3$:3C#L(EB1=7L"W9Y+3:V3 MQ#BMB"B=>WF G+K^[$# *L7^5I"T.A'/K(G%9I+PGL'_HD6?1H[!]=962,2 M4XY)^--0NJC@($%UW_J'1%,1$;2"I\>CL;V?X"3#TFH4=<*P'PS[(2DBXQD. MC%#*-QMPE%9/YZ%JL)>)E]%1_031 + >G)]7]RM7)\<)%S[-LJHG*@OT$Q1- MRNTY@T*:,HXDT]@J'VDDQ4L.#I-4]^IKPUDL*;660/@8]5<]93E;K-!SK%L^Q.7B.X*X:-32=S M($$U@,'7=CJ]7V1%?(--QK!DVO[M48F)I%KEVC6-.#>PO1@",D%0SA(QJOBD MLQ-)K(O%P:"RE30WG-P:@.4OL_GHUL[CQ]2!CY1K(:A-R,@\#0"V S]%#G:T MXT8H^-OB/7Q/H:^NC?A2@!Q,8@V@<;=A\W8:_WT7Q_Y^8=QXY2+7@: 0+=PO M'FQIZQ8,Y QS[ZDO/@>Y UEU@RDM^R?G2Z\E0.[:T,K@49[ F:(&2:]RG:9R MR"F?4-2>)T>==KYT7*\#68U8BJ6@L ]JA>32*-1F#R=V72Z':6(Q,&1#3A9S M8&8[1Q3"W,A$M*>"E_9.NM#5"-A*@:$#V'I)IB6TO;I_^/$?HS@%HK[>OX_? MX\TRDJ!4$&XYEBP/DZ(8V3R2PG/IG;"2LN*- +M15C?,W-Q]6TJ&+2'SZ6G; MWM\ZVN MEEICI'3(_:>L08YXAH(/1F/KM$ZE79*3"&Q$,Q9$2!?E6$1<+6'Q MW?C;W7RVX!A9C\:+DADXJV"T8(XXTP%IZC!RW HOC">8#Y8'NTU.(S@K#X)] M<.LID4;!1==M-R36)%F*5+39;]<*&0XF!2,A#Y2(QHO2#0,.D-/(XUL5<)TC MD4;!Q1YF=DM,*(9S$H6!K82(M&(8,2Q%B$2YH 8SZK;):21R4@5KNGU$>(:L2!? M'D!["WE+2K,!F#X6A#Y><(\/1E>6J1 ,XPB[S#.?-X*#0-X9P9@@Q(O2V#Q, M42-69W5 %I1; R@$)J7UN)0G'-VU,^J,IIQP,(,L6%N4$F":8X@*27 ,5+KB M7=B[4]>(V5H=G0/)\W2DFB52Q_$Z=QR\+ C8>9Q]LO?91MJY*V /#](@0H7- MA0IJT<<+Q8BUDUJ1D$IWVSA"TL\?&R\%S7*2*XW'8=H@?+#3Z<)T*='Q8&NQ MDLT-#E/Z$GT,#!:,*ZJ1USC/_/$".>,Q,D8;;H*+(I9.L'N1/@:O[I\60?PZ MG=Q]@V.U=/&(P4;F\1S)4PJ(UQ+V3!4B2KN$33($E^Z0UH6N1ER/OB@Y\#Y7 M1B0-F&^O[F:@FV>S"__ON]%L]%C!+%1*(2>:,0QZ.KEX+,]UXLEV>J6'59]H$/C=H_9X]L%&@E:E;Y_SF=H"$M8 M9H;PX#G"@L-IX [<2($IPBXRY7' *G1Z]^R"A9KZH8>P-L5]!NW>[(EQ&0;7- \'4(GP JM Y 3]ID8@)D4?7R>$Y(O)G'ZTL]'-$-BG!OP:L MRD?]MT/[/4SI?FA"_-I^6S0H?@PW$2-S2SF- G:+9N@1/#WB4 !V1J&)YWZX MXI+S:&XD$#V4O_.B(FT PK^ 3>__RW.OT["DYS7UO M/0)+CB1&B(^J=$;8'E):<;!? @^;M7<%A-, QM:.P^O)K1LMQSWE<9? P,PQ MX-8(9+B*[2Y#]_=7B>5PNY&(T$6;XIB0CL8C%I@RUC/%=>G0X1EDMF)^5\#F MT$(MAMNB3Q^_3B;AS]'-S?J_%WX^^@Y;Z_$ ]\/<>_@$DN$@K//$LT:32/M0D+!2^62QIC$TLV,3R*PKPI< M?^SSY.;F[63ZIYV&*ZH2ANUY9#@QN18B(2LI07 6G)?)2VQ*J[@=9-2]7H=# MR::^ZBN!!N[1]19RC28#[>#HOBH=5%#:\NIP@:1 MR]T?C#1.6^FUP:7?,P[14]=2&@HWO3E?<-)%?QR]N_T&%N5R7-)L=A6HU1%; MBY+*8P.=C,@*3E @8*HEY30UI3,T=U-2-^0P%'9Z<+N=;+7U9H Q<70]7G9" M]?>74SN>+<=QK0?!7 4,9%#'X-Y.\ NXKG L<$*.&ZQH'JQ%2AN;@[; M4! K+)6FE-65=]:!9WR%TE-/,W/$A+.O1<61>G @E& *\ACM:+>N,;5[ GBB1.%=R^V"(N;*Y(2P91HQD5*<'&A]KV&09/(S[Y*5CI M: J=(H M#]_? 3_JJ093Q2 L9"YEC@RNP) STB1X6B0&(4L'T0Z0T[]F;K7T:N[)JSB. M:32_,HER'.%4I=Q-D5LID#'>H@!^@< 1*T)*MZ7>0TI=U50*"=LU;_WYWH1U M_$M*T<\?9G/"CCZ#P[=\F+D;C:\_?EL]RH"6Q3922Q1BDMN<:V%A;YB#JJ78 M6>\"YJ5#[MVIJQLN&@IF TFG^3NPA"E^:+FR=]R+&.2'(*:U,EQP!H84H2![ MG]TZ9A$F1*D('IHJ'MZO<*=YQBF&$X.(TPYV:10R!/Q69@410L+6Q6"[_%GN MM%.0T/5..X7O#3QZG:(SK3 M7^QT#/O/\\^OK $K,J>Q2AGR@Y"@R%B,48QPCTO"4Q#NV/57GJRZKRJE 5E9 M;&V:8*\GM[>C90CP#7*&$E$8_< M(<-TKO-RQ@L=I16E:]EW4U+73^:CZZ76:)VMJP4\M)+ M#GXNB@0K8$CBR CKD"=!Q) ?K;H-*#U2++/]Y;JH*2'+23'&-@6+2_C_6)62 M2INPR/7%PBF!.&41@?G(X!=%G6%)A%2BDFK?]^L55?65YUYHG,GPAI35T,BK(](:MM([^-L%N,JUCJ^?A_!2EC\\F$R_[]QGOU4 MV&E\Z(QX?SEY%3_94;AB!A.>G$))Y,F0/B?_*7!/6;3!6&9)W"RSW&,\G4U" MW3!D88B]H#1:T&T=-WH9I[K6NCQ]7J8;;B%>"X%=7/+A]"' M+R*+1@'W&")>#O*^8@QVE3/*-#' 18TML@"*GIRYX>>7D\\QP8GXUVC^=33^$'_,+P$9\3?@Z]?95611$IH3Q1B! M0V*909K1_*S@O0/_/3J%>RFLXS1TPICZ"V"LM#S:?#5>O8%_BM,O7T$"/5Z* M]ZQ4X'6X"XV%7H37*0'K;SUF@C)N0G(&X<1!TD1)I!WWB,K$@R JMS,IG6ZT MAY:^EOP7_S6&NYOX,5W 00JCF[M\%7_)3?(7??1_^>%O[H"5;^'T@:+]=K>4 MV,>T2= RH CR]YI(AP(Q&%1O]*1.SW$2,B-!Y(HC1R&BND3?1_NXWH" M^UO S.HIC#C#A 1#4BB>-RX4[6E_-8']>G'VVCC^M)(IN4 MX%]MP3]K0&N]I9Q2BY1,@/I$,#B-TJ(8J0 &<)5BIT>^X@U\BS^R%!/\V?QK M((+]V!LQ)T)\3%_F$__'0OT%PP*72B&EE4=<"(X,%P%%'#2!O2CI2GX!LR(LN)J '=/Z5^E\A -.E-8C@@C-K]K!^2"E'GRF(7_BPS853J5>(N* MR@9K&?%.BO*Z?FAPV8!AV0OXG^/1?'W':B:=< KAP$16V 99T-(H@.9UG&.F MU4:UT][ W^XO5$ZN[BFV26D>-J V>BK@Q\"H9QR.#A=(1JT0-TH@'>&WCL;H MP;BWGOG"RJ84[77S!1JZ#*N H8%#\*\XNOXZC^'B>YS:Z_CA+I]D4!1Y4[./ M=_/9W(X#[/1-YDT,CY48B]T^Q-*8\E0$Q5"P*<"N"456"(TP#6"U,N\]+AVC M+$-Y7;5W;?1JZ3 FO.!H"AD+LI)'BXU M'Y%)."3EA)"\M"=_(HEU;>A6D5M(I.]Z9?+FOUY,Q M['JV,,^R*SR[,B$*E21&.2R/.'/@5T<,7@BVFH!/G+")A0%[&H5U-6T3)N^ M(FU Q?9D\2KC+U$7-#,"$4YR'9LPR($3C7#"E!+AM$VE*[2*$%Y7'3X9BI\NN 2P#X^XW5[]Q&2\ MLXCNF8D'G[GZ'/T$=-P]R'[S6X^AP7.YTOD#YP;R8?W5JNO/+-/,^A"\<\$J M3O6I\GF(S1]A2\VGE\669NL'J3?PW\5+;#^$;:]735X'^3[IQ(3*XGD'IOGW M45SL=F#V\'S2C0&59?-A M,OX0)R6$\GRE:M(XR.O)D8TW=*]$6/)V-3XUZ]=B%\S6PM64VKF6016S)FAL;^YGH]DE^"&OX._^*&%W;R]: MI5:\@.V]ESV5I?=E_L>GJ?\XO9Q-5[7"P,OE,/0RDNST@2KEV'VD>@K;*DOX MZ?-0.56Z?]4JM=!]9'F40>U<@,OF$>N;.A8ZHIT^4*7\N-!E>91ME27\%A:= MC.-ZIV!T?["W_SXWW?V9I1&?D7]DRD(0T#AZ <[P:&IUXH^?&T+$J#&;NQX1?"[VV\Y MI08VL&I(5\1V.^^+G4#15*"J%V?;\*]<2TR>])Q\W7#B3?W&R2-XJ% MDDCV+UPO^^J@*":G\:6RZ#[%20$Y/:Y2,Z?D.*\G!S9>/\D'2/I01!R;:U7+ M'CE5*'N8\'>NXDO>-'_G)_Z=GWB:;,)_7TX6_GC?X_%\I6II5(=.Q\[-UA; MSR>=-E[9:'\%NUB@FS?,_%TG6I):H=.Q(Z-UC9J5]26 M";IMKU;OVN[GQ[?V?O%Z\B7>1#^/886AWD\7NU>L=Y&<)Z^#?*GMIP IX<&H M_YC2R,.Z;\=ESMKQU>NIP/-DV9E?M75FC--?IY.[;XLR]7(2/;1NM>S<<_7H M<1[5UJA?6K=:7NZYVO4XCZJ?Q:H%9'F M62VHT@=2BRO4O2O7RS#MHU>/,:IV9L6BM7H>G;YD);@WM]\6Y=JC!,3D@<*E MI'OBI^HEG)XI[O-86=MMW% SO\\6E\BB.]?7R0UP^?.\E"=YVJ?JY:J>';L[ MAY7-R?]#G+\;^\EMH1AZIP_42UDM)NO];&M.PEM!YJ$D?>!#G23>5.SH##96 MEOP.]9-WO@I^E1%ZUV]TDG=+T:<3F=?<(?\X_QJG Y_OW=_H).J6 E#*N^HD,!VK==)7BT%C XPI840?Y'VF$\7 MZB2@EJ(\N]A0W0B9]$Z57*_121XMQ6 V-M]&FG=O<9R:KTI;"I,TF*8Z&?\* MALN*L#=QYJ>CQ3-,H3S5X\MW$F)+ 9#N+*M^+X51ILO><$R_/^ZNU//SL=4[ M2;:E6$AGAK7:4./B3SL-EZ/;Q5RY01IK[/Y"D08;'8@OT&AC^97;Q2>VP'#> M0=BY8I]SNUKPM_&W45ZTT'G=NVJ]HK5#LGAV,(]QI+:F7=-7L&_WOC7K%:F? M+*TFVW&OJ?L$GYU/;\?A[8V]+B*IYRM6*Z8Z64X[.=&(E/*)?SV>A6DY,6TL M6:U0ZBSMM\V+1@3UC\F?C_25U8![EJY6%76RX [SIK9COKY31[HLN@Y<:>'@S5Z#F1PO)P_DEGOC[K)^M2*ITXY@-RXU*\^! MQ%BO9*J ]!H16MV61\,Y98=Y_G<3I+^;(/5)(EB>?_C'1P[-6;/*GZU=UUGN M=(H.,J4!82VR45[965S4J,;Q;,6_::X.STV(9Z_N'__-)WN_F!62-_.XHW'X M=&/'^=GCS>36CL:%93X(B56.]V$P3%Y.,@T [Y?;;S>3^QB_S,%(^_AM.>#M MB"H_!SW[OU-%>[R(="C!2L^CZZ_SF=?+CY_&006Q[]7 M)<)7 QZ=65_;[MMUZ9:8]'%PX6H-#/JY46U-]UB0^,]QF-[<7W^)_FXZFH]B M[X%-^U>MU[G@-*D=8DD+(OOEQ]1_FHY\@?/UN%2]5@2G"6=K\RU(Y%>X >9Y M?/A;.YKF^NH"HMFQ9KW^ J?):#\[*@OK^@5T%ETWYK2:AO-N/!L!%R^G=C'3^(E-5C07Y\!GBB3D=-U&@:R/, MF.K>9?N4I#TL]RK/2.L?H]^Y8,7PXC%9/"M".\",VJ6##Z3U#LYO+%5--@>Y MO5,JC4035U'I';JD3'A^_\(-R.I F/XH0_ZC'[@&L1^[GJ&_G[;^?MHZ+9-F M/KVYC-/;V<=T.0V KS*)& >6K7:&3K,1CC.FNJ60J2H1*7R^4K4[FTBP$R1;-6'R;1[[Y^7N6[-:?N=I M0@D^6ZY:]N8YBG 7(QI2 MAI?3V_&\K"Y\LF2U3,WS5>$V0]K2A(4$MG_5:L_"O?1@Q ^1QONX4<3LGIS-UT05D!(#TO5>Q$^1SJ;'&A"+$]2"*ZO+[[;T4WO M/GH'UJWW/'R.P [RYN=X9?PTN1EYV,"GZ<0/^,KX[#,#O#+NWT;Q5\:GG]K" M2('GQMWK]XK%KY8/3YP._(K^IO++OH_#"9KT@M$T;N M_I5&HLH]Y7R ?\-K]-5?Y%^&-E;V-E+FAT;=U:75,; M.19]WU^AA=H$JFSC;\"05)&$J6$?,K,9JF;?MN26&FM1MWHDM8WGU^^Y4AML M;),FPQ((#\;=NI*N[CDZ]ZK;IQ.?Z?>G$\G%^[^=_KW99)],4F8R]RRQDGLI M6.E4?L5^%])=LV:SLOIHBKE55Q//NNUNC_UN[+6:\MCNE=?R_6*C04[?]T=M 5 MYK&/\W,MW^UD*F].),T_ZG=;AX/"G\R4\)-1I]W^Q\ZJ*;=7L!X;[TTV&L*R MNN--09>P3DWNX9C%1/%KG&]]UI6ACC"4ES>^R;6ZRDLUVEUV*KK=9U. )"TS^KUQ_,OEQ<_77P\N[SXY?-O]=U^5BT,VR?KGQ=L MPJ>263E5I3$=[@DX@REU$%S,00:)LA!8F.7H#D^$M&PV4X]'7+)4 MY8@IP7,7PP;@ACF:[5*[RE/L%^X5QE%YHDN!,8'34L :P%A9/6<%PDP,(>9H M?4>!*OKNWM1@F5 T<(,L2@T#X&X 3IC.!7\2[B8LU6;F%J2P\DHY;SDFXG0S M^@TO&TO8NH4S:]Z^'GC;AX"WOQ7>RY58O'45=)5^$_5-FBI&1^.RFX($UI:IGZ46_X_3<_W]_&CD_2P2E$ M*RCEUZ%LD(@GO'3UNY":CB5@J6:*^FQ*BP&P"Z?*A;T-*YF'<:BDN%.%966Q M4O. [*L5-"<:MH 2JFD:!U.8U4.I+VL"U< MR -!"8R3< @%>^A45 LJ2M2*#MN!TEZ"RE$$!T+=<25S9#,- M:J%%%L19,D%-%>D#;JL"ZO6:"12$*-E*H/,IUV78K11='#A0":@IXN(V9/0W MNT?=SN&)JZ,^\7)SD@]\042;+RHP,(6 MD#$2\"? 31.\4LB#9HCMFA&CN8X*G2>JQ!U:-D+_"*6@?&*2I+04^R7QWC!J M9IS'?7H8@+%<@H'^**']&'K/WZ^D4M 'N_>>7>4R*E(9#D%T/LK+6X_VHS\3 M[FYS'.W[0#HV M'/G%@GB-NZU'2K ,_MTN)! ?D=#62I-;USC*$V^LN\TAX0:&S' H]E(^H',? M#+(4M7]2\"\,L@>B0%837).@Q#0=)#P5$>#2Q.%$^"O"J[HNGI@U[E@MT M=/)VRVXE1U5VH L01G70B%G%(:6X,@,^"%4\PU8JN?'P_=I31D!Z>YEYALR0 M6NR;!N(NPU8'1@O=#I971Z]_9B2]B,A M5[$*88O-U8N1PW;KC7C$S8O%Q-5KDU9H.O!BO>VPU1GVM[:V6YVM;0^- MVFNU>]TG'[7?ZA\>/?FH1^W6<7=8:]B#$-T886#H"IZ_V^GM+#I4!!]UBQO6 M6:4W<7X-1E,\6]E*R_\$/5E-F=5Z'UA*FQ:RL\%T^*VKCKQ]UH5_AIAE8^C9 M82.\T%Q9?X7IPI-%QT%8]C<&Y[N8OFYR?I@_&35KK3F\T'T!W'RSVT?^#9^/ M6/L+!7']K>JFK?:\>Z7*O50:P):%1ZAL$8#_LW;5*R^.:A)EN;QXH0O^03GT M(]+DY3/A5XN#K)#56ZN/$R53=GXCDY*>8;)?XD.0ET..[\^C)XCYWJ_QR3R. M?&NAWE^/]4$XL7S[$>WA<]Z]WX 5QH67YJ/XSFPJM_XJK)JV?=>%CZ&#I=_> MY:_^D*SZC+]_.PB_N_L?4$L#!!0 ( -6!9U?B:[54U@< ((G > M97@S,3)E;&%N8V\M,C R,S Y,S!X8V9O8V4N:'1MW5K;IF28[LR3IV_""+ M1 -H]#DXW2!U/G19^O9\2#)^^\/YC_6Z^*"C,J/KVR>J^+B5&#H1/M9KLC_M#F1HUD:'?*I?1V.L[Y0;@^/_"3G/=U/'E['JN1 M4/&;'25;IU&WTY%$;7G8:79.FPE%?3KI)'UJG43]?[=VT!7FH8]UDY3>[&0J MKP^)Y^\=MAO'W<*=C57LAKU6L_FOG653:0:P[FOG=-8[@F5UQ^F"+V&=Z-S! M,8.)PMSX:U6#3#I%.M>GM-OW?&;?4$YFI=-)[ M?6&43%_7K,QMW9)126BVZK^$16!H?SFNUHC>J=/5^^NKD6G MU6B+9=>W=3H"0&2>U.OWEY^OKSY>O;^XOOKYTV_;N_VD3E[5Q+6.8_%;0_RE MRWQ0$Q$9IY*)<$/I7NUV3\Z>J>>MQJO=UE'S;/7S2@SEB(2AD:(Q]K4;*HNK M0ALG="X^:I.)5K/^J]")N$QE'FEQD:M,IN(GDJD;BBO<,C!G54 (3A\0@D7. M_:>T',DGC4I[8U3>28M88/W91-SD>IQ2/*#:4G!B35;D&HJ(>:3*A(QI>+A$U*3)(K)5FPB:9O"',NS"FQ;T8 MSF#*U&LMYF"#2!EH*\QR=(&>.?AB)-(5(Z8,CSS&-8 -\S1;!;: M59Y@OTBG,([*H[2,,29P6@A8#1@KDTY$@3 S0Y@Y:3JG0!5]>V=JL"Q6/'"- M+OAQX MF\> ]W CO-=+L7AM*^@J_6;JZR11N/3QN1+2D$<"D57]E#AB@@!_/U5VR.9L MEF';\];GZUC9*-6V1#\6!*/3 $EA=$0Q;ENQ!P1B J0AS)>WT5#F Q(7V&N? MRQ06K8ZLM[I[M.^[MKIQN J7BI-R'JC XPO>D L,"8BQ+UM/E"Q-E& B7N== MWL""<\0#\]M9(6/6E'I*B>MUCK[]YI?[F]CQ@2R<0K2\4GX9RAJ+>"1+NWT7 M5M,^ 99JIJ#/NC08 +MPI*S?V["BW(_#)<5<%1:5Q5 J/@0AKQ6I?S2*5E:??;POH\X)5 6X)#J-5]IT*" M8%&92A8P+,L[,4\1Z!$2SF*>Q+<^L2$T!OT?7B0\)QYYE>EOR:.M-^P*G;;? MZENS"DP8QIH MN62Z4&UXZ;RM%E24J!4MM@.GO0B58^P=\'7'@')DLQ340@L5S%DV04T5Z -N MJP+J]9()Y(4HVDB@RY%,2[];.;J4X-3KU AQL6LR^JO=DW;K^,QNHS[A?N5E()Z(/=>\>NT?%/SS@^R!*) 5 MR[*%_UPD37E-?Y<*[GL.EWGD3TG[WW$1>X%3))L*"'-.PEW1<0_M'$]$3Y(,"KNB^>= '^7G\XF/$VH^$7,7*ARTT5^]$3MJ-X\,3 M?BWB$#<73R>NWI@T_!N3 Q>OMG4;IT?'&UN;C=;&MOM&;3<..YVO/FJG<72\ MN?6QHYYT&MW.=L,>^.B&" -#6\C\S4YG9]JA(GBO7=R*UC*]F?,K,.KBR\]2FKR0G36F1X]==>#MDR[\$\0LZT//CFO^7>;2^BM,IYY, M.W;]LA\9G&]B^K+)^6[RU:BYU9K]N]QGP,U7NX?(O_[S 6M_OGMMZ9WJNHWV MM#NERKQ<&,!6^ >H8KKV_W,TMRLN3K:DR6)Q\4P7_/W1YWMDR/,GP>4M124_ MJ!2_JXC$+P8'VIBJMU?OAXH2\7%V,OFY>ACR?,CR[7GU%3#8^R4\HD>$5V*] MOQKK W]T>?Q9[?X#WYW?@17:^K?GO?#R;$0;?QE63=N<=Y%]2&+I-G?YIS\F MJS[#;^ ._&_O_@=02P,$% @ U8%G5]!6J7PA!0 VB$ !X !E>#,R M96QA;F-O+3(P,C,P.3,P>'-E8W1I;RYH=&WM6EMSVC@4?M]?<9;,IND,$-O< MPJ69H<29T.F0-)!>GG9D6P9M;:UN^U& MITDB3O^T*JJ)XKJ/T,J+/*C'CM04U_GM-I]YI M);I_Q0*]Z-F6]5=E593(.4I[0FL1]]HH65S1(C%#E X%UQB81$?YS]S?;:]? M,M7%H:;7ND8B-N>]+#F%[5+?%Y&0O1TK^_3-3"TD,8N6O2=#R4CTI*H(5S5% M)0OS:<7^I8@)36?#JP(R:D>,TS(%MF- NV]/QL_',V@XJS >",#'VE'YG1!T M[D0P#">C\?!E"6E;X9Q=G$\OAI,9S$YAZHXRSG6M=L$[F [/GP\G[K1V^O:E M^PZ&HYF9<2SK.RRO.S:?!YK])U6:A)5*$H!<4 MID1ZA%-5.[V.Z!*&OC8S)I&PIU*OT%"P1Y[N[MAMJT]X 'M>,4#1TJ;=:%E5 M\!6PO,IH$^K0(F_*.-(>4"EPB2AE A# MYN/(S+D1X;Z (6"$DD@O8(R79"*D.0&K0#A>"!CA!,K+)J ]8W9WY\!Q MK/Y(Q GARVQD]]%U(#",!9746P*Z,E7!,(BNFC0918\J7<3&)+SGXBJBP9SN M[K0.^EO+A1D">Y42B16*EG!.,5<(DL.QD#'85NT5A$)F\#_D4D"Q+%@VBD6- M/1PWL,993_%I=C^JE_DMBUJD'<(T0G\^CB*&>;]B6$,S+^F'E$EJ&I&LV#=< M0KH!AF*W]H*/UJ;43R73QH)[C43CXVFF"8R3@BB',"^)@/P@RA&,\, M? *3,).!1%)E?%>-!(DB0$UJTHR1J02#P1FC&#*.+#37T6; ,NO&&TJE41ZZ M2&C.._49^/K#V'+3^ZQ!C1F+,2D3>@7G(B;\'I)TU^)(OK#+H#7Q< 47$7A" MXB*M82 1213ME3_Z 5-)1)8]QC-[F5)_%9YI B_-0O-)5*R ;#'DTT5_V.W6 M#UH-TR)JW'%U4#HNNL=ZUCWNZ^#V7!/;S/:]LU;=OG?NBU:M>J/1?'2S3HGR M<8/MU-NMSEIF][/TYBG&(BKDZ;-*HU(J)"0(\*ZBYR378*_N6A$-;]=1)#]J M%\ON'XYPD:[NPP7>[8,R$9?YOMK)M]5O0Y3=U7P.*5]@/Q35[DZSTU?9]_:7 MZ 4-0XF=T:0.4Q;'N,&O8%IS*5D&6F6M/*PA6FS$YIQ 65 B8@&4"?C*?'XM M/]8[:P[6),JG9\V& GY<#FT.B7Y%GFP^%8)G&LC1@E&\Q[G&SE:S M2PJG^9W/YI#CY_/H$7*^=R89MN\)]N^W4OUT&8B"&!:AW,/K\B@S9?!+< M-&ZOL6V#N]KHXX]/:7^WT=^YC;Z5ZCO:Z/WL,?##GWM_^6^WS]XO2(3*'LOW M)(V(H+ACICJ^U6^]26%XCM_MV(_>Z?C/U!+ 0(4 Q0 ( M -6!9U?M;@(4>44! *JL$P 1 " 0 !E;&%N+3(P,C,P M.3,P+FAT;5!+ 0(4 Q0 ( -6!9U?.FL>BG0\ 'ZB 1 M " :A% 0!E;&%N+3(P,C,P.3,P+GAS9%!+ 0(4 Q0 ( -6!9U?HD?Q4 MH1@ .?F 5 " 715 0!E;&%N+3(P,C,P.3,P7V-A;"YX M;6Q02P$"% ,4 " #5@6=7\B/)!DA0 #SA0, %0 @ %( M;@$ 96QA;BTR,#(S,#DS,%]D968N>&UL4$L! A0#% @ U8%G5]IVOL$- MT@ TPH! !0 ( !P[X! &5L86XM,C R,S Y,S!?9S$N:G!G M4$L! A0#% @ U8%G5VT_(H,?UP A/,( !4 ( ! I$" M &5L86XM,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0 ( -6!9U<:'O%![H( M ([W!0 5 " 51H P!E;&%N+3(P,C,P.3,P7W!R92YX;6Q0 M2P$"% ,4 " #5@6=7*WA&-F;V-E+FAT;5!+ 0(4 Q0 ( -6!9U?05JE\(04 -HA > M " 9/[ P!E>#,R96QA;F-O+3(P,C,P.3,P>'-E8W1I;RYH 8=&U02P4& H "@"P @ \ $ end

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